| Symbol | CRDL |
|---|---|
| Name | CARDIOL THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 2265 UPPER MIDDLE ROAD EAST,SUITE 602, OAKVILLE, Ontario, L6H 0G5, Canada |
| Telephone | +1 289 910-0850 |
| Fax | — |
| — | |
| Website | https://www.cardiolrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001702123 |
| Description | Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Companys lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Additional info from NASDAQ: |
2026-04-28 11:27
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Read more
2026-04-21 13:06
Understanding Clinical Trials: What Each Stage Means and Why Phase III Matters
Read more
2026-04-14 11:24
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Read more
2026-03-31 17:48
New Form 40-F - Cardiol Therapeutics Inc. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001104659-26-037844 <b>Size:</b> 8 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT01581697 | Impact of Consumption of Oats in Lipid Profile of Children and Adolescents With… | Phase1 | Atherosclerosis | Unknown | — | — | ClinicalTrials.gov |
| NCT00960921 | Study of the Effects of Iron on Lung Blood Pressure at High Altitude | Phase2 | Hypertension, Pulmonary | Withdrawn | — | — | ClinicalTrials.gov |
| NCT01327833 | CODE Registry - Cardiac Arrest Outcomes Data Evaluation | — | Cardiac Arrest | Completed | — | — | ClinicalTrials.gov |
| NCT07500025 | Categorizing Patient Risk for Tricuspid Regurgitation (TR) Intervention With Ad… | — | Tricuspid Regurgitation (TR) | Not_Yet_Recruiting | 2027-07-10 | 2028-07-10 | ClinicalTrials.gov |
| NCT06177704 | Recurrent or Persistent Device Related Thrombus After Left Atrial Appendage Occ… | — | Percutaneous Left Atrial Appendage Occlusion (LAAO) | Not_Yet_Recruiting | 2026-12-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT07558018 | Evaluation of the Systemic Microcirculation as a Surrogate for Coronary Microci… | — | Angina, Microvascular | Not_Yet_Recruiting | 2026-08-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07477405 | Drug-coatEd Balloon Multicentric Registry in Spain and PORTugal | — | Coronary Artery Disease (CAD) | Not_Yet_Recruiting | 2026-08-01 | 2029-12-30 | ClinicalTrials.gov |
| NCT06413160 | The Cardiovascular-Renal-Metabolic (CRM) Syndrome Survey in Jordan | — | Cardiovascular-renal-metabolic Syndrome | Not_Yet_Recruiting | 2026-07-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT07563725 | Vascular Aging and Microcirculation: Physiological Aspects of Vascular Aging in… | — | Aging Problems | Not_Yet_Recruiting | 2026-06-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07450287 | CardioNETPOL National Registry of Carcinoid Heart Disease | — | Carcinoid Heart Disease | Not_Yet_Recruiting | 2026-06-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT07234422 | The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evalu… | Phase3 | Heart Failure | Not_Yet_Recruiting | 2026-05-01 | 2030-12-01 | ClinicalTrials.gov |
| NCT07462910 | Diaphragmatic Evaluation by Fluoroscopy to Identify Phrenic Nerve Dysfunction R… | Na | Atrial Fibrillation | Not_Yet_Recruiting | 2026-05-01 | 2027-05-31 | ClinicalTrials.gov |
| NCT07567378 | CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-s… | — | Psoriatic Arthritis | Not_Yet_Recruiting | 2026-05-01 | 2029-05-01 | ClinicalTrials.gov |
| NCT07534163 | III Brazilian Registry of Heart Failure | — | Heart Failure | Not_Yet_Recruiting | 2026-04-20 | 2028-10-01 | ClinicalTrials.gov |
| NCT07552948 | Radial vs Vena No-Touch Assessment | Na | Coronary Artery Atherosclerosis | Recruiting | 2026-04-06 | 2029-04-01 | ClinicalTrials.gov |
| NCT07419139 | Calibration Study PREDICT - Prehospital Triage for Suspected Acute Coronary Syn… | — | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Not_Yet_Recruiting | 2026-04-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT07539701 | An Initial Experience With the Disposable Celsio Cryocatheter System for Diagno… | Na | Lung Cancer (Diagnosis) | Not_Yet_Recruiting | 2026-03-23 | 2028-03-23 | ClinicalTrials.gov |
| NCT07372859 | Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Sy… | Na | Healthy Volunteer | Not_Yet_Recruiting | 2026-03-22 | 2026-09-30 | ClinicalTrials.gov |
| NCT07409441 | Korea Acute Myocardial Infarction Registry | — | Myocardial Infarction, Acute | Not_Yet_Recruiting | 2026-03-01 | 2031-12-31 | ClinicalTrials.gov |
| NCT07409831 | Incretin-based Therapies, Nutrition, and Physical Activity | Na | Obesity & Overweight | Not_Yet_Recruiting | 2026-03-01 | 2028-03-01 | ClinicalTrials.gov |
| NCT07435337 | Effect of Nalbuphine Versus Fentanyl on Hemdoynamic Effects of Laryngoscopy | Phase4 | Laryngoscopy | Recruiting | 2026-02-21 | 2026-05-21 | ClinicalTrials.gov |
| NCT07511257 | Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With … | Phase4 | Coronary Artery Ectasia | Recruiting | 2026-02-11 | 2029-06-01 | ClinicalTrials.gov |
| NCT07327853 | How Often Does the Fecal Test for Occult Blood Turn Positive After Using Blood … | — | Gastrointestinal Bleeding | Not_Yet_Recruiting | 2026-02-01 | 2027-04-30 | ClinicalTrials.gov |
| NCT07370467 | Transcatheter Mitral and Tricuspid Interventions: a Cardiac Magnetic Resonance … | — | Mitral Insufficiency | Not_Yet_Recruiting | 2026-01-30 | 2026-01-30 | ClinicalTrials.gov |
| NCT07310992 | Effect of Meditation as an Adjunct to Cardiac Rehabilitation | Na | High Blood Pressure (& [Essential Hypertension]) | Not_Yet_Recruiting | 2026-01-15 | 2028-01-15 | ClinicalTrials.gov |
| NCT07343674 | PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™… | — | Severe Symptomatic Aortic Stenosis (Defined as New York Heart Association (NYHA) Class ≥ II) | Recruiting | 2026-01-14 | 2028-04-01 | ClinicalTrials.gov |
| NCT07346898 | Insertion of a Transoesophageal Echocardiography Probe Using McGRATH | Na | Echocardiography, Transesophageal | Not_Yet_Recruiting | 2026-01-01 | 2026-06-30 | ClinicalTrials.gov |
| NCT07543666 | The ISAR InflEx Trial (Inflammation and Exercise) | Na | Inflammation | Recruiting | 2026-01-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT07298668 | Cardiovascular Risk Factors in Middle Eastern Patients With Stroke | — | Stroke | Not_Yet_Recruiting | 2025-12-31 | 2027-01-31 | ClinicalTrials.gov |
| NCT07251660 | Comparison of Early Postoperative Outcomes Between Minimally Invasive Valve Sur… | Na | Heart Valve Diseases or Prosthesis | Not_Yet_Recruiting | 2025-12-15 | 2026-08-15 | ClinicalTrials.gov |
| NCT04218786 | Effect of Colchicine in Patients With Myocardial Infarction | Phase2 | Myocardium; Injury | Withdrawn | 2025-12-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT07366723 | The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients … | Na | Mitral Valve Prolapse | Active_Not_Recruiting | 2025-12-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07238426 | ATTRACT-52: Primary Care Cardiac Amyloidosis Screening in Ordu, Turkey | — | Cardiac Amyloidosis | Enrolling_By_Invitation | 2025-12-01 | 2026-10-31 | ClinicalTrials.gov |
| NCT06952348 | HYPERtension Reduction Through WALKing Stairs Versus Brisk Walking | Na | Metabolic Disease | Recruiting | 2025-11-27 | 2029-05-01 | ClinicalTrials.gov |
| NCT07181317 | WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction:… | — | Myocardial Infarction, Acute | Recruiting | 2025-11-25 | 2029-09-30 | ClinicalTrials.gov |
| NCT07508930 | Russian Extreme Hypertriglyceridemia Registry | — | Hypertriglyceridemia | Recruiting | 2025-11-20 | 2045-12-01 | ClinicalTrials.gov |
| NCT07456085 | Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves | Phase3 | Valvular Heart Disease Patients | Enrolling_By_Invitation | 2025-11-13 | 2027-04-12 | ClinicalTrials.gov |
| NCT07369856 | Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy… | Na | Heart Failure | Recruiting | 2025-11-04 | 2027-12-30 | ClinicalTrials.gov |
| NCT07193225 | Microflow3D - Non-invasive Mapping of Coronary Arteries and the Cerebral Vascul… | Na | Carotid Atherosclerosis | Not_Yet_Recruiting | 2025-11-01 | 2027-11-30 | ClinicalTrials.gov |
| NCT07208331 | Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway… | — | Atherosclerotic Cardiovascular Disease (ASCVD) | Not_Yet_Recruiting | 2025-10-06 | 2030-10-01 | ClinicalTrials.gov |
| NCT07294937 | Study Protocol: 10-Year Follow-Up of Patients Screened for Cardiovascular Risk … | — | Cardiovascular Diseases (CVD) | Recruiting | 2025-10-01 | 2026-10-01 | ClinicalTrials.gov |
| NCT07176507 | MULTIVALVE : A Prospective Multicentre Study of Multiple and Mixed Valvular Hea… | — | Valvular Heart Disease | Not_Yet_Recruiting | 2025-10-01 | 2032-10-01 | ClinicalTrials.gov |
| NCT07500610 | Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact … | — | Peripheral Vascular Disease | Recruiting | 2025-09-25 | 2026-07-01 | ClinicalTrials.gov |
| NCT07157670 | Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic St… | — | Cardiotoxicity | Not_Yet_Recruiting | 2025-09-15 | 2028-09-15 | ClinicalTrials.gov |
| NCT06833138 | Atrioventricular Node Ablation and Conduction System Pacing in Patients With We… | Na | Heart Failure With Preserved Ejection Fraction | Recruiting | 2025-09-10 | 2029-12-31 | ClinicalTrials.gov |
| NCT07112391 | Pressure-Volume Loop Assessment in Valvular Heart Disease | — | Heart Failure | Recruiting | 2025-09-04 | 2027-09-04 | ClinicalTrials.gov |
| NCT07144189 | AI Assessment of Low-Gradient Aortic Stenosis Severity Based on Echocardiography | — | Low-gradient Aortic Stenosis | Recruiting | 2025-08-20 | 2026-08-20 | ClinicalTrials.gov |
| NCT06917729 | Breathing Exercises of CardioBreath Application on Autonomic and Vascular Funct… | Na | Hypertension | Not_Yet_Recruiting | 2025-08-01 | 2027-09-20 | ClinicalTrials.gov |
| NCT06878729 | Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI | Na | Coronary Artery Disease | Recruiting | 2025-07-28 | 2028-09-30 | ClinicalTrials.gov |
| NCT07341295 | Perception of Stress and Safety Culture: Analysis of Critical Factors in Health… | — | Work Stress | Completed | 2025-07-14 | 2025-09-10 | ClinicalTrials.gov |
| NCT07254572 | Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With C… | Phase4 | Coronary Artery Disease | Recruiting | 2025-07-10 | 2029-08-01 | ClinicalTrials.gov |
| NCT07021313 | Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation | Na | Atrial Fibrillation | Recruiting | 2025-06-20 | 2028-06-01 | ClinicalTrials.gov |
| NCT06736665 | Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified… | Na | Coronary Arterial Disease (CAD) | Recruiting | 2025-06-12 | 2027-12-01 | ClinicalTrials.gov |
| NCT07034274 | National Tunisian Clinical Registry on CardioVascular Secondary Prevention Clin… | — | Secondary Prevention | Recruiting | 2025-06-09 | 2025-07-31 | ClinicalTrials.gov |
| NCT06986733 | Study of Management Alterations Resulting From CaRi-Heart® Technology in Patien… | — | Cardiovascular Diseases | Not_Yet_Recruiting | 2025-06-01 | 2025-12-31 | ClinicalTrials.gov |
| NCT07245927 | Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmon… | — | Pulmonary Embolism Acute Massive | Recruiting | 2025-06-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT07330622 | Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusi… | — | Coronary Occlusion | Recruiting | 2025-05-21 | 2026-06-01 | ClinicalTrials.gov |
| NCT07019077 | Incidence of Late Haemorrhage After Invasive Gastroenterological Endoscopic Man… | — | Bleeding | Recruiting | 2025-05-19 | 2027-06-30 | ClinicalTrials.gov |
| NCT06818435 | Portuguese Registry With Meril Myval THV Series - MyPORTuVal Registry | — | Aortic Valve Stenosis | Recruiting | 2025-05-13 | 2028-11-01 | ClinicalTrials.gov |
| NCT06985082 | This is an Observational Study That Aims to Demonstrate Postoperative Risk Fact… | — | Arrhythmia | Not_Yet_Recruiting | 2025-05-01 | 2025-08-01 | ClinicalTrials.gov |
| NCT06943365 | Role of Anti-TREK-1 Autoantibodies in SCVF | — | Short-coupled Ventricular Fibrillation | Enrolling_By_Invitation | 2025-05-01 | 2028-12-31 | ClinicalTrials.gov |
| NCT07094737 | The Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-… | — | Cardiac Rehab | Recruiting | 2025-05-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT06546137 | National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthca… | — | Cardiomyopathy, Hypertrophic | Recruiting | 2025-04-30 | 2026-08-31 | ClinicalTrials.gov |
| NCT06708299 | CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | Phase3 | Recurrent Pericarditis | Recruiting | 2025-04-07 | 2026-10-21 | ClinicalTrials.gov |
| NCT06922994 | Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH) | Phase2 | Arrhythmogenic Cardiomyopathy | Recruiting | 2025-03-31 | 2026-11-30 | ClinicalTrials.gov |
| NCT06655480 | Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF | Phase2 | HFpEF | Recruiting | 2025-03-18 | 2027-12-31 | ClinicalTrials.gov |
| NCT06565793 | A MAajor RAdiation-based PCI Study in STEMI and NSTEMI | — | Myocardial Infarction (MI) | Not_Yet_Recruiting | 2025-03-01 | 2025-12-31 | ClinicalTrials.gov |
| NCT07240441 | Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven V… | Na | Ventricular Tachycardias | Recruiting | 2025-02-03 | 2030-11-30 | ClinicalTrials.gov |
| NCT06687122 | Egg Intake, Metabolic Outcomes and Choline Levels | Na | Obesity and Obesity-related Medical Conditions | Recruiting | 2025-01-24 | 2025-12-01 | ClinicalTrials.gov |
| NCT06832644 | Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular D… | Na | Cardiovascular Risk | Recruiting | 2025-01-22 | 2030-01-01 | ClinicalTrials.gov |
| NCT06798714 | The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac… | Phase4 | Coronary Artery Disease | Recruiting | 2025-01-20 | 2026-02-20 | ClinicalTrials.gov |
| NCT06742970 | Telematic Intervention for Reversing Frailty Among Older Patients with Aortic S… | Na | Aortic Stenosis | Not_Yet_Recruiting | 2025-01-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT06764056 | Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver… | Na | Metabolic Associated Fatty Liver Disease | Not_Yet_Recruiting | 2025-01-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT05314140 | Towards Optimal Screening and Management of Coronary Artery Disease in Diabetes… | — | Diabetes Mellitus | Withdrawn | 2025-01-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT06645249 | Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion … | Phase4 | Atrial Fibrillation (AF) | Not_Yet_Recruiting | 2024-12-10 | 2026-10-01 | ClinicalTrials.gov |
| NCT06748924 | Chronic Coronary Syndrome Snapshot Study | — | Chronic Coronary Syndrome | Recruiting | 2024-12-02 | 2025-06-02 | ClinicalTrials.gov |
| NCT06688448 | Valvular Assessment of New Generation Aortic Replacement Devices | Na | Aortic Regurgitation Disease | Recruiting | 2024-12-01 | 2036-12-01 | ClinicalTrials.gov |
| NCT06500143 | Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agon… | — | Gastric Retention | Completed | 2024-10-09 | 2025-02-28 | ClinicalTrials.gov |
| NCT06683001 | National Heart Failure Registry | — | Chronic Heart Failure | Recruiting | 2024-10-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT06579807 | Cardiac Rehabilitation and Coronary Artery Disease | Na | Coronary Artery Disease | Recruiting | 2024-10-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT06753591 | PRemature Acute Myocardial Infarction Register of Serbia | — | Acute Coronary Syndromes | Recruiting | 2024-09-25 | 2026-09-25 | ClinicalTrials.gov |
| NCT07452991 | ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Pat… | Na | Pulmonary Embolism (PE) | Recruiting | 2024-09-10 | 2030-09-10 | ClinicalTrials.gov |
| NCT05293080 | Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STR… | Phase3 | Acute Ischemic Stroke | Not_Yet_Recruiting | 2024-09-01 | 2029-03-01 | ClinicalTrials.gov |
| NCT06814951 | Acute Effect of the Thoraco-abdominal Rebalance Method Postoperative Cardiac Su… | Na | Respiratory Complications | Recruiting | 2024-09-01 | 2026-04-01 | ClinicalTrials.gov |
| NCT07124377 | Phenotypic Manifestations of Hereditary ATTR Amyloidosis | — | Hereditary Amyloidosis, Transthyretin-Related | Recruiting | 2024-09-01 | 2027-03-01 | ClinicalTrials.gov |
| NCT06469814 | Snapshot Study on Patients With Heart Failure | — | Heart Failure | Not_Yet_Recruiting | 2024-09-01 | 2025-06-01 | ClinicalTrials.gov |
| NCT05785065 | Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung … | Phase2 | Systemic Sclerosis With Lung Involvement | Recruiting | 2024-08-29 | 2028-12-01 | ClinicalTrials.gov |
| NCT06949319 | Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Dia… | — | Atrial Fibrillation (AF) | Recruiting | 2024-08-16 | 2025-09-01 | ClinicalTrials.gov |
| NCT07017296 | Microencapsulated Pomegranate Juice as Anti-Hypertensive | Na | Clinical Trial | Completed | 2024-08-15 | 2025-05-01 | ClinicalTrials.gov |
| NCT06535620 | Comparison of the Effect of Red Wine With Alcohol on Flow-mediated Dilation Ver… | Phase1 | Healthy | Not_Yet_Recruiting | 2024-08-13 | 2024-11-15 | ClinicalTrials.gov |
| NCT04512456 | Cardiovascular Responses to Exercise in People Living With HIV/AIDS: Effects of… | Na | HIV Infections | Recruiting | 2024-08-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT06447532 | Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammato… | — | Breast Cancer | Enrolling_By_Invitation | 2024-08-01 | 2027-02-01 | ClinicalTrials.gov |
| NCT06509074 | Beta-Blockers in Takotsubo Syndrome Study | Phase4 | Takotsubo Cardiomyopathy | Not_Yet_Recruiting | 2024-08-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT07127640 | Effect of an Aerobic Exercise Session on Cardiovascular and Autonomic Parameter… | Na | Cardiomyopathy, Hypertrophic | Active_Not_Recruiting | 2024-07-29 | 2026-06-01 | ClinicalTrials.gov |
| NCT06521307 | Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing … | Na | Acute Kidney Injury | Not_Yet_Recruiting | 2024-07-24 | 2026-07-24 | ClinicalTrials.gov |
| NCT06514170 | Gastrointestinal Dysfunction in Aortic Surgery Patients | — | Aortic Aneurysm | Recruiting | 2024-07-23 | 2026-06-01 | ClinicalTrials.gov |
| NCT06452901 | PROgressive struCturEd Simulation-based Surgical Training Program (PROCESS) - O… | Na | Vascular Diseases | Not_Yet_Recruiting | 2024-07-21 | 2025-01-15 | ClinicalTrials.gov |
| NCT06499714 | HighCycle Study: Effect of High Altitude on Acute Mountain Sickness in Women Re… | — | Acute Mountain Sickness | Recruiting | 2024-07-15 | 2025-12-31 | ClinicalTrials.gov |
| NCT06498505 | HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compar… | Phase4 | High Altitude | Recruiting | 2024-07-15 | 2025-12-31 | ClinicalTrials.gov |
| NCT06187077 | Techquity by FAITH! | Na | Health Equity | Recruiting | 2024-07-11 | 2026-06-30 | ClinicalTrials.gov |
| NCT06627920 | Validation of a Smartwatch for Blood Pressure Monitoring | — | Blood Pressure | Completed | 2024-07-10 | 2024-11-21 | ClinicalTrials.gov |
| NCT06489730 | HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pres… | — | High Altitude Pulmonary Hypertension | Not_Yet_Recruiting | 2024-07-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT06465459 | Post-marketing Clinical Study of the LAMBRE System for Left Auricle Closure | — | Atrial Fibrillation | Recruiting | 2024-06-10 | 2027-12-01 | ClinicalTrials.gov |
| NCT06789211 | Outcomes in Moderate Mixed Aortic Valve Disease | — | Mixed Aortic Valve Disease | Recruiting | 2024-06-06 | 2026-12-01 | ClinicalTrials.gov |
| NCT06540352 | A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Dru… | Phase2 | Atrial Fibrillation | Active_Not_Recruiting | 2024-06-03 | 2026-12-31 | ClinicalTrials.gov |
| NCT06683040 | Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Art… | Phase2 | Pulmonary Arterial Hypertension | Active_Not_Recruiting | 2024-06-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT06420830 | Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry W… | — | Aortic Valve Stenosis | Recruiting | 2024-05-16 | 2034-09-01 | ClinicalTrials.gov |
| NCT06799273 | MECKI-Amyloidosis: Assessment of the Exercise Capacity and Prognosis of Patient… | — | Cardiac Amyloidosis | Recruiting | 2024-05-07 | 2027-05-01 | ClinicalTrials.gov |
| NCT06400927 | Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure | Na | Heart Failure | Recruiting | 2024-05-07 | 2027-09-13 | ClinicalTrials.gov |
| NCT06007495 | Pilot Physiological Evaluation of an Investigational Mask with Expiratory Washo… | Na | Acute Hypercapnic Respiratory Failure | Recruiting | 2024-05-06 | 2025-12-01 | ClinicalTrials.gov |
| NCT07213531 | Enhanced Valves Interventions and Safe AI Generated End Results | — | Heart Valve Disease | Recruiting | 2024-05-01 | 2029-05-01 | ClinicalTrials.gov |
| NCT06641921 | Strategy TO Prevent Decompensated Heart Failure | Na | Heart Failure | Completed | 2024-05-01 | 2025-11-01 | ClinicalTrials.gov |
| NCT05395598 | Incidence of Major Complication in Case of Thoracic Aortic Aneurysm | — | Thoracic Aortic Aneurysm | Recruiting | 2024-04-18 | 2031-10-01 | ClinicalTrials.gov |
| NCT06633159 | MitraClip in Patients With Heart Failure | — | Mitral Regurgitation | Recruiting | 2024-04-15 | 2025-12-01 | ClinicalTrials.gov |
| NCT06372509 | A Proteomic Analysis for Understanding the Link Between Migraine and Cardiovasc… | — | Coronary Artery Disease | Unknown | 2024-04-03 | 2025-10-30 | ClinicalTrials.gov |
| NCT07430644 | TotalCardiology Letters Study | Na | Cardiovascular Diseases (CVD) | Completed | 2024-04-02 | 2025-12-31 | ClinicalTrials.gov |
| NCT06331819 | Clinical Association Between Obstructive Sleep Apnea, Facial Pigmentation, and … | — | Obstructive Sleep Apnea | Recruiting | 2024-03-10 | 2026-03-01 | ClinicalTrials.gov |
| NCT06288633 | Cardioneuroablation for Bradyarrhythmia | Na | Bradycardia | Recruiting | 2024-03-04 | 2027-02-01 | ClinicalTrials.gov |
| NCT06278519 | CARdiAc Mri and BiOLogical samplEs at the Acute Phase of a Myocardial Infarctio… | Na | Myocardial Infarction | Active_Not_Recruiting | 2024-03-01 | 2026-08-01 | ClinicalTrials.gov |
| NCT05859048 | Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of… | Na | Heart Failure | Recruiting | 2024-03-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT06279663 | Management Tactics for Patients High Risk With Acute Coronary Syndrome Without … | Na | Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients | Recruiting | 2024-02-29 | 2029-12-31 | ClinicalTrials.gov |
| NCT06262295 | A Safety and Effectiveness Monitoring in France for AVEIR VR LP and AVEIR AR LP… | — | Pacemaker | Recruiting | 2024-02-14 | 2029-09-01 | ClinicalTrials.gov |
| NCT06241534 | Supporting Methods in Cardiovascular Diseases Rehabilitation | Na | Cardiovascular Diseases | Completed | 2024-02-01 | 2024-05-31 | ClinicalTrials.gov |
| NCT06704321 | Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut… | Na | Non-Alcoholic Fatty Liver Disease | Recruiting | 2024-01-31 | 2025-12-01 | ClinicalTrials.gov |
| NCT06376630 | Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Ad… | Na | Myocardial Infarction | Recruiting | 2024-01-29 | 2030-01-29 | ClinicalTrials.gov |
| NCT06199869 | Cardiovascular Patients With no Standard Modifiable Risk Factors | — | Cardiovascular Risk Factors | Completed | 2024-01-22 | 2025-01-31 | ClinicalTrials.gov |
| NCT06282302 | Effect of Isometric and Aerobic Physical Exercise on Blood Pressure Levels in H… | Na | Hypertension,Essential | Unknown | 2024-01-20 | 2024-04-30 | ClinicalTrials.gov |
| NCT05879679 | Pilot Study on the Validity of the Metacognitive Hub Model of Craving in Bulimi… | — | Bulimia Nervosa | Recruiting | 2024-01-08 | 2025-10-01 | ClinicalTrials.gov |
| NCT06179329 | One-year Patency Comparison Between Radial Artery and No-touch Saphenous Vein G… | Na | Cardiac Disease | Recruiting | 2024-01-01 | 2027-12-30 | ClinicalTrials.gov |
| NCT06584266 | Multimodal Cardiac Imaging Registry in Patients with Atrial Fibrillation | — | Atrial Fibrillation and Flutter | Recruiting | 2024-01-01 | 2027-09-01 | ClinicalTrials.gov |
| NCT05745272 | Cardiovascular Risk Categories and Attaining LDL-C Targets in Middle Eastern Ad… | — | Atherosclerotic Cardiovascular Risk | Terminated | 2023-12-11 | 2023-12-24 | ClinicalTrials.gov |
| NCT06139653 | CardioBreathApp vs IMT in Heart Failure | Na | Congestive Heart Failure | Completed | 2023-12-01 | 2025-01-31 | ClinicalTrials.gov |
| NCT06156670 | Russian Registry of Endovascular Closure of PFO | — | Patent Foramen Ovale | Recruiting | 2023-12-01 | 2025-12-31 | ClinicalTrials.gov |
| NCT06048003 | Armenian National Registry of Myocardial Infarction | — | ST Elevation Myocardial Infarction | Unknown | 2023-12-01 | 2025-12-30 | ClinicalTrials.gov |
| NCT06838611 | ChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid Regurgi… | — | Tricuspid Regurgitation | Recruiting | 2023-11-14 | 2028-07-01 | ClinicalTrials.gov |
| NCT06173960 | 3-year Follow-up of Patients Treated With Jetstream Combined With Ranger for Ca… | — | Peripheral Artery Disease | Completed | 2023-11-03 | 2024-01-29 | ClinicalTrials.gov |
| NCT05923138 | Nutritional Approach in Adults Followed up in Spanish Hospitals for Heart Failu… | Na | Heart Failure | Unknown | 2023-11-02 | 2024-12-01 | ClinicalTrials.gov |
| NCT05934409 | Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic … | Na | Diabetes Mellitus Type 2 | Recruiting | 2023-11-01 | 2028-05-01 | ClinicalTrials.gov |
| NCT06169241 | Effect of Nitrate Supplementation on Blood Pressure and Microvascular Function … | Early_Phase1 | Arterial Hypertension | Recruiting | 2023-11-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT06275763 | Optimal Medical Treatment of Difficult-to-treat Hypertension | Phase4 | Hypertension | Unknown | 2023-10-20 | 2025-12-31 | ClinicalTrials.gov |
| NCT05980923 | Thyroid Profiles in Patients With Acute Illness | — | Thyroid Dysfunction | Withdrawn | 2023-10-15 | 2025-01-30 | ClinicalTrials.gov |
| NCT05992012 | Myocardial Infarction Triggers and Onset in Jordan Study 2 | — | Triggers of Acute Myocardial Infarction | Terminated | 2023-10-01 | 2023-12-25 | ClinicalTrials.gov |
| NCT06248658 | Assessment of the Impact of Clinical Decision Support Systems Included in Elect… | — | Chronic Heart Failure (CHF) | Completed | 2023-10-01 | 2025-05-31 | ClinicalTrials.gov |
| NCT06015997 | Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR | — | ATTR Amyloidosis Wild Type | Unknown | 2023-10-01 | 2025-11-01 | ClinicalTrials.gov |
| NCT06190743 | Perception of Cardiovascular Risk | — | Cardiovascular Diseases | Unknown | 2023-09-29 | 2024-09-01 | ClinicalTrials.gov |
| NCT06503965 | Tunisian Registry of Trans Catheter Aortic Valve Implantation | — | Tunisian Patients Already Implanted With a TAVI | Recruiting | 2023-09-23 | 2025-12-31 | ClinicalTrials.gov |
| NCT06049992 | STylet-driven vs. LumenlEss Lead in Left-Bundle-Branch Pacing | Na | Left Bundle-Branch Pacing | Unknown | 2023-09-21 | 2025-09-22 | ClinicalTrials.gov |
| NCT06584734 | Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemo… | Na | Renal Dialysis | Completed | 2023-09-17 | 2024-10-30 | ClinicalTrials.gov |
| NCT06013813 | Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI | Na | STEMI - ST Elevation Myocardial Infarction | Unknown | 2023-09-07 | 2025-02-01 | ClinicalTrials.gov |
| NCT06085014 | Clinical and Electrophysiological Predictors of Arrhythmic Recurrence in Patien… | — | Atrial Fibrillation Paroxysmal | Unknown | 2023-09-06 | 2024-09-01 | ClinicalTrials.gov |
| NCT05948969 | Transform CV Risk in Diabetes | Na | Type 2 Diabetes | Unknown | 2023-09-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT03672760 | Inspiratory Muscle Training X CardioBreath App Effects On Vagal Modulation And … | Na | Postmenopausal Disorder | Recruiting | 2023-09-01 | 2025-07-30 | ClinicalTrials.gov |
| NCT06002321 | Right Ventricular Dysfunction in Chronic Heart Failure | — | Chronic Heart Failure | Not_Yet_Recruiting | 2023-09-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT05877326 | Anaesthetic Depth and Short Term Delirium Post Cardiac Surgery Intervention | Na | Post-operative Delirium | Unknown | 2023-09-01 | 2025-05-10 | ClinicalTrials.gov |
| NCT05992116 | Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced E… | — | Iron Deficiency | Completed | 2023-09-01 | 2025-02-22 | ClinicalTrials.gov |
| NCT07147595 | Chronic Effect of Isometric Exercise on Blood Pressure in Patients With Hyperte… | Na | Hypertension (HTN) | Completed | 2023-08-31 | 2025-02-28 | ClinicalTrials.gov |
| NCT05960968 | Gender Specific Registry in Subjects Hospitalized With Heart Failure in Santiago | — | Heart Failure | Recruiting | 2023-08-11 | 2026-07-01 | ClinicalTrials.gov |
| NCT06341166 | Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With M… | — | Mitral Valve Prolapse | Recruiting | 2023-06-19 | 2026-06-19 | ClinicalTrials.gov |
| NCT05956249 | Online Cognitive Behavioral Groupherapy for Mothers of Babies With Congenital H… | Na | Depressive Symptoms | Completed | 2023-06-10 | 2025-02-18 | ClinicalTrials.gov |
| NCT06587074 | Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmo… | — | Idiopathic Pulmonary Arterial Hypertension | Active_Not_Recruiting | 2023-05-30 | 2025-07-22 | ClinicalTrials.gov |
| NCT06337461 | Computational mOdelliNg of myoCardial pERfusion to Improve ouTcome Prediction B… | — | Chronic Coronary Syndrome | Recruiting | 2023-05-22 | 2026-05-30 | ClinicalTrials.gov |
| NCT06410690 | Trustworthy, Integrated Artificial Intelligence Tools for Predicting High-risk … | — | Coronary Artery Disease | Unknown | 2023-05-22 | 2026-01-22 | ClinicalTrials.gov |
| NCT05869214 | Middle East African Registry Women CardioVascular Disease | — | Heart Failure | Unknown | 2023-05-10 | 2023-07-10 | ClinicalTrials.gov |
| NCT06070974 | ExosoMe as Integrative Tool for pRognostic Stratification of Adverse Cardiac re… | — | STEMI | Recruiting | 2023-05-03 | 2026-04-30 | ClinicalTrials.gov |
| NCT05591443 | Artificial Intelligence and Smart Wearable Technologies for Early Detection of … | — | Heart Failure，Congestive | Not_Yet_Recruiting | 2023-05-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT05973188 | Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Le… | Phase4 | Left Ventricular Thrombus | Unknown | 2023-05-01 | 2024-06-30 | ClinicalTrials.gov |
| NCT06070519 | A Dynamic Evaluation of Chronic Heart Failure Prognosis: the MECKI Score | Na | HF - Heart Failure | Recruiting | 2023-05-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT05560776 | Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLC | Na | Lung Cancer | Active_Not_Recruiting | 2023-05-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT06103123 | MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Su… | — | Myocarditis | Unknown | 2023-04-23 | 2025-04-23 | ClinicalTrials.gov |
| NCT05454150 | Balloon-Expandable Versus Self-expanding Transcatheter Heart Valve for Treatmen… | Na | Aortic Valve Stenosis | Active_Not_Recruiting | 2023-04-19 | 2035-12-29 | ClinicalTrials.gov |
| NCT05793398 | Biomaterial Collection - and Analysis in Cardiac Sarcoidosis | — | Cardiac Sarcoidosis | Not_Yet_Recruiting | 2023-04-01 | 2029-04-01 | ClinicalTrials.gov |
| NCT05619601 | Gender Differences in Prevention Strategies and Therapeutic Adherence After Acu… | — | Gender Differences | Completed | 2023-03-08 | 2026-01-18 | ClinicalTrials.gov |
| NCT05432024 | Evaluation of Ablation Lesions Using Cardiovascular Magnetic Resonance Imaging | — | Atrial Fibrillation | Recruiting | 2023-03-08 | 2028-04-01 | ClinicalTrials.gov |
| NCT05149859 | Compuls-BED-Severity | — | Binge-Eating Disorder | Recruiting | 2023-03-07 | 2025-12-31 | ClinicalTrials.gov |
| NCT05748496 | Study to Evaluate Efficacy of Brief Behavioral and Sleep Hygiene Education With… | Na | Sleep | Completed | 2023-02-20 | 2023-04-28 | ClinicalTrials.gov |
| NCT07149714 | Temporary MCS With the iVAC 2L Transaortic Device in High-risk PCI | Na | Ischemic Cardiovascular Disease | Recruiting | 2023-02-17 | 2029-02-17 | ClinicalTrials.gov |
| NCT05660798 | Effects of Switching From Cigarettes to Tobacco Heating System on Coronary Athe… | Na | Coronary Artery Disease | Recruiting | 2023-02-09 | 2025-12-31 | ClinicalTrials.gov |
| NCT05242835 | Management of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Sur… | Na | Obesity | Recruiting | 2023-02-03 | 2027-03-01 | ClinicalTrials.gov |
| NCT05701319 | Left Main Intervention in Myocardial Infarction and Acute Coronary Syndromes | — | LMN Disease | Unknown | 2023-02-01 | 2025-02-01 | ClinicalTrials.gov |
| NCT06311708 | Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against A… | — | Arrhythmogenic Right Ventricular Cardiomyopathy | Recruiting | 2023-01-31 | 2030-07-11 | ClinicalTrials.gov |
| NCT06031974 | Dietary Intervention to Stop Coronary Atherosclerosis in Computed Tomography: L… | — | Coronary Artery Disease | Unknown | 2023-01-13 | 2024-03-31 | ClinicalTrials.gov |
| NCT05459233 | Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheteriza… | Na | Aortic Valve Stenosis | Recruiting | 2023-01-11 | 2029-09-01 | ClinicalTrials.gov |
| NCT06721442 | Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes P… | Phase4 | Arrhythmias, Cardiac | Completed | 2023-01-10 | 2024-07-10 | ClinicalTrials.gov |
| NCT05494788 | Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) | Phase2 | Recurrent Pericarditis | Completed | 2023-01-09 | 2024-09-06 | ClinicalTrials.gov |
| NCT05457712 | Nutrition In Preoperative Pediatric Congenital Heart Disease | Na | Congenital Heart Defects | Unknown | 2023-01-09 | 2024-05-02 | ClinicalTrials.gov |
| NCT05964738 | Effect of Diuretics Withdrawal in Chronic Heart Failure With Reduced Ejection F… | Phase2 | Heart Failure | Completed | 2022-12-19 | 2024-10-31 | ClinicalTrials.gov |
| NCT05629767 | Tracking of Lipid Lowering Therapy in Jordan | — | Dyslipidemias | Terminated | 2022-12-11 | 2024-01-02 | ClinicalTrials.gov |
| NCT05146375 | Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2) | — | Thoracic Aortic Aneurysm | Unknown | 2022-11-24 | 2025-11-30 | ClinicalTrials.gov |
| NCT04291898 | Comparison of Devices for Atrial Septal Defects Closure: A Pilot Study | Na | Atrial Septal Defect | Unknown | 2022-11-23 | 2024-10-01 | ClinicalTrials.gov |
| NCT05773170 | Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intra… | — | Paroxysmal Atrial Fibrillation | Completed | 2022-11-11 | 2023-06-01 | ClinicalTrials.gov |
| NCT06277297 | Prognotic Role of CMR in Takotsubo Syndrome | — | Takotsubo Cardiomyopathy | Recruiting | 2022-11-09 | 2032-11-01 | ClinicalTrials.gov |
| NCT05955950 | Gratitude Intervention in Promoting Self-care in Patients With Myocardial Infar… | Na | Myocardial Infarction, Acute | Unknown | 2022-11-05 | 2024-07-05 | ClinicalTrials.gov |
| NCT05195866 | CRP for Respiratory Diagnosis in Kyrgyz Pediatric Practice | Na | Antibiotic Resistance | Completed | 2022-11-01 | 2023-04-06 | ClinicalTrials.gov |
| NCT05782023 | Secondary Cardiovascular Prevention Post-acute Myocardial Infarction (AMI) Thro… | Na | Acute Myocardial Infarction | Unknown | 2022-10-18 | 2025-09-01 | ClinicalTrials.gov |
| NCT05625607 | Polish Transcatheter Transfemoral Mitral Valve-in-Valve Implantation (Mitral Vi… | — | Mitral Insufficiency | Recruiting | 2022-10-17 | 2026-05-31 | ClinicalTrials.gov |
| NCT05729009 | The Evolution of Systemic Microvascular Reactivity in Heart Transplant Patients | — | Heart Transplantation | Recruiting | 2022-10-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT05572814 | Transform: Teaching, Technology, and Teams | Na | Heart Failure | Unknown | 2022-09-30 | 2023-12-31 | ClinicalTrials.gov |
| NCT05728047 | Evaluation of Systemic Microcirculation of Patients Undergoing Heart Valve Surg… | — | Microvascular Rarefaction | Completed | 2022-09-10 | 2024-09-01 | ClinicalTrials.gov |
| NCT05624658 | Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerabili… | Na | Dyslipidemias | Unknown | 2022-09-02 | 2024-05-01 | ClinicalTrials.gov |
| NCT05454111 | CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persi… | Na | Persistent Atrial Fibrillation | Unknown | 2022-09-01 | 2025-12-31 | ClinicalTrials.gov |
| NCT06065163 | Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome | Na | Cardiorenal Syndrome Type 1 | Unknown | 2022-09-01 | 2025-03-31 | ClinicalTrials.gov |
| NCT05750420 | Psychological Status and Self-care in Chronic Cardiovascular Disease | — | Anxiety | Completed | 2022-07-28 | 2023-01-12 | ClinicalTrials.gov |
| NCT05689970 | ST-segment Elevation Not Associated With Acute Cardiac Necrosis (LESTONNAC) | — | STEMI - ST Elevation Myocardial Infarction | Unknown | 2022-07-25 | 2024-07-24 | ClinicalTrials.gov |
| NCT05491200 | Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugr… | Phase4 | ST Elevated Myocardial Infarction | Recruiting | 2022-07-22 | 2028-08-01 | ClinicalTrials.gov |
| NCT06192524 | OPTImal PHARMacological Therapy for Patients With Heart Failure: The OPTIPHARM-… | — | Heart Failure | Unknown | 2022-07-18 | 2025-10-01 | ClinicalTrials.gov |
| NCT04703504 | RAndomized Controlled Trial of a Multiple INtervention proGram to Decrease Hear… | Na | Heart Decompensation | Terminated | 2022-07-15 | 2024-09-20 | ClinicalTrials.gov |
| NCT07386028 | Full Sternotomy vs Mini-sternotomy for Ascending Aortic Pathology | Na | Ascending Aortic Aneurysm | Recruiting | 2022-07-10 | 2027-12-01 | ClinicalTrials.gov |
| NCT06025864 | Protocol to Support Breastfeeding for Postpartum Women and Mothers of Babies Wi… | Na | Breastfeeding | Unknown | 2022-07-01 | 2024-02-20 | ClinicalTrials.gov |
| NCT05434923 | PORTHOS - PORTuguese Heart Failure Observational Study | — | Heart Failure | Completed | 2022-06-30 | 2023-09-18 | ClinicalTrials.gov |
| NCT05434962 | The Left Bundle Cardiac Resynchronization Therapy Trial | Na | Left Bundle-Branch Block | Active_Not_Recruiting | 2022-06-27 | 2025-08-31 | ClinicalTrials.gov |
| NCT05180240 | Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis | Phase2 | Acute Myocarditis | Completed | 2022-06-22 | 2025-02-04 | ClinicalTrials.gov |
| NCT05339841 | Italian Digital Primary Cardiovascular Prevention Study | Na | Healthy Population | Active_Not_Recruiting | 2022-06-10 | 2029-12-01 | ClinicalTrials.gov |
| NCT05795400 | Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amylo… | Na | Heart Failure With Reduced Ejection Fraction | Completed | 2022-06-01 | 2025-09-30 | ClinicalTrials.gov |
| NCT05367141 | Improvement Adherence to Clinical Practice Guidelines Using the Clinical Decisi… | Na | Atrial Fibrillation | Completed | 2022-05-17 | 2023-08-22 | ClinicalTrials.gov |
| NCT05579561 | Vegetarian Ketogenic Diet VS Omnivore Ketogenic Diet - Protocol of a Keto-vege … | Na | Diabetes Mellitus Type 2 in Obese | Unknown | 2022-05-11 | 2023-12-30 | ClinicalTrials.gov |
| NCT05770167 | Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure | — | Heart Failure | Unknown | 2022-05-06 | 2025-04-01 | ClinicalTrials.gov |
| NCT05764655 | Comparison of Troponin Assay With New POCT Method in the Decision-making Pathwa… | — | Chest Pain | Unknown | 2022-05-06 | 2023-07-01 | ClinicalTrials.gov |
| NCT05948241 | Online Psychological Support Group for Patients With Heart Failure and Depressi… | Na | Heart Failure | Unknown | 2022-05-05 | 2023-12-05 | ClinicalTrials.gov |
| NCT05916898 | The Lower Silesia Shockwave Registry | — | Safety Issues | Recruiting | 2022-05-01 | 2027-05-01 | ClinicalTrials.gov |
| NCT06451146 | Lower Silesian Orbital Atherectomy Registry (LOAR) | — | Safety Issues | Recruiting | 2022-05-01 | 2027-05-01 | ClinicalTrials.gov |
| NCT05029570 | Heart Rate Regularization in Atrial Fibrilation and Heart Failure | Na | Heart Failure | Recruiting | 2022-04-29 | 2030-09-01 | ClinicalTrials.gov |
| NCT05369585 | Mode of Action (MoA) Study of TOTUM-63 in Individuals at Increased Cardio-metab… | Na | Prediabetic State | Completed | 2022-04-25 | 2023-04-12 | ClinicalTrials.gov |
| NCT05167058 | Electrocardiographic Diagnostic Performance of the Apple Watch Augmented With a… | — | Atrial Fibrillation | Completed | 2022-04-21 | 2023-03-31 | ClinicalTrials.gov |
| NCT05754489 | Exercise Oxygen Kinetic and Cardiac Output in Hypertrophic Cardiomyopathy | — | Cardiopulmonary Exercise Test | Unknown | 2022-04-20 | 2024-04-01 | ClinicalTrials.gov |
| NCT05252507 | Art for Hearts/Black Women's Hearts Paint Night | Na | Stress | Completed | 2022-04-06 | 2022-10-04 | ClinicalTrials.gov |
| NCT05344963 | Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echo… | — | Sodium-GLucose coTransporter-2 Inhibitors | Completed | 2022-04-01 | 2024-06-01 | ClinicalTrials.gov |
| NCT04946396 | Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Functi… | Na | Laparoscopic Surgery | Completed | 2022-04-01 | 2025-08-30 | ClinicalTrials.gov |
| NCT06239415 | PAtients With Symptomatic Peripheral Artery Disease on Rivaroxaban-acetylsalicy… | — | Peripheral Atherosclerotic Disease | Unknown | 2022-03-31 | 2024-03-31 | ClinicalTrials.gov |
| NCT05775822 | Coronary Artery Calcium and Cardiovascular Risk Factors Analysis After RT or Br… | Na | Breast Cancer | Completed | 2022-03-24 | 2024-01-31 | ClinicalTrials.gov |
| NCT05770453 | Double Anaerobic Threshold in Athletes | — | Cardiopulmonary Exercise Test | Unknown | 2022-03-15 | 2023-12-01 | ClinicalTrials.gov |
| NCT05305612 | Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions | Phase4 | Mitral Regurgitation | Enrolling_By_Invitation | 2022-03-13 | 2025-08-01 | ClinicalTrials.gov |
| NCT07481565 | Speech Therapy Online Approach for Children With Congenital Heart Desease in Pr… | Na | Deglutition Disorders in Children | Completed | 2022-03-01 | 2024-05-30 | ClinicalTrials.gov |
| NCT05245747 | Vitls Feasibility Physiologic Monitoring | — | Vital Signs | Completed | 2022-02-28 | 2023-05-16 | ClinicalTrials.gov |
| NCT05456204 | Refralon in Patients With Recurrence Paroxysmal and Persistent Forms of Atrial … | Na | Atrium; Fibrillation | Completed | 2022-02-15 | 2024-06-30 | ClinicalTrials.gov |
| NCT05246683 | LATIN SHOCK: Latin American Registry of Cardiogenic Shock in the Context of Acu… | — | Cardiogenic Shock | Unknown | 2022-02-15 | 2022-12-18 | ClinicalTrials.gov |
| NCT05161065 | Comparison of QT Interval Readings Between Smartwatch Combined With Cardiologs … | — | Atrial Fibrillation | Completed | 2022-02-12 | 2023-02-28 | ClinicalTrials.gov |
| NCT05117086 | DASH Diet in Heart Failure Outpatients | Na | Heart Failure | Active_Not_Recruiting | 2022-02-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT05966376 | Efficacy and Safety of Hemostatic Methods in Distal Radial Artery Approach for … | Na | Coronary Intervention | Unknown | 2022-02-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT06844032 | Predictors of Poor Prognosis in HFpEF | — | HFpEF | Recruiting | 2022-01-31 | 2026-12-31 | ClinicalTrials.gov |
| NCT05445297 | Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atr… | Phase4 | Atrial Fibrillation Paroxysmal | Completed | 2022-01-26 | 2023-06-30 | ClinicalTrials.gov |
| NCT06030661 | The HF-POL Study - Multicenter Study of Polish Patients With HF and LVEF >40% | — | Heart Failure | Unknown | 2022-01-07 | 2025-09-01 | ClinicalTrials.gov |
| NCT04396418 | Stroke Prevention and Rhythm Control Therapy STEEER-AF | Na | Atrial Fibrillation | Active_Not_Recruiting | 2021-12-29 | 2025-12-30 | ClinicalTrials.gov |
| NCT04705337 | Levosimendan In Ambulatory Heart Failure Patients | Phase4 | Heart Failure New York Heart Association Class III | Terminated | 2021-12-15 | 2024-08-15 | ClinicalTrials.gov |
| NCT05167240 | ESH ABPM COVID-19 STUDY | — | Ambulatory Blood Pressure | Unknown | 2021-12-03 | 2022-12-30 | ClinicalTrials.gov |
| NCT05188612 | International Survey of Acute Coronavirus Syndromes-COVID-19 | — | COVID-19 | Recruiting | 2021-12-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05105321 | Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome… | Phase4 | Metabolic Syndrome | Not_Yet_Recruiting | 2021-12-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT06253481 | Genetics of Cardiovascular Disease | — | Atherosclerosis | Unknown | 2021-11-24 | 2025-12-31 | ClinicalTrials.gov |
| NCT05113407 | Observatory on the Use of the Shockwave Medical C2 Coronary Lithotripsy System … | — | Lithotripsy | Recruiting | 2021-11-16 | 2027-12-01 | ClinicalTrials.gov |
| NCT05147623 | Colombian Surgical Outcomes Study - COLSOS | — | Surgery | Unknown | 2021-11-16 | 2023-05-22 | ClinicalTrials.gov |
| NCT05209919 | Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid r… | — | Functional Tricuspid Regurgitation | Unknown | 2021-11-11 | 2024-12-01 | ClinicalTrials.gov |
| NCT05045456 | Observational Clinical Investigation of EKG Diagnostic Performance of the Apple… | — | Atrial Fibrillation | Completed | 2021-11-09 | 2022-02-23 | ClinicalTrials.gov |
| NCT04800913 | The Role of Multimodality Imaging in Left Atrial Appendage Closure | Na | Atrial Fibrillation | Recruiting | 2021-11-08 | 2029-12-01 | ClinicalTrials.gov |
| NCT04513184 | Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patient… | Phase2 | Covid19 | Completed | 2021-11-05 | 2021-11-13 | ClinicalTrials.gov |
| NCT05186220 | Cardioneuroablation Versus Pacemaker Implantation for the Treatment of Symptoma… | Na | Sinus Node Dysfunction | Unknown | 2021-11-01 | 2023-11-01 | ClinicalTrials.gov |
| NCT05081414 | Efficacy of the PEAC-IC: a Randomized Controlled Clinical Trial | Na | Heart Failure | Completed | 2021-10-26 | 2023-03-30 | ClinicalTrials.gov |
| NCT04695106 | Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS… | Phase4 | Atrial Fibrillation | Unknown | 2021-10-25 | 2026-03-31 | ClinicalTrials.gov |
| NCT04872959 | TRANSFORM Heart Failure with Reduced Ejection Fraction | Na | Heart Failure, Systolic | Withdrawn | 2021-10-22 | 2024-05-01 | ClinicalTrials.gov |
| NCT04938310 | Impact of Wearing a Support Garment Following Parietal Gastrectomy | Na | Obesity | Terminated | 2021-10-04 | 2021-12-01 | ClinicalTrials.gov |
| NCT04929496 | Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatme… | Na | Coronary Artery Disease | Active_Not_Recruiting | 2021-09-10 | 2026-03-01 | ClinicalTrials.gov |
| NCT05992337 | New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity. | — | Cardiotoxicity | Unknown | 2021-09-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT05233124 | Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia | Phase2 | Acute Coronary Syndrome | Unknown | 2021-09-01 | 2024-07-30 | ClinicalTrials.gov |
| NCT06061120 | Non-invasive Differentiation of Supraventricular Tachyarrhythmia | — | Supraventricular Arrhythmia | Recruiting | 2021-09-01 | 2026-09-30 | ClinicalTrials.gov |
| NCT04732754 | Effect of Cocoa Supplementation and Aerobic Exercise on Pressure Parameters | Na | Sedentary Behavior | Unknown | 2021-09-01 | 2022-12-10 | ClinicalTrials.gov |
| NCT04975503 | Risk Factors in Young Middle Eastern Women With Cardiovascular Disease | — | Cardiovascular Diseases | Completed | 2021-08-22 | 2023-10-31 | ClinicalTrials.gov |
| NCT06033690 | Intervention in the Surgical Treatment of Obesity | Na | Obesity, Morbid | Completed | 2021-08-08 | 2022-12-31 | ClinicalTrials.gov |
| NCT05911880 | The Effect of a Plant-based Diet on the Active Rheumatoid Arthritis Activity. | Na | Rheumatoid Arthritis | Unknown | 2021-07-15 | 2024-12-15 | ClinicalTrials.gov |
| NCT05199116 | National Registry of Cardiovascular Surgery in Argentine | — | Cardiovascular Diseases | Unknown | 2021-07-08 | 2022-08-31 | ClinicalTrials.gov |
| NCT06298682 | Characterization of Exosomes Platelets-released | — | Platelet Thrombus | Recruiting | 2021-07-08 | 2027-07-07 | ClinicalTrials.gov |
| NCT05122780 | Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). | Phase4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | Active_Not_Recruiting | 2021-07-01 | 2025-07-01 | ClinicalTrials.gov |
| NCT04878263 | Evaluation and Support Care Process Within the Care Pathway of Heart Failure Pa… | Na | Heart Failure Acute | Completed | 2021-06-28 | 2023-12-14 | ClinicalTrials.gov |
| NCT05762406 | Effect of the Use of Protective Masks on the Ability to Perform Daily Activitie… | Na | Heart Failure | Completed | 2021-06-16 | 2024-04-30 | ClinicalTrials.gov |
| NCT04913389 | Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD | Phase3 | Chronic Obstructive Pulmonary Disease | Unknown | 2021-06-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT05864729 | The Association Between Systemic Microvascular Endothelial Function and Coronar… | Na | Myocardial Ischemia | Completed | 2021-06-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT04766554 | Cerebral Oxygen Saturation Monitoring In Cardiac Surgery (COSMICS) | Na | Cardiac Disease | Completed | 2021-05-19 | 2024-08-20 | ClinicalTrials.gov |
| NCT04674475 | OPTImized Coronary Interventions eXplaIn the bEst cliNical outcomEs | — | Coronary Artery Disease | Unknown | 2021-05-03 | 2023-06-16 | ClinicalTrials.gov |
| NCT04901845 | VEIN Health - CVD Prevalence and Characteristics | — | Chronic Venous Disease | Unknown | 2021-05-01 | 2021-09-01 | ClinicalTrials.gov |
| NCT04915365 | Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD… | Phase3 | Right Heart Function | Unknown | 2021-05-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04615949 | Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors | Phase2 | COVID-19 | Terminated | 2021-04-30 | 2022-11-30 | ClinicalTrials.gov |
| NCT04850417 | Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneou… | Phase4 | Spontaneous Coronary Artery Dissection | Not_Yet_Recruiting | 2021-04-30 | 2028-12-31 | ClinicalTrials.gov |
| NCT04885816 | Drug-eluting Balloon Versus Drug-eluting Stent for High Bleeding Risk Angioplas… | Na | High Bleeding Risk | Terminated | 2021-04-20 | 2021-09-29 | ClinicalTrials.gov |
| NCT04935515 | C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Pat… | Na | COVID -19 | Completed | 2021-04-15 | 2021-06-06 | ClinicalTrials.gov |
| NCT04604665 | Evaluation of Two Levels of Frequency of Repositioning in the Reduction of Pres… | Na | Critical Illness | Completed | 2021-04-10 | 2023-12-10 | ClinicalTrials.gov |
| NCT04914481 | Anatomic Stenosis Severity as a Prognostic Marker in Patients With Low-Flow Low… | — | Low-Flow, Low-Gradient Aortic Stenosis | Unknown | 2021-04-01 | 2025-12-31 | ClinicalTrials.gov |
| NCT05081115 | Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imag… | — | Coronary Artery Disease | Recruiting | 2021-04-01 | 2030-12-31 | ClinicalTrials.gov |
| NCT04792905 | Exploratory Study of Apple Watch Electrocardiographic Diagnostic Performance En… | — | Atrial Fibrillation | Completed | 2021-03-30 | 2021-07-19 | ClinicalTrials.gov |
| NCT04719845 | DilAtation Versus Endoscopic Laser Resection in Simple Benign trAcheal sTEnosis | Na | Tracheal Stenosis | Unknown | 2021-03-17 | 2025-03-01 | ClinicalTrials.gov |
| NCT03634189 | Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C | Phase1 | Heart Failure | Unknown | 2021-03-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT04705688 | Platelet-activation and Optimal Inhibition in Patients With Atrial Fibrillation… | — | Atrial Fibrillation | Unknown | 2021-02-24 | 2024-12-01 | ClinicalTrials.gov |
| NCT04776538 | Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivati… | Phase2 | Xerostomia Following Radiotherapy | Unknown | 2021-02-09 | 2024-03-01 | ClinicalTrials.gov |
| NCT04707352 | Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure . | Phase3 | Heart Failure | Completed | 2021-02-08 | 2023-03-26 | ClinicalTrials.gov |
| NCT06601270 | SCAD : a Registry of Spontaneous Coronary Artery Dissection | — | Spontaneous Coronary Artery Dissection | Recruiting | 2021-01-30 | 2027-10-01 | ClinicalTrials.gov |
| NCT04696185 | Dapagliflozin After Transcatheter Aortic Valve Implantation | Phase4 | Aortic Stenosis | Completed | 2021-01-27 | 2024-12-30 | ClinicalTrials.gov |
| NCT04723355 | A Comparative Study of an Innovative 3-lead Wireless Water Resistant Holter Sys… | Na | Cardiac Arrhythmia | Completed | 2021-01-26 | 2021-11-16 | ClinicalTrials.gov |
| NCT05361759 | National Tunisian Registry of Cardiac Implantable Electronic Devices | — | Cardiac Implantable Electronic Devices | Completed | 2021-01-18 | 2023-08-15 | ClinicalTrials.gov |
| NCT04553094 | Effects of Personalized Training at Home Combining Endurance and Resistance in … | Na | Marfan Syndrome | Completed | 2021-01-04 | 2022-09-30 | ClinicalTrials.gov |
| NCT05218161 | Hemodynamic Effect of Dexmedetomidine Alone With Dexmedetomidine Plus Ketamine … | Na | Hemodynamic Instability | Unknown | 2021-01-01 | 2022-03-01 | ClinicalTrials.gov |
| NCT03332888 | Safety of HMA-CD20 in Patients With HFrEF | Phase2 | Heart Failure With Reduced Ejection Fraction | Unknown | 2021-01-01 | 2021-07-15 | ClinicalTrials.gov |
| NCT05256329 | A Predictive Score for Arterial Thrombosis Associated With Cancer | — | Cancer | Unknown | 2021-01-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT04533997 | Hypertonic Saline Therapy in Ambulatory Heart Failure Unit. | Phase3 | Heart Failure | Completed | 2021-01-01 | 2023-09-30 | ClinicalTrials.gov |
| NCT04591964 | Effects of Remote Monitoring of Patients With Heart Failure Based on Smartphone… | Early_Phase1 | CHF | Unknown | 2021-01-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT04691778 | Coronary CTO PCI Using Antegrade Wiring Strategy With a First-choice Gladius Gu… | Na | Coronary Artery Disease | Completed | 2021-01-01 | 2024-01-30 | ClinicalTrials.gov |
| NCT04676880 | Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulat… | Na | Atrial Fibrillation | Active_Not_Recruiting | 2021-01-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT03962309 | Selection of People at Low Cardiovascular Risk: Development of an Inexpensive P… | — | Epidemiology of Cardiovascular Risk | Completed | 2020-12-18 | 2024-08-31 | ClinicalTrials.gov |
| NCT04657705 | Application of High Power Radio Frequency Energy in the Ventricular Tachycardia… | Na | Ventricular Tachycardia | Completed | 2020-12-05 | 2023-01-27 | ClinicalTrials.gov |
| NCT04658979 | Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study | Na | Chronic Pulmonary Disease | Unknown | 2020-12-01 | 2022-01-01 | ClinicalTrials.gov |
| NCT04730921 | Impact of Left Bundle Branch Area Pacing vs. Right Ventricular Pacing in Atriov… | Na | Atrioventricular Block | Completed | 2020-11-13 | 2025-12-01 | ClinicalTrials.gov |
| NCT04586894 | Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors | — | Cancer | Completed | 2020-11-06 | 2022-07-01 | ClinicalTrials.gov |
| NCT04624854 | Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT… | Phase4 | Coronary Artery Disease | Completed | 2020-10-28 | 2025-09-23 | ClinicalTrials.gov |
| NCT04624503 | Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With C… | — | Covid19 | Unknown | 2020-10-01 | 2021-10-01 | ClinicalTrials.gov |
| NCT04660240 | Randomized Trial Comparing Two Sirolimus-Eluting Stents in Diabetes Mellitus | Na | Diabetes Mellitus | Unknown | 2020-10-01 | 2025-09-01 | ClinicalTrials.gov |
| NCT05014477 | Therapy Strategies After LAA Occluder Device Embolization | — | Left Atrial Appendage Occluder | Unknown | 2020-09-30 | 2023-12-31 | ClinicalTrials.gov |
| NCT04775888 | Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophil… | — | Health Services Accessibility | Unknown | 2020-09-21 | 2021-05-21 | ClinicalTrials.gov |
| NCT04915235 | Prevalence and Prognosis of Cardiac Amiloidosis in Turkey | — | Cardiac Amyloidosis | Unknown | 2020-09-18 | 2025-12-31 | ClinicalTrials.gov |
| NCT04405102 | COVID-19 Ozanimod Intervention Study | Phase2 | COVID-19 | Terminated | 2020-09-16 | 2022-05-12 | ClinicalTrials.gov |
| NCT04154982 | N-Acetylcysteine Protection Against Radiation Induced Cellular Damage | Phase2 | Cardiac Arrhythmia | Completed | 2020-09-02 | 2024-12-02 | ClinicalTrials.gov |
| NCT04321473 | Registry on Left Main Coronary Artery Bifurcation Percutaneous Intervention | — | Coronary Arteriosclerosis | Unknown | 2020-09-01 | 2021-09-30 | ClinicalTrials.gov |
| NCT04388410 | Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-… | Phase2 | COVID-19 | Unknown | 2020-08-25 | 2020-12-31 | ClinicalTrials.gov |
| NCT04570254 | Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19 | Na | Pneumonia, Viral | Completed | 2020-08-19 | 2020-12-01 | ClinicalTrials.gov |
| NCT04529525 | Ivermectin to Prevent Hospitalizations in COVID-19 | Phase2 | Covid19 | Completed | 2020-08-19 | 2021-02-22 | ClinicalTrials.gov |
| NCT04359095 | Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colo… | Phase2 | COVID-19 | Completed | 2020-08-18 | 2021-06-30 | ClinicalTrials.gov |
| NCT04765943 | Prognosis Impact of NSVTs After an AMI (TeVeO Study). | — | Death, Sudden | Active_Not_Recruiting | 2020-08-15 | 2025-06-30 | ClinicalTrials.gov |
| NCT04344743 | Balloon Cryoablation Without Contrast | Na | Paroxysmal Atrial Fibrillation | Unknown | 2020-08-13 | 2022-06-01 | ClinicalTrials.gov |
| NCT04561648 | Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Arte… | Na | Radial Artery Occlusion | Unknown | 2020-08-01 | 2026-03-01 | ClinicalTrials.gov |
| NCT06239402 | Therapeutic Strategy with Direct Oral Anticoagulants and Antiaggregant Drugs in… | — | Atrial Fibrillation | Completed | 2020-07-28 | 2024-07-28 | ClinicalTrials.gov |
| NCT04631198 | Effects of Conventional Physiotherapy and Thoracoabdominal Rebalancing in Post-… | Na | Respiratory Complication | Completed | 2020-07-20 | 2022-12-10 | ClinicalTrials.gov |
| NCT04475367 | Evaluation of the Effect of an APP in Improving Treatment Adherence in Hyperten… | Na | Blood Pressure | Unknown | 2020-07-10 | 2021-12-30 | ClinicalTrials.gov |
| NCT04509479 | National Tunisian Registry of Valvulopathies (NATURE-VALVE) | — | Valvular Heart Disease | Completed | 2020-07-06 | 2022-07-30 | ClinicalTrials.gov |
| NCT03783429 | Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatien… | Phase4 | Heart Failure | Completed | 2020-07-01 | 2025-11-13 | ClinicalTrials.gov |
| NCT04583371 | The Use of Pulmonary Hyperinflation With the Mechanical Ventilator in Cardiac P… | Na | Heart Diseases | Unknown | 2020-07-01 | 2021-03-01 | ClinicalTrials.gov |
| NCT04906837 | Pre TAVI Membranous Septum Measurement Predicts High Grade Iatrioventricular Co… | — | Conduction Disturbance | Completed | 2020-06-20 | 2021-02-26 | ClinicalTrials.gov |
| NCT04415242 | IMPACT OF OPERATIVE POSITIONING ON THE DEVELOPMENT OF SHOULDER PAIN AFTER PULMO… | Na | Post-thoracotomy Pain Syndrome | Unknown | 2020-06-18 | 2021-03-30 | ClinicalTrials.gov |
| NCT04278547 | Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Ag… | Phase4 | Heart Transplant Infection | Unknown | 2020-06-12 | 2023-03-25 | ClinicalTrials.gov |
| NCT04403100 | Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People Wit… | Phase3 | COVID-19 | Unknown | 2020-06-03 | 2021-02-01 | ClinicalTrials.gov |
| NCT04443777 | Analysis of Ergogenic Potential and Risks Associated With Acute and Chronic Use… | Phase4 | Resistance Training | Unknown | 2020-06-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT04531007 | Imaging and Physiology for Intermediate Left Main Stem Stenosis | Na | Coronary Artery Disease Left Main | Unknown | 2020-06-01 | 2022-12-30 | ClinicalTrials.gov |
| NCT04359238 | activeDCM - Interventional Clinical Trial of Individualized Activity and Exerci… | Na | Cardiomyopathy, Dilated | Completed | 2020-06-01 | 2025-07-04 | ClinicalTrials.gov |
| NCT04406545 | Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of … | — | Coronavirus Infection | Completed | 2020-05-15 | 2022-01-10 | ClinicalTrials.gov |
| NCT04374110 | Drug Safety and the Occurrence of Complications During Hospitalization in Patie… | — | COVID | Unknown | 2020-05-05 | 2021-08-24 | ClinicalTrials.gov |
| NCT04368637 | Acute Cardiovascular Events Triggered by COVID-19-Related Stress | — | Acute Myocardial Infarction | Unknown | 2020-05-03 | 2020-08-30 | ClinicalTrials.gov |
| NCT04371757 | Influence of the Autonomic Nervous System in Response to Exercise in Hypertensi… | Na | Autonomic Nervous System | Unknown | 2020-04-30 | 2021-12-23 | ClinicalTrials.gov |
| NCT04366921 | European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in… | — | COVID | Unknown | 2020-04-10 | 2022-04-01 | ClinicalTrials.gov |
| NCT04344327 | Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Crit… | — | Infection Viral | Completed | 2020-04-10 | 2020-04-21 | ClinicalTrials.gov |
| NCT04577105 | Risk Factors and Computed Tomography Findings in COVID-19. | — | Covid19 | Completed | 2020-04-01 | 2020-10-01 | ClinicalTrials.gov |
| NCT04338009 | Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 20… | Na | COVID-19 | Completed | 2020-03-31 | 2020-08-20 | ClinicalTrials.gov |
| NCT05769140 | Measurement of Cardiopulmonary Variables After Acute Exposure to High Altitude | — | High Altitude Effects | Recruiting | 2020-03-25 | 2026-12-01 | ClinicalTrials.gov |
| NCT04458337 | SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVI… | — | Covid-19 | Completed | 2020-03-13 | 2022-04-13 | ClinicalTrials.gov |
| NCT04382443 | Oral Colchicine in Argentina to Prevent Restenosis | Phase4 | Coronary Artery Disease | Completed | 2020-03-12 | 2022-04-30 | ClinicalTrials.gov |
| NCT04281212 | Observational Study Evaluating the Management of Chronic Coronary Occlusions In… | — | Coronary Occlusion | Completed | 2020-03-09 | 2022-08-02 | ClinicalTrials.gov |
| NCT05105009 | Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubu… | Phase1 | Chronic Kidney Failure | Completed | 2020-03-03 | 2024-08-27 | ClinicalTrials.gov |
| NCT04357314 | Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF … | — | Myocardial Infarction | Completed | 2020-03-01 | 2020-05-31 | ClinicalTrials.gov |
| NCT04815447 | Cardiopulmonary Fitness and Its Clinical Determinants of a Population of Childh… | — | Childhood Cancer | Completed | 2020-03-01 | 2021-02-20 | ClinicalTrials.gov |
| NCT04058782 | Impact of Peripheral Vascular Stiffness Assessment on Risk Prediction in Patien… | — | Myocardial Infarction | Active_Not_Recruiting | 2020-02-17 | 2030-03-01 | ClinicalTrials.gov |
| NCT04402931 | Randomized Trial of Transcatheter Valve-in-Valve vs Redo Surgery for Bioprosthe… | Na | Mitral Prosthetic Valve Stenosis and Regurgitation | Completed | 2020-02-17 | 2025-08-01 | ClinicalTrials.gov |
| NCT04198779 | Interest of the Smartphone Application "MonCœur" in the Follow-up of Patients W… | Na | Heart Failure | Terminated | 2020-02-12 | 2023-11-27 | ClinicalTrials.gov |
| NCT04913870 | Angiotensin Receptor Blockers in Aortic Stenosis | Phase4 | Aortic Stenosis | Recruiting | 2020-02-01 | 2027-02-01 | ClinicalTrials.gov |
| NCT04219761 | National Tunisian Registry of Percutaneous Coronary Intervention | — | ACS - Acute Coronary Syndrome | Completed | 2020-01-30 | 2022-03-30 | ClinicalTrials.gov |
| NCT03895541 | Noninvasive Elastography Evaluation of Myocardial Stiffness in Elderly Patients… | Na | Cardiovascular Diseases in Old Age | Recruiting | 2020-01-24 | 2025-12-31 | ClinicalTrials.gov |
| NCT04272762 | A Randomized Sham-controlled Study of Pulmonary Vein Isolation in Symptomatic A… | Na | Atrial Fibrillation | Completed | 2020-01-23 | 2024-03-04 | ClinicalTrials.gov |
| NCT05575895 | Evaluation of Systemic Microvascular Reactivity After Ingestion of an Energy Dr… | — | Endothelial Function | Completed | 2020-01-10 | 2022-06-30 | ClinicalTrials.gov |
| NCT03956394 | Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging | Na | Takayasu Arteritis | Completed | 2020-01-08 | 2021-12-31 | ClinicalTrials.gov |
| NCT05060159 | Conventional Hemodialysis Versus Post-Dilution Hemofiltration in Incident RRT | Na | Dialysis; Complications | Completed | 2020-01-06 | 2021-07-01 | ClinicalTrials.gov |
| NCT04353232 | Impact of Lifetime Exposure to Air and Noise Pollution on Cardiovascular Diseas… | — | Cardiovascular Diseases | Active_Not_Recruiting | 2020-01-02 | 2026-09-01 | ClinicalTrials.gov |
| NCT04344353 | Analysis and Comparative Evaluation of Aortic Calcium by Computed Tomography an… | — | Aortic Calcification Valve | Completed | 2020-01-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT03982758 | Acute Effect of Isometric Exercise on Blood Pressure in Hypertensive Patients | Na | Arterial Hypertension | Unknown | 2019-12-09 | 2022-03-18 | ClinicalTrials.gov |
| NCT05231161 | Diagnostic Performance of Exercise Stress Tests for the Detection of Epicardial… | — | Coronary Artery Disease | Completed | 2019-12-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT04152330 | Proposal for Parental Guidance and Early Stimulation in Children With Congenita… | Na | Congenital Heart Disease | Completed | 2019-11-30 | 2020-08-30 | ClinicalTrials.gov |
| NCT04303377 | Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarc… | Phase2 | ST-elevation Myocardial Infarction | Withdrawn | 2019-11-18 | 2020-07-24 | ClinicalTrials.gov |
| NCT04165304 | Impact on Drinking Behaviour in Sixth-grade Students Through Changing the Schoo… | Na | Students of the 6. Grade | Terminated | 2019-11-13 | 2020-03-30 | ClinicalTrials.gov |
| NCT03928145 | Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on B… | Phase3 | Hypertension | Unknown | 2019-11-13 | 2021-07-01 | ClinicalTrials.gov |
| NCT04876209 | Reference Values of Aerobic Fitness in the Contemporary Paediatric Population | — | Healthy | Completed | 2019-11-01 | 2021-05-01 | ClinicalTrials.gov |
| NCT04129905 | Assessment of the Relations Between Endothelial and Venous Dysfunctions and Lef… | Na | Hypertrophic Cardiomyopathy | Completed | 2019-10-22 | 2021-12-14 | ClinicalTrials.gov |
| NCT04197401 | Screening & Health Education in Barbershop Centers for Hypertension | — | Hypertension | Completed | 2019-09-13 | 2019-11-25 | ClinicalTrials.gov |
| NCT04066517 | STereotactic RadioAblation by Multimodal Imaging for VT (STRA-MI-VT) | Na | Refractory Ventricular Tachycardia | Unknown | 2019-09-13 | 2025-06-13 | ClinicalTrials.gov |
| NCT04691791 | Italian Registry of Cardiovascular Magnetic Resonance on Congenital Anomalies o… | — | Congenital Coronary Artery Abnormality | Completed | 2019-09-01 | 2022-10-31 | ClinicalTrials.gov |
| NCT04012294 | Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People W… | Phase3 | Musculoskeletal Degeneration | Unknown | 2019-08-30 | 2021-02-28 | ClinicalTrials.gov |
| NCT04069598 | Statin Intolerance in Patients With Myocardial Infarction | — | Statin Adverse Reaction | Unknown | 2019-08-26 | 2020-03-31 | ClinicalTrials.gov |
| NCT04161339 | Anti-Inflammatory Drug and Endothelial Function | Phase4 | Cardiovascular Diseases | Unknown | 2019-07-01 | 2020-06-30 | ClinicalTrials.gov |
| NCT04298593 | Assessment of Arrhythmic BuRdEn With Post-ProCedural COntinuous ElectRocarDiogr… | Na | TAVI | Active_Not_Recruiting | 2019-06-28 | 2026-12-01 | ClinicalTrials.gov |
| NCT03837925 | Pharmaco-metabolomic Effects of Statins: METASTATINE | Phase3 | Cardiovascular Diseases | Completed | 2019-06-13 | 2022-12-21 | ClinicalTrials.gov |
| NCT03955159 | Effects of Probiotic Supplementation in Hypertensive Women on Menopause | Na | Systemic Arterial Hypertension | Unknown | 2019-06-10 | 2021-08-10 | ClinicalTrials.gov |
| NCT03918005 | Effects of Hypocaloric Diets With Different Glycemic Loads on Pulse Wave Veloci… | Na | Glycemic Index | Unknown | 2019-06-01 | 2021-07-31 | ClinicalTrials.gov |
| NCT04233528 | Evaluation of Systemic Microvascular Endothelial Function in Metabolically Heal… | Na | Obesity | Completed | 2019-06-01 | 2022-12-30 | ClinicalTrials.gov |
| NCT03976921 | Impact of Stress CT Myocardial Perfusion on Downstream Resources and Prognosis | Na | Coronary Artery Disease | Unknown | 2019-06-01 | 2022-10-01 | ClinicalTrials.gov |
| NCT03928158 | LCZ696 in Advanced LV Hypertrophy and HFpEF | Phase2 | Heart Failure | Completed | 2019-05-31 | 2023-12-31 | ClinicalTrials.gov |
| NCT04081012 | N-acetyl Cysteine in Post-reperfusion Pulmonary Injury in Chronic Thromboemboli… | Na | Chronic Thromboembolic Pulmonary Hypertension | Unknown | 2019-05-21 | 2023-05-21 | ClinicalTrials.gov |
| NCT04508920 | A Survey to Assess Effects of Covid-19 on Cardiovascular Patients | — | Cardiovascular Diseases | Unknown | 2019-05-15 | 2021-07-15 | ClinicalTrials.gov |
| NCT03938285 | Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal | Na | Hemodiafiltration | Unknown | 2019-05-02 | 2020-08-01 | ClinicalTrials.gov |
| NCT04238026 | Distal Radial Artery Approach to Prevent Radial Artery Occlusion (DAPRAO) | Na | Radial Artery Occlusion | Completed | 2019-05-02 | 2020-03-31 | ClinicalTrials.gov |
| NCT03494751 | Heart Monitoring Device After Acute Myocardium Infarction | Na | Acute Myocardial Infarction | Unknown | 2019-05-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT04338490 | Effect of the Use of a Visual Feedback Device in RCP Trainings | Na | Simulation Training | Completed | 2019-05-01 | 2019-11-10 | ClinicalTrials.gov |
| NCT04141800 | Spanish Study of Hyperkalaemia Incidence and Prognosis in Patients With Heart F… | — | Heart Failure With Reduced Ejection Fraction | Completed | 2019-04-30 | 2021-03-31 | ClinicalTrials.gov |
| NCT04137029 | Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of B… | Na | Health, Subjective | Unknown | 2019-04-24 | 2020-10-01 | ClinicalTrials.gov |
| NCT03485742 | Statin Eligibility Prior to Myocardial InfarCtion | — | Statins | Terminated | 2019-04-22 | 2019-06-10 | ClinicalTrials.gov |
| NCT04013503 | National Tunisian Registry of Hypertension | — | Hypertension | Completed | 2019-04-15 | 2019-05-15 | ClinicalTrials.gov |
| NCT06494566 | Omega-3 Supplementation After Surgical Treatment of Obesity | Early_Phase1 | Obesity | Completed | 2019-04-10 | 2023-12-04 | ClinicalTrials.gov |
| NCT04029064 | Management of Prenatally Diagnosed Isolated Right Aortic Arch | — | Isolated Right Aortic Arch | Completed | 2019-04-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT03846752 | Complex Large-bore Radial Percutaneous Coronary Intervention (PCI) Trial | Na | Complex Coronary Lesions | Completed | 2019-03-05 | 2020-05-20 | ClinicalTrials.gov |
| NCT05807152 | Furosemide-induced Diuresis With Matched Dehydration Compared to Standard Diure… | Na | Acute Decompensated Heart Failure | Unknown | 2019-02-19 | 2024-12-31 | ClinicalTrials.gov |
| NCT03845010 | Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment | Na | Ventricular Premature Beats | Completed | 2019-02-12 | 2023-01-17 | ClinicalTrials.gov |
| NCT06714019 | PL_GNT01_ISR_Grant 53234273 | — | Transthyretin Cardiomyopathy (TTR-CM) | Enrolling_By_Invitation | 2019-02-11 | 2025-11-01 | ClinicalTrials.gov |
| NCT05290324 | Propofol or Midazolam for Sedation and Early Extubation Following Coronary Arte… | Na | Coronary Artery Disease | Completed | 2019-02-01 | 2020-02-01 | ClinicalTrials.gov |
| NCT03931096 | Quality of Life Assessment of Children With Congenital Heart Disease Aged 5 to … | — | Congenital Heart Disease | Completed | 2019-02-01 | 2019-12-31 | ClinicalTrials.gov |
| NCT03753087 | Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Fu… | Phase4 | Heart Failure, Diastolic | Completed | 2019-01-16 | 2022-01-10 | ClinicalTrials.gov |
| NCT04397302 | Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced E… | — | Heart Failure, Left Sided | Completed | 2019-01-13 | 2020-03-16 | ClinicalTrials.gov |
| NCT03515460 | Acute Effects of Oral Carbohydrate and Fat Loads on Systemic Microvascular Endo… | Na | Metabolic Syndrome | Completed | 2018-12-10 | 2023-12-20 | ClinicalTrials.gov |
| NCT03767322 | Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney In… | Phase2 | Contrast-induced Nephropathy | Unknown | 2018-12-05 | 2019-12-01 | ClinicalTrials.gov |
| NCT03763500 | Evaluation of the Added Value of an Internet-based Educational Program for Pati… | Na | Atrial Fibrillation | Unknown | 2018-12-03 | 2022-12-30 | ClinicalTrials.gov |
| NCT04906356 | Canadian SCAD Study | — | Spontaneous Coronary Artery Dissection | Recruiting | 2018-12-01 | 2033-12-01 | ClinicalTrials.gov |
| NCT03867227 | Non-pharmacological Prevention of Stroke in Patients With Non-valvular Atrial F… | — | Atrial Fibrillation | Completed | 2018-12-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT03445273 | Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoi… | — | Coronary Disease | Unknown | 2018-11-21 | 2019-11-20 | ClinicalTrials.gov |
| NCT03732924 | Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement | Na | Hypertension | Completed | 2018-11-15 | 2020-07-15 | ClinicalTrials.gov |
| NCT03683355 | Characterization of RadiOlabeled Tracer Uptake Pattern in Noninfected Transcath… | — | Infective Endocarditis | Completed | 2018-11-09 | 2025-03-01 | ClinicalTrials.gov |
| NCT04202172 | Functional Assessment of the Infart-related Artery With Bioactive and Polymer-f… | Phase4 | Endothelial Dysfunction | Completed | 2018-11-05 | 2020-09-01 | ClinicalTrials.gov |
| NCT04241770 | TURKish Acute Myocardial Infarction Registry | — | Acute Myocardial Infarction | Unknown | 2018-11-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT03791320 | Fast Assessment of STenosis Severity- FASTII Study | — | Coronary Artery Disease | Completed | 2018-10-15 | 2019-11-01 | ClinicalTrials.gov |
| NCT04235647 | A Nurse Led Intervention to Promote Physical Activity | Na | Sedentary Behavior | Completed | 2018-10-01 | 2020-01-01 | ClinicalTrials.gov |
| NCT03799133 | Safety and Efficacy of the Gastric Reactance (XL) in Patients Post-operated of … | Na | Cardiac Failure | Completed | 2018-09-26 | 2019-12-28 | ClinicalTrials.gov |
| NCT06348459 | Registry of Catheter Intervention in Pulmonary Embolism | — | Pulmonary Embolism | Recruiting | 2018-09-18 | 2030-12-31 | ClinicalTrials.gov |
| NCT03027804 | Ross Operation Failure Database | — | Ross Operation | Withdrawn | 2018-09-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT03536312 | Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance | Na | Ascending Aortic Aneurysm Enlargement | Recruiting | 2018-09-01 | 2035-05-31 | ClinicalTrials.gov |
| NCT03512782 | Post-discharge Monitoring of Patients With Heart Failure | Na | Heart Failure | Unknown | 2018-09-01 | 2019-04-30 | ClinicalTrials.gov |
| NCT03568890 | Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Th… | Phase4 | Left Atrial Appendage Closure | Active_Not_Recruiting | 2018-09-01 | 2030-09-01 | ClinicalTrials.gov |
| NCT03645252 | Sequence of Vessel Interruption and Circulating Tumor Cells in Surgical Lung Ca… | Na | Circulating Tumor Cell | Unknown | 2018-08-31 | 2024-08-31 | ClinicalTrials.gov |
| NCT05550792 | Cardiac Contractility Modulation in Patients With Chronic Heart Failure and the… | Na | Heart Failure | Completed | 2018-08-31 | 2022-03-30 | ClinicalTrials.gov |
| NCT03524768 | Microvascular Endothelial Function in a Cohort of Patients With the Cardiac For… | — | Chagas Cardiomyopathy | Completed | 2018-08-20 | 2020-08-01 | ClinicalTrials.gov |
| NCT03437148 | Non-Invasive Shunt Quantification in Interatrial Communication | Na | Congenital Heart Diseases | Terminated | 2018-07-18 | 2022-10-03 | ClinicalTrials.gov |
| NCT03434015 | Post-approval Study of Percutaneous Left Atrial Appendage Closure ( FLAAC-2 ) | — | Atrial Fibrillation | Completed | 2018-07-09 | 2021-10-07 | ClinicalTrials.gov |
| NCT03536806 | Clinical Efficacy of Potassium Canrenoate in Sinus Rhythm Restoration Among Pat… | Phase4 | Atrial Fibrillation, Paroxysmal | Unknown | 2018-06-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT04160533 | Registry of Arterial Hypertension | — | Arterial Hypertension | Recruiting | 2018-06-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT03537924 | Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders O… | Phase4 | Altitude Hypoxia | Unknown | 2018-06-01 | 2022-12-31 | ClinicalTrials.gov |
| NCT03363932 | French Observatory of Congenital Ventricular Septal Defect With Pulmonary Overl… | — | Congenital Heart Disease | Active_Not_Recruiting | 2018-06-01 | 2030-06-01 | ClinicalTrials.gov |
| NCT03424941 | The TransCatheter Valve and Vessels Trial | Na | Aortic Stenosis | Completed | 2018-05-31 | 2024-06-26 | ClinicalTrials.gov |
| NCT03540901 | Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Re… | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2018-05-22 | 2018-08-02 | ClinicalTrials.gov |
| NCT03536455 | Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Tha… | Phase4 | Altitude Hypoxia | Completed | 2018-05-15 | 2018-08-02 | ClinicalTrials.gov |
| NCT03536507 | Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than … | Phase4 | Altitude Hypoxia | Completed | 2018-05-15 | 2018-08-02 | ClinicalTrials.gov |
| NCT03536520 | Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Yea… | Phase4 | Altitude Hypoxia | Completed | 2018-05-15 | 2018-08-02 | ClinicalTrials.gov |
| NCT03561675 | Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 … | Phase4 | Acute Mountain Sickness | Completed | 2018-05-15 | 2019-08-31 | ClinicalTrials.gov |
| NCT03536429 | Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years a… | Phase4 | Altitude Hypoxia | Completed | 2018-05-15 | 2018-08-02 | ClinicalTrials.gov |
| NCT03974581 | Pharmacoinvasive Strategy vs. Primary PCI in STEMI: A Prospective Registry in a… | — | Myocardial Infarction, Acute | Completed | 2018-04-30 | 2020-07-14 | ClinicalTrials.gov |
| NCT03518723 | Effect and Feasibility of Non-linear Periodized Resistance Training in People W… | Na | Pulmonary Disease | Completed | 2018-04-16 | 2023-03-01 | ClinicalTrials.gov |
| NCT03613779 | CLUSTER-HF: Lung Ultrasound Guided Therapy in Heart Failure | Na | Heart Failure | Completed | 2018-04-10 | 2019-12-07 | ClinicalTrials.gov |
| NCT03304496 | Subcutaneous Nitroglycerin to Facilitate Trans-radial Access. | Phase4 | Coronary Artery Disease | Suspended | 2018-03-30 | 2026-03-31 | ClinicalTrials.gov |
| NCT03753048 | Total Arterial Revascularization (TAR) | Na | Coronary Artery Disease | Unknown | 2018-03-13 | 2024-03-01 | ClinicalTrials.gov |
| NCT03959748 | DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL | — | Chronic Thromboembolic Pulmonary Hypertension | Recruiting | 2018-03-01 | 2028-02-28 | ClinicalTrials.gov |
| NCT03144258 | Evaluation of the Microcirculation During the Corrective Surgery of Congenital … | — | Congenital Heart Disease | Completed | 2018-02-20 | 2018-12-30 | ClinicalTrials.gov |
| NCT03236285 | Microvascular and Metabolic Effects of High-intensity Interval Exercise Training | Na | Obesity | Withdrawn | 2018-02-20 | 2021-10-01 | ClinicalTrials.gov |
| NCT03392948 | PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant… | — | Acute Myocardial Infarction | Unknown | 2018-02-09 | 2023-02-01 | ClinicalTrials.gov |
| NCT03365700 | Cryoballon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation | Na | Persistent Atrial Fibrillation | Unknown | 2018-02-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT03309839 | HLA-DR Expression in Neonates After Cardiac Surgery Under Cardiopulmonary Bypass | — | Cardiac Surgery | Completed | 2018-01-29 | 2019-04-13 | ClinicalTrials.gov |
| NCT03431415 | Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or … | Na | Non-small Cell Lung Cancer Stage I | Withdrawn | 2018-01-28 | 2025-02-01 | ClinicalTrials.gov |
| NCT03445949 | Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure | Phase4 | Atrial Fibrillation | Recruiting | 2018-01-23 | 2027-06-23 | ClinicalTrials.gov |
| NCT03101995 | Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advance… | Phase2 | Cervical Cancer | Recruiting | 2018-01-16 | 2025-11-01 | ClinicalTrials.gov |
| NCT03142399 | Effect of Whey Protein' Supplementation and Exercise in Patients With Heart Fai… | Na | Heart Failure | Unknown | 2018-01-02 | 2019-06-30 | ClinicalTrials.gov |
| NCT03384355 | Ecchymosis and Coldness in Patients With Varicose Vein | — | Varicose Veins | Unknown | 2018-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT03321032 | Second-generation Drug-eluting Stents in Diabetes | Phase4 | Coronary Artery Disease | Unknown | 2017-12-19 | 2022-01-28 | ClinicalTrials.gov |
| NCT03296540 | CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI | Phase4 | Cardiovascular Diseases | Completed | 2017-11-28 | 2021-05-01 | ClinicalTrials.gov |
| NCT03343522 | The Effects of Exercise Training in Vascular Function of Patients Living With H… | Na | HIV/AIDS | Completed | 2017-11-10 | 2023-03-03 | ClinicalTrials.gov |
| NCT03949439 | Pre-frailty and Rehospitalization in Cardiac Surgery | — | Frailty Syndrome | Completed | 2017-11-01 | 2018-07-30 | ClinicalTrials.gov |
| NCT03262675 | NAtional TUnisian REgistry of Heart Failure | — | Heart Failure | Completed | 2017-10-16 | 2019-01-12 | ClinicalTrials.gov |
| NCT03015831 | Effect of Low Dose ColchiciNe on the InciDence of POAF | Phase3 | Atrial Fibrillation | Terminated | 2017-10-02 | 2019-05-01 | ClinicalTrials.gov |
| NCT03281707 | NIRS and DO2i Correlation | — | Multiorgan Failure | Unknown | 2017-09-30 | 2018-10-30 | ClinicalTrials.gov |
| NCT03332862 | Continuous Versus Discontinuous Design of Encircling Lesions During Ablation fo… | Na | Atrial Fibrillation | Unknown | 2017-09-15 | 2018-01-31 | ClinicalTrials.gov |
| NCT03481322 | Low Sodium Cooking Study | Na | Heart Disease | Completed | 2017-09-05 | 2018-07-10 | ClinicalTrials.gov |
| NCT03450304 | Lung Perfusion Measured With Dual-Energy CT in Patients With Chronic Thromboemb… | — | Multidetector Computed Tomography | Unknown | 2017-09-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT03383445 | Transcatheter Aortic Valve Replacement Versu Surgical Aortix Valve Replacement … | Na | Degenerative Aortic Valve Disease | Active_Not_Recruiting | 2017-08-08 | 2027-05-30 | ClinicalTrials.gov |
| NCT04332952 | Damage and Renal Clearance of Glycocalyx in Cardiac Surgery | — | Glycocalyx | Completed | 2017-08-01 | 2017-12-31 | ClinicalTrials.gov |
| NCT03413813 | Registry of Patients With a Bioabsorbable Magnesium Stent Implant MAGMARIS in U… | — | Coronary Artery Disease | Completed | 2017-07-26 | 2021-06-07 | ClinicalTrials.gov |
| NCT03178357 | "Cardiac Rehabilitation in Patients With Hypertrophic Cardiomyopathy". | Na | Cardiac Rehabilitation | Unknown | 2017-07-10 | 2020-12-01 | ClinicalTrials.gov |
| NCT03158532 | Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglyce… | Phase3 | Injury of Radial Artery | Completed | 2017-07-06 | 2021-11-01 | ClinicalTrials.gov |
| NCT03364140 | A Registry of Peripartum Cardiomyopathy in Turkey | — | Peripartum Cardiomyopathy | Unknown | 2017-07-02 | 2018-01-15 | ClinicalTrials.gov |
| NCT03234348 | MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infar… | Phase3 | Acute Coronary Syndrome | Completed | 2017-07-01 | 2019-10-31 | ClinicalTrials.gov |
| NCT03208153 | the Invasive and Conservative Strategies in Elderly Frail Patients With Non-STE… | Na | Non-ST Elevation Myocardial Infarction | Completed | 2017-06-30 | 2021-12-31 | ClinicalTrials.gov |
| NCT05004545 | Compare Hemodynamic Parameters of Propofol and Sevoflurane During CPB Time in U… | Na | Hemodynamic Instability | Unknown | 2017-06-10 | 2021-12-30 | ClinicalTrials.gov |
| NCT03174093 | Mhealth Application for anTicoagulation Care in Atrial Fibrillation | Na | Atrial Fibrillation | Unknown | 2017-06-01 | 2018-11-01 | ClinicalTrials.gov |
| NCT03561805 | Prolonged Continuous ECG Monitoring Prior to Transcatheter Aortic Valve Implant… | Na | Aortic Valve Stenosis | Active_Not_Recruiting | 2017-06-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT05090540 | Transcatheter Versus Standard Surgical Mitral Valve Operation for Secondary Mit… | — | Severe Mitral Valve Regurgitation (Disorder) | Enrolling_By_Invitation | 2017-06-01 | 2025-12-30 | ClinicalTrials.gov |
| NCT03165656 | Right Ventricular Function at Rest in Highlanders/Lowlanders | — | High Altitude Pulmonary Hypertension | Completed | 2017-05-24 | 2017-08-16 | ClinicalTrials.gov |
| NCT03173508 | Effect of Acetazolamide on Right Ventricular Function at Rest in Patients With … | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2017-05-24 | 2018-08-02 | ClinicalTrials.gov |
| NCT03177811 | Effect of Acetazolamide on Postural Control in Patients With Respiratory Diseas… | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2017-05-24 | 2018-08-02 | ClinicalTrials.gov |
| NCT03165890 | Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Al… | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2017-05-24 | 2017-07-24 | ClinicalTrials.gov |
| NCT03156231 | Effect Of Acetazolamide On Altitude Related Illness In Patients With Respirator… | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2017-05-24 | 2018-08-02 | ClinicalTrials.gov |
| NCT03167034 | Effect of Acetazolamide on Right Ventricular Function During Exercise in Patien… | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2017-05-24 | 2018-08-02 | ClinicalTrials.gov |
| NCT03177837 | Effect of Acetazolamide on Exercise Performance in Patients With Respiratory Di… | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2017-05-24 | 2018-08-02 | ClinicalTrials.gov |
| NCT03172429 | Cerebral Tissue Oxygenation in Highlanders/Lowlanders | — | High Altitude Pulmonary Hypertension | Completed | 2017-05-24 | 2017-08-16 | ClinicalTrials.gov |
| NCT03177850 | Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients Wit… | Phase4 | Chronic Obstructive Pulmonary Disease | Completed | 2017-05-24 | 2018-08-02 | ClinicalTrials.gov |
| NCT03273634 | The Effect of Proton Pump Inhibition on Palpitations | Phase4 | Arrhythmia | Completed | 2017-05-20 | 2018-06-01 | ClinicalTrials.gov |
| NCT03234257 | Evaluation of the Carotid Plaque Stability by Ultrafast-ultrasound Imaging (UF) | Na | Carotid Stenosis | Completed | 2017-05-18 | 2020-09-30 | ClinicalTrials.gov |
| NCT03520101 | Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValv… | Na | Aortic Valve Stenosis | Active_Not_Recruiting | 2017-05-10 | 2030-05-31 | ClinicalTrials.gov |
| NCT03125083 | Role of Inflammation in Psychiatric Disorders in Patients With Cutaneous Lupus | Na | Skin Restricted Lupus | Completed | 2017-05-05 | 2018-10-24 | ClinicalTrials.gov |
| NCT03073447 | WAMIF : Young Women Presenting Acute Myocardial Infarction in France | Na | Acute Myocardial Infarction | Completed | 2017-05-04 | 2020-10-06 | ClinicalTrials.gov |
| NCT03112460 | Cardiopulmonary Resuscitation Training Program Based on Quality Control | — | Cardiopulmonary Resuscitation | Unknown | 2017-05-01 | 2017-08-31 | ClinicalTrials.gov |
| NCT02931695 | Influence of Sex Hormones Variation During Third Trimester of Pregnancy and Pos… | Na | Pregnancy | Completed | 2017-04-24 | 2023-10-24 | ClinicalTrials.gov |
| NCT03071731 | Glittre ADL-test: Responsiveness to Acute Bronchodilation in Chronic Obstructiv… | Na | Chronic Obstructive Pulmonary Disease | Unknown | 2017-04-13 | 2019-06-15 | ClinicalTrials.gov |
| NCT04646278 | Coronary Hemodynamics by Coronary Angiography | Na | Coronary Artery Disease | Completed | 2017-04-11 | 2020-03-25 | ClinicalTrials.gov |
| NCT03035123 | Therapeutic Education Strategy for Patients With Acute Heart Failure | Na | Heart Failure | Completed | 2017-04-01 | 2024-12-30 | ClinicalTrials.gov |
| NCT03096158 | Cardiac and Endothelial Function Response to Early Exercise Training After Coro… | Na | Coronary Artery Bypass Grafting | Completed | 2017-04-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT03082989 | Evolving Routine Standards in Intracoronary Physiology | — | Myocardial Ischemia | Completed | 2017-03-13 | 2017-10-20 | ClinicalTrials.gov |
| NCT03231449 | A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa | — | Acute Coronary Syndrome | Unknown | 2017-02-01 | 2021-02-01 | ClinicalTrials.gov |
| NCT04174261 | Ticagrelor in Remote Ischemic Preconditioning Study | Phase4 | Periprocedural Myocardial Infarction | Completed | 2017-01-29 | 2018-01-17 | ClinicalTrials.gov |
| NCT07115836 | Standard Versus "Single Loop" Bypass After Parietal Gastrectomy | Na | Obesity, Morbid | Active_Not_Recruiting | 2017-01-06 | 2028-01-06 | ClinicalTrials.gov |
| NCT02919982 | Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular … | — | Nonvalvular Atrial Fibrillation | Completed | 2017-01-01 | 2019-09-01 | ClinicalTrials.gov |
| NCT03000842 | Effects of Transcutaneous Vagal Nerve Stimulation on Hemodynamics Parameters | Na | Hypertension | Unknown | 2017-01-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02949804 | Relation Between Vasovagal Tendency and Smoking Among University Students | — | Vasovagal Syncope | Completed | 2016-12-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02991742 | Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy i… | — | Acute Kidney Failure | Unknown | 2016-12-01 | 2020-11-01 | ClinicalTrials.gov |
| NCT03917199 | Utility of Regadenoson Low-dose Dynamic Computed Tomography for Myocardial Perf… | — | Myocardial Perfusion Imaging | Completed | 2016-11-01 | 2019-07-11 | ClinicalTrials.gov |
| NCT02946320 | Optimal Predilatation Technique for BVS Implantation | Phase3 | Coronary Artery Stenosis | Unknown | 2016-11-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT03049995 | Stress Echo 2020 - The International Stress Echo Study | — | Coronary Artery Disease | Unknown | 2016-11-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT02826408 | Effect of Proton Pump Inhibitors on Palpitations | Na | Signs and Symptoms | Completed | 2016-10-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02925819 | Management and Clinical Outcomes of Patients With Severe Mitral Valve Disease N… | — | Mitral Valve Disease | Recruiting | 2016-10-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02959515 | The Effects of Different Types of Non-ventilated Lung Management on DO2 During … | Na | One-Lung Ventilation | Unknown | 2016-10-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT03105895 | Prevention of Incisional Hernia With an Onlay Mesh Visible on MRI | — | Incisional Hernia | Unknown | 2016-09-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT03013270 | Aerobic, Resistance, Inspiratory Training Outcomes in Heart Failure | Na | Heart Failure | Completed | 2016-09-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT03343314 | Effective Management of Calcific Aortic Stenosis in the Elderly | — | Calcific Aortic Stenosis | Completed | 2016-09-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT04222608 | The BRAvAdO Registry | — | ACS - Acute Coronary Syndrome | Unknown | 2016-09-01 | 2021-09-01 | ClinicalTrials.gov |
| NCT03942822 | Chia Supplementation and Non Alcoholic Fatty Liver Disease | Na | Non-Alcoholic Fatty Liver Disease | Completed | 2016-09-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT03511885 | EUROASPIRE V Survey on Cardiovascular Disease Prevention and Diabetes | — | Cardiovascular Diseases | Completed | 2016-08-23 | 2018-12-28 | ClinicalTrials.gov |
| NCT02931773 | Autonomic Cardiovascular Neuropathy in Recently Diagnosed DM2 Patients (ACNDM2) | — | Dysautonomia | Unknown | 2016-08-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02680483 | Atrial Fibrillation Registry in Jordan | — | Atrial Fibrillation | Terminated | 2016-08-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02672345 | Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Se… | — | Inflammatory Response | Completed | 2016-08-01 | 2020-06-01 | ClinicalTrials.gov |
| NCT02818127 | Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method (TC… | Na | Coronary Angiography | Unknown | 2016-07-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT03015064 | Post-Myocardial Infarction Patients in Santa Catarina, Brazil - Catarina Heart … | — | Myocardial Infarction | Active_Not_Recruiting | 2016-07-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT02173860 | Strategies for Revascularization in Patients Undergoing Heart Valve Surgery Wit… | Na | Coronary Artery Disease | Unknown | 2016-07-01 | 2021-08-01 | ClinicalTrials.gov |
| NCT04174937 | PA Tolerability, Safety and Pharmacokinetics in Healthy Volunteers | Phase1 | Infections, Respiratory | Completed | 2016-06-17 | 2019-09-15 | ClinicalTrials.gov |
| NCT02783248 | French National Observatory of Percutaneous Mitral Commissurotomy | — | Mitral Stenosis | Completed | 2016-06-01 | 2022-06-30 | ClinicalTrials.gov |
| NCT02854007 | Costs, Effectiveness, QALYs, and Efficiency of Bioabsorbable Devices in Daily C… | — | Coronary Stenosis Treated With Implant of Bioresorbable Devices | Unknown | 2016-06-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT06896461 | Surfactant Derived Protocol in Heart Failure | Na | Heart Failure | Completed | 2016-05-06 | 2024-12-31 | ClinicalTrials.gov |
| NCT03167424 | Restenosis Intrastent: Treatment of Bioresorbable Vascular Scaffolds Restenosis | — | Coronary In-stnent Restenosis | Unknown | 2016-05-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT02710825 | Osteopathy and Children With Congenital Heart Disease Surgery | Na | Congenital Heart Disease | Completed | 2016-05-01 | 2017-02-23 | ClinicalTrials.gov |
| NCT02741583 | Kyrgyz Asthma Rehabilitation at High Altitude | Na | Effect of High Altitude | Completed | 2016-05-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT03213496 | Promotion of Ambulation Before Non-cardiac Surgery | Na | Non-cardiac Surgery | Completed | 2016-05-01 | 2017-12-31 | ClinicalTrials.gov |
| NCT03019848 | Effect of Oral Supplementation With Curcumin in Patients With Proteinuric Diabe… | Phase2 | Proteinuria | Unknown | 2016-05-01 | 2017-05-01 | ClinicalTrials.gov |
| NCT02666651 | Regional Tolvaptan Registry | Phase4 | Decompensated Heart Failure | Unknown | 2016-05-01 | 2020-01-01 | ClinicalTrials.gov |
| NCT04448691 | "SIMULATION MODELING OF CORONARY ARTERY DISEASE: A TOOL FOR CLINICAL DECISION S… | Na | Management/Treatment of Coronary Artery Disease | Completed | 2016-04-14 | 2017-12-30 | ClinicalTrials.gov |
| NCT03112070 | Post-Exercise Hypotension After Water Exercise | Na | Postexercise Hypotension | Completed | 2016-04-04 | 2017-04-30 | ClinicalTrials.gov |
| NCT02805621 | Machine leArning Based CT angiograpHy derIved FFR: a Multi-ceNtEr, Registry | — | Coronary Heart Disease | Completed | 2016-04-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02717143 | French National Observatory Tracking Viral Myocarditis: Mortality, Cardiovascul… | — | Myocarditis | Completed | 2016-04-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT02915328 | Role of the Type of Carotid Stent and Cerebral Protection on Cerebral Microembo… | Na | Carotid Stenosis | Unknown | 2016-04-01 | 2018-04-01 | ClinicalTrials.gov |
| NCT01787084 | Alternative Access Approaches for Transcatheter Aortic Valve Replace (TAVR) in … | — | Severe Symptomatic Aortic Stenosis | Completed | 2016-04-01 | 2025-03-01 | ClinicalTrials.gov |
| NCT02671084 | Sevoflurane and Percutaneous Coronary Intervention by Stent | Phase4 | Myocardial Infarction | Terminated | 2016-02-01 | 2020-04-01 | ClinicalTrials.gov |
| NCT02691286 | Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock | — | STEMI | Unknown | 2016-02-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT03168269 | Can CCTA Technicians Provide Accurate Interpretation of Findings in Patients Pr… | — | Coronary Artery Disease | Completed | 2016-01-27 | 2016-02-25 | ClinicalTrials.gov |
| NCT03365726 | Intraoperative Dobutamine Stress Test With Speckle Tracking to Decrease Postope… | Na | Mortality After Major Non Cardiac Surgery | Unknown | 2016-01-19 | 2019-01-19 | ClinicalTrials.gov |
| NCT02686866 | Body Composition Measurements in Chronic Heart Failure | Phase4 | Cachexia | Unknown | 2016-01-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02940340 | Evaluation of Systemic Microvascular Endothelial Dysfunction in Patients Presen… | — | Infective Endocarditis | Completed | 2016-01-01 | 2017-11-22 | ClinicalTrials.gov |
| NCT02509754 | Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With… | Phase4 | Persistent Atrial Fibrillation | Unknown | 2016-01-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT03707561 | RUS-registry of PH | — | Pulmonary Hypertension | Unknown | 2016-01-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT03069066 | Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment With Scoring … | Phase4 | Coronary In-stent Restenosis | Unknown | 2016-01-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT03214965 | The Use of the Social Networking to Promote Educational and Consultative Action… | Na | Kidney Transplantation | Completed | 2016-01-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02937922 | Effect of Exercise on Endothelial Injury in Hypertensive Patients | Na | Hypertension | Completed | 2016-01-01 | 2020-01-01 | ClinicalTrials.gov |
| NCT02635477 | Get Going: Accelerometer-Based Intervention to Promote Physical Activity in Fra… | Na | Coronary Artery Disease | Unknown | 2016-01-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT02699957 | Left Atrial Appendage Occlusion Registry (LAAO Registry) | — | Atrial Fibrillation | Recruiting | 2015-12-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT02650388 | Frailty and Cognitive Function Assessment of TAVI Patients | Phase4 | Quality of Life | Unknown | 2015-11-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT03338582 | STIMTAVI : Evolution of Atrioventricular Conduction Disorders After TAVI | — | Pacemaker Implantation | Unknown | 2015-11-01 | 2018-04-19 | ClinicalTrials.gov |
| NCT02548364 | Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial… | Phase3 | Myocardial Infarction | Completed | 2015-10-01 | 2023-05-01 | ClinicalTrials.gov |
| NCT02591992 | Computed Tomography as the First-Choice Diagnostics in High Pre-Test Probabilit… | Na | Coronary Artery Disease | Unknown | 2015-10-01 | 2018-05-01 | ClinicalTrials.gov |
| NCT02571803 | Dietary Intervention to Stop COronary Atherosclerosis in Computed Tomography | Na | Coronary Artery Disease | Unknown | 2015-10-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT05436730 | "Escape" Phenomenon of the Antihypertensive Therapy Efficacy | — | Arterial Hypertension | Unknown | 2015-09-29 | 2025-12-30 | ClinicalTrials.gov |
| NCT02868216 | Management of Anger in Patients With Acute Myocardial Infarction (MAPAMI) | Na | Myocardial Infarction | Completed | 2015-09-15 | 2017-07-15 | ClinicalTrials.gov |
| NCT02598505 | Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation | Phase3 | Heart Failure | Completed | 2015-09-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT04767490 | Single Anastomosis Versus Standard Duodenal Switch | Na | Obesity | Recruiting | 2015-09-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT02537041 | Non-invasive Evaluation of Myocardial Stiffness by Elastography | Na | Diastolic Heart Failure | Completed | 2015-09-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT03302195 | Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obe… | Na | Cardiopulmonary Bypass | Recruiting | 2015-08-21 | 2027-12-31 | ClinicalTrials.gov |
| NCT02369978 | CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) | Phase2 | Chagas Disease | Unknown | 2015-08-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02484144 | Evaluation of the Information of the Patient Before a Scheduled Coronarography | — | Cardiac Disease | Completed | 2015-07-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02578329 | An Intervention Study to Assess the Effect of the Mediterranean Diet on the Pla… | Na | Coronary Artery Disease | Unknown | 2015-07-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT02451020 | Acclimatization of Healthy Subjects During a Stay at 3200 m | Na | Effects of High Altitude | Completed | 2015-06-08 | 2015-08-09 | ClinicalTrials.gov |
| NCT02347982 | Epidemiology of Cardiovascular Disease in Elderly Turkish Population | — | Cardiovascular Diseases | Completed | 2015-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02523560 | Applying Telemedicine in a Model of Implementing Cardiac Rehabilitation in Hear… | Na | Chronic Heart Failure | Completed | 2015-06-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT06855550 | Postoperative Incidence of Atrial Fibrillation Following Cardiac Surgery | — | Atrial Fibrillation (AF) | Completed | 2015-05-04 | 2022-12-12 | ClinicalTrials.gov |
| NCT02450968 | Altitude Related Illness In Patients With Respiratory Disease | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2015-05-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02450994 | Effect of Dexamethasone on Sleep Related Breathing Disturbances in Patients Wit… | Phase4 | Chronic Obstructive Pulmonary Disease (COPD) | Completed | 2015-05-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02565290 | Effect of Mother's Supplementation Omega-3 in the Dynamics of Fetal Ductus Arte… | Na | Pregnancy | Unknown | 2015-05-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02458885 | Pilot Study on ST Elevation Acute Myocardial Infarction | — | Myocardial Infarction | Unknown | 2015-04-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02457130 | Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery disea… | Phase4 | Coronary Artery Disease | Unknown | 2015-04-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02517632 | Physical Exercise Program in Chronic Chagas Heart Disease | Phase3 | Chagas Disease | Completed | 2015-03-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02343276 | Randomized Clinical Trial Comparing Transradial Catheterization With or Without… | Phase3 | Cardiac Catheterisation | Completed | 2015-02-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02790801 | The First Russian Observational Survey of Heart Failure Patients With Atrial Fi… | — | Chronic Heart Failure | Completed | 2015-02-01 | 2017-05-31 | ClinicalTrials.gov |
| NCT04347200 | REGistry of Long-term AnTithrombotic TherApy-1 | — | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | Recruiting | 2015-01-15 | 2026-12-31 | ClinicalTrials.gov |
| NCT04347187 | REGistry of Long-term AnTithrombotic TherApy-2 | — | Atrial Fibrillation | Recruiting | 2015-01-15 | 2026-12-31 | ClinicalTrials.gov |
| NCT04304794 | Iodinated Contrast Media Induced Hyperthyroidism | — | Hyperthyroidism/Thyrotoxicosis | Completed | 2015-01-02 | 2020-02-20 | ClinicalTrials.gov |
| NCT03361202 | Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Pe… | — | Atrial Fibrillation | Unknown | 2015-01-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02892981 | Dead Space Evaluation in Pulmonary Hypertension | Na | Pulmonary Hypertension | Completed | 2015-01-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02961972 | Effects of Oral Supplementation With Creatine on Systemic Microvascular Endothe… | Na | Endothelial Dysfunction | Completed | 2015-01-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT03607981 | Spanish Registry on Spontaneous Coronary Artery Dissection | — | Spontaneous Coronary Artery Dissection | Unknown | 2015-01-01 | 2020-01-01 | ClinicalTrials.gov |
| NCT02640794 | Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI | Phase4 | Aortic Valve Disease | Completed | 2015-01-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02601768 | Occluder Size Determination in Transcatheter ASD II Closure Based on 3D TEE Ass… | — | Ostium Secundum Atrial Septal Defect | Unknown | 2015-01-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02327871 | Esophageal Temperature Management After Cardiac Arrest | Na | Cardiac Arrest | Completed | 2014-12-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02317848 | PRevalence, Persistence and prOgnostic ValuE of Sleep Apnea Syndrome in Acute H… | Na | Sleep Apnea Syndrome | Completed | 2014-12-01 | 2019-05-29 | ClinicalTrials.gov |
| NCT02306616 | CCC Project- Acute Coronary Syndrome | — | Acute Coronary Syndrome | Completed | 2014-11-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT02260362 | Observatory of Pulmonary Arterial Hypertension of Congenital Heart Disease | — | Pulmonary Arterial Hypertension of Congenital Heart Disease | Completed | 2014-10-01 | 2022-07-31 | ClinicalTrials.gov |
| NCT02260466 | Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloi… | Na | Heart Disease | Unknown | 2014-10-01 | 2024-12-31 | ClinicalTrials.gov |
| NCT02748603 | Appropriateness of Coronary Angioplasty in PAtients With isCHEmic Heart Disease | — | Non ST Elevation Acute Coronary Syndromes | Unknown | 2014-10-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02620995 | Effects of Sildenafil on Penile Vascular Function in Hypertensive Men With Erec… | Phase4 | Arterial Hypertension | Completed | 2014-10-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02533752 | Canadian WATCHMAN Registry | — | Atrial Fibrillation | Unknown | 2014-09-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT02238054 | French Observatory Evaluating the Use of Intracoronary Prosthesis ABSORB BVS | — | Intracoronary Angioplasty | Completed | 2014-09-01 | 2022-05-30 | ClinicalTrials.gov |
| NCT02292199 | Transcutaneous Electrical Nerve Stimulation on Nervous System in Patients With … | Na | Cardiovascular Diseases | Unknown | 2014-08-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02139085 | Great Saphenous Vein Electrocoagulation | Phase2 | Venous Disease | Unknown | 2014-08-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02202265 | Polymorphisms in CD36 and STAT3 Genes and Different Dietary Interventions Among… | Na | Coronary Artery Disease | Unknown | 2014-08-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT02212470 | Drug Eluting Balloon Angioplasty Versus Nitinol Stent Implantation in the Super… | Phase4 | Peripheral Arterial Disease | Completed | 2014-07-01 | 2019-10-01 | ClinicalTrials.gov |
| NCT02635230 | What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Ora… | — | Atrial Fibrillations | Unknown | 2014-06-01 | 2022-01-01 | ClinicalTrials.gov |
| NCT02188069 | Canadian SCAD Study | — | Spontaneous Coronary Artery Dissection | Unknown | 2014-06-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT02925936 | Choice of Tube Extremity in Emission of Lowest Radiation Dose in Pediatric Pati… | Na | Radiation Absorption | Completed | 2014-06-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02567617 | Polyphenols Supplementation on Prostaglandin E2 in Women - Randomized Clinical … | Phase2 | Inflammatory Disorder of the Cardiovascular System | Completed | 2014-05-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02156583 | Frailty: Prevalence and Response to Left Ventricular Assist Device Therapy in O… | — | Systolic Heart Failure | Completed | 2014-05-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT02266251 | Optimizing Health Outcomes in Patients With Symptomatic Aortic Valve Disease | — | Aortic Valve Disease | Completed | 2014-05-01 | 2017-05-30 | ClinicalTrials.gov |
| NCT02732223 | Combined Bioactive Therapy Effects Over Cardiovascular Markers in Statin Treate… | Na | Cardiovascular Diseases | Completed | 2014-05-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02144090 | Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study | Na | Stable Angina | Completed | 2014-05-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT03305094 | The Effect of Remote Ischemic Preconditioning in Aortic Valve Replacement Surge… | Na | Aortic Valve Stenosis | Unknown | 2014-04-11 | 2024-12-01 | ClinicalTrials.gov |
| NCT02574806 | Normal Values of Brain Natriuretic Peptide in Healthy Newborn | — | Reference Values of BNP in Healthy Newborn | Completed | 2014-04-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02672878 | Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI) | Phase4 | Coronary In-stent Restenosis | Unknown | 2014-04-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT02928133 | NOACs for Atrial Tachyarrhythmias in Congenital Heart Disease | — | Congenital Heart Defects | Unknown | 2014-04-01 | — | ClinicalTrials.gov |
| NCT02109055 | Application of Exercises Based on the Pilates in Coronary Artery Bypass Grafting | Na | Cardiovascular Diseases | Unknown | 2014-04-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02186314 | Effect of Right Bifocal Ventricular Cardiac Pacing on Serum Level Natriuretic P… | Na | Heart Failure | Unknown | 2014-02-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT01956539 | FREnch Survey on Heart Failure | — | Heart Failure | Completed | 2014-02-01 | 2022-05-31 | ClinicalTrials.gov |
| NCT05912634 | Repair Versus Non-repair of the Aortic Arch in Type A Aortic Dissection | — | Aortic Dissection | Enrolling_By_Invitation | 2014-01-01 | 2025-12-30 | ClinicalTrials.gov |
| NCT02000661 | Routine Versus Selective Use of FFR to Guide PCI | Phase4 | Acute Coronary Syndrome | Terminated | 2014-01-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT03001271 | Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects | Early_Phase1 | Hypertension | Unknown | 2014-01-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02208869 | Russian Familial Hypercholesterolemia Registry | — | Familial Hypercholesterolemia | Recruiting | 2014-01-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT02441504 | Effects of Low Intensity Aerobic Exercise on the Microvascular Endothelial Func… | Na | Diabetes Mellitus, Type 1 | Completed | 2014-01-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02153307 | Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atr… | Na | Aortic Valve Disease | Recruiting | 2014-01-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT02061696 | ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access Wi… | Na | Coronary Artery Disease | Terminated | 2014-01-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02256449 | REPARA Study: REgistry of PAtients With bioResorbable Device in Daily Clinical … | — | Coronary Artery Lesions With Implantation of Coronary Device | Unknown | 2014-01-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT02010905 | Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-a… | Phase2 | Tetralogy of Fallot | Unknown | 2013-12-01 | 2018-01-01 | ClinicalTrials.gov |
| NCT02022878 | Computed Tomography Angiography Prediction Score for Percutaneous Revasculariza… | — | Coronary Artery Disease | Completed | 2013-12-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT02059681 | Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in … | Phase1 | Chronic Myocardial Ischemia | Completed | 2013-12-01 | 2022-02-01 | ClinicalTrials.gov |
| NCT02716493 | Feasibility of a 8-week Telerehabilitation Program for Patients With Thoracic N… | Na | Lung Cancer | Unknown | 2013-11-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT01979965 | Effect of Ranolazine on Valvular Disease in Patients With Pacemakers | Phase4 | Ischemic Mitral Regurgitation | Unknown | 2013-11-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02181049 | Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (… | — | Childhood and Adolescence Cancer (Survivors and Deceased) | Active_Not_Recruiting | 2013-10-01 | 2028-10-01 | ClinicalTrials.gov |
| NCT01850277 | Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study | Phase4 | Atrial Fibrillation | Unknown | 2013-10-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02518984 | Atrial Fibrillation General Registry | — | Atrial Fibrillation | Completed | 2013-10-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT02252861 | French Database of Left Atrial Appendage Closure | — | Atrial Fibrillation and Other Dysrhythmias | Patient | Completed | 2013-10-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT01837823 | YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Infla… | Phase2 | Obstructive Coronary Artery Disease | Completed | 2013-07-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01997242 | The Surgery After Stenting (SAS) Registry | — | PERCUTANEOUS CORONARY INTERVENTION | Completed | 2013-06-10 | 2014-12-31 | ClinicalTrials.gov |
| NCT01857856 | PHOspholamban RElated CArdiomyopathy STudy - Intervention | Phase3 | Phospholamban R14del Mutation-related Cardiomyopathy | Completed | 2013-05-01 | 2021-10-01 | ClinicalTrials.gov |
| NCT01741558 | The Effects of mETHotrexate Therapy on ST Segment Elevation MYocardial Infarcti… | Phase2 | Myocardial Infarction | Unknown | 2013-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT06284057 | Lower Silesia Culotte Bifurcation Registry (LSCBR). | — | Safety Issues | Recruiting | 2013-04-01 | 2028-04-01 | ClinicalTrials.gov |
| NCT04331405 | Allogeneic Cord Blood Cells for Adults With Severe Acute Contusion Spinal Cord … | Phase1 | Spinal Cord Contusion | Completed | 2013-03-18 | 2018-09-05 | ClinicalTrials.gov |
| NCT02156414 | Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Loca… | — | Secondary Malignant Neoplasm of Lymph Node | Completed | 2013-03-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01841346 | The First Jordanian PCI Registry: Events at 1 Year | — | Percutaneous Coronary Intervention | Completed | 2013-03-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02073253 | Noninvasive Ventilation and Thoracic-abdominal Kinematics in Heart Failure Pati… | Na | Heart Failure | Completed | 2013-03-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01868854 | Risk Assessment of Peritoneal Dialysis Failure Based on Catheter Tip Location. | — | Renal Failure | Unknown | 2013-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01831193 | Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Protei… | Phase3 | Proteinuria | Completed | 2013-02-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01777828 | Registry of Aortic Valve Bioprostheses Established by Catheter | — | Transcatheter Aortic Valve Implantation | Recruiting | 2013-02-01 | 2034-02-01 | ClinicalTrials.gov |
| NCT03579810 | Impact of a Pedagogical Intervention on Children Cardiovascular Risk Factors | Na | Cardiovascular Health | Completed | 2013-02-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT01885754 | Characterization of Peripheral Muscle Function in Patients With Non-small-cell … | — | Non-Small-cell Lung Cancer | Unknown | 2013-02-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01708265 | The Dutch Asymptomatic Mitral Regurgitation Trial | Na | Heart; Disease, Mitral(Valve) | Terminated | 2013-02-01 | 2021-02-01 | ClinicalTrials.gov |
| NCT01803841 | Korea Transradial Coronary Intervention Prospective Registry (KOTRI) | Phase4 | Coronary Artery Disease | Completed | 2013-02-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01794325 | Transradial and Transfemoral Coronary Angiography by EXPERienced operaTors | Na | Exposure to Ionizing Radiation | Completed | 2013-02-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT02240914 | Vascular Ultrasound Versus Intravascular Ultrasound for Diagnosing Iliac Vein O… | — | Iliac Vein Obstruction | Unknown | 2013-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01984411 | Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic C… | Phase3 | Ischemic Heart Diseases | Completed | 2013-01-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT05977842 | Drug-coated Balloon in de Novo Chronic Total Occlusions | — | Coronary Artery Disease | Completed | 2012-12-15 | 2025-01-01 | ClinicalTrials.gov |
| NCT01714752 | Evaluation of Left Ventricular Filling Pressures During Exercise | Na | Heart Failure With Preserved Ejection Fraction (HFPEF) | Completed | 2012-12-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01777503 | The Elderly ACS II Trial | Phase4 | Acute Coronary Syndrome | Completed | 2012-11-01 | 2017-12-19 | ClinicalTrials.gov |
| NCT01527279 | Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation | Phase4 | Paroxysmal Atrial Fibrillation | Completed | 2012-11-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT05302115 | S-ICD French Cohort Study (HONEST) | — | Sudden Cardiac Death | Unknown | 2012-10-13 | 2024-12-31 | ClinicalTrials.gov |
| NCT03021343 | Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surg… | Phase3 | Arrhythmia | Completed | 2012-10-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01710748 | Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Ever… | Phase3 | Coronary Artery Disease | Unknown | 2012-10-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT02263482 | Inspiratory Muscle and Peripheral Muscle Training in Chronic Heart Failure | Na | Chronic Heart Failure | Completed | 2012-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02261948 | Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET) | Phase4 | Heart Failure | Completed | 2012-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02543502 | Treatment of Periodontal Disease in Patients With Acute Myocardial Infarction | Na | Periodontitis | Completed | 2012-08-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02449460 | Cardiovascular Epidemiology in Russian Federation | — | Hypertension | Unknown | 2012-07-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT06919731 | PLATELET TISSUE FACTOR AS BIOMARKER OF THROMBOTIC RISK IN CORONARY ARTERY DISEA… | — | Cardiovascular Diseases | Completed | 2012-05-01 | 2023-04-30 | ClinicalTrials.gov |
| NCT01887769 | Body Composition Analysis for Patient With Lung Cancer Using Computed Tomograph… | — | Lung Cancer | Unknown | 2012-05-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01559298 | Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Impla… | Phase4 | Aortic Valve Disease | Completed | 2012-03-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT01608477 | Building Research Initiative Group: Chronic Illness Management and Adherence in… | — | Heart Transplantation | Unknown | 2012-03-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT01835808 | Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease | — | Coronary Artery Disease | Completed | 2012-03-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT03114137 | Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose | — | Sickle Cell Anemia | Unknown | 2012-03-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT01732952 | Dyslipidemia International Survey-China | — | the Prevalence,Lipid Abnormalities, | Unknown | 2012-02-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01545180 | Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capil… | — | Heart Failure | Completed | 2012-02-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT01774955 | The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospectiv… | — | Acute Coronary Syndrome | Completed | 2012-02-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01516723 | Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Oc… | Phase3 | Coronary Artery Disease | Unknown | 2012-02-01 | 2020-05-01 | ClinicalTrials.gov |
| NCT01917955 | Cardiac MRI in Ischemic Stroke Study | — | Stroke | Completed | 2012-01-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT04306822 | Epidemiology of Cardiovascular Diseases and Their Risk Factors in Regions of Ru… | — | Risk Factor, Cardiovascular | Completed | 2012-01-01 | 2020-01-01 | ClinicalTrials.gov |
| NCT01321255 | Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention. | Phase3 | Myocardial Infarction | Completed | 2012-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01992458 | Primary Prevention ICD French Registry | — | Evaluation of Primary Prevention ICD in Real Life | Completed | 2012-01-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01477775 | Customized Choice of Oral P2Y12 Receptor Blocker | Phase4 | Acute Coronary Syndrome | Unknown | 2012-01-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01520610 | TAKO-TSUBO Cardiomyopathy and Genetic | — | Tako-TSUBO Cardiomyopathy | Completed | 2011-11-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01675830 | Heat Retention Head Wrap Use for Re-warming of Infants Requiring Cardio-Pulmona… | Phase1 | Impaired Thermoregulation | Completed | 2011-11-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01408875 | Cardiac Rehabilitation and Low Frequency Electrical MyoStimulation in Chronic H… | Na | Chronic Heart Failure | Completed | 2011-10-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01433627 | Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic … | Phase3 | Acute Coronary Syndromes | Unknown | 2011-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01466452 | Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Un… | Phase2 | Coronary Arteriosclerosis | Unknown | 2011-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01406236 | SAFE-PCI for Women | Na | Percutaneous Coronary Intervention | Terminated | 2011-08-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01366625 | Renal Denervation in Patients With Resistant Hypertension and Obstructive Sleep… | Na | Hypertension | Completed | 2011-07-01 | 2016-11-28 | ClinicalTrials.gov |
| NCT01393015 | Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Oxygenthera… | Na | COPD Exacerbation | Unknown | 2011-07-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01390142 | Remote Ischemic Preconditioning Combined to Local Ischemic Postconditioning in … | Phase3 | Myocardial Infarction | Completed | 2011-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01368770 | Stress Testing Compared to Coronary Computed Tomographic Angiography in Patient… | Phase3 | Coronary Artery Disease | Completed | 2011-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01394549 | Causes, Analysis of the Sub-evaluating Coronary Syndromes Acute and Disparities… | — | Coronary Acute Syndrome | Completed | 2011-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01390740 | Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiograp… | — | Abdominal Aortic Aneurysms | Completed | 2011-05-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01334931 | Use of Large Field of View During Image Acquisition for Coronary Angiography | Phase3 | Exposure to Ionizing Radiation | Completed | 2011-04-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00989248 | Comparative Study of Cardiopulmonary Exercise Test Land Versus Water | Phase2 | Congestive Heart Failure | Unknown | 2011-04-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT01266694 | Cochicine Treatment for Post- Operative Pericardial Effusion | Phase4 | Pericardial Effusion | Completed | 2011-04-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT02184442 | The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B | Na | Severe | Completed | 2011-03-09 | 2017-05-30 | ClinicalTrials.gov |
| NCT01428557 | BREATHE Registry - I Brazilian Registry of Heart Failure | — | Heart Failure | Completed | 2011-03-01 | 2019-09-01 | ClinicalTrials.gov |
| NCT01265758 | Telemetric Arrhythmia Diagnosis in Adults | Na | Atrial Fibrillation | Unknown | 2011-02-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01265290 | Optimizing Diagnostics Of Syncope Events Using Intelligent Telemetric Solutions. | Na | Cardiac Arrhythmia | Unknown | 2011-02-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT01140399 | REWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure | Phase4 | Acute Decompensated Heart Failure | Terminated | 2011-02-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT01265303 | Telemetric Arrhythmia and Syncope Diagnosis - Evaluation of Arrhythmia Treatmen… | Na | Atrial Fibrillation | Unknown | 2011-02-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01293188 | Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement | — | Aortic Valve Disease | Completed | 2011-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01186445 | Morphine In Acute Myocardial Infarction | Phase3 | Acute Myocardial Infarction | Completed | 2011-01-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01377207 | Optical Coherence Tomography Assessment of Gender diVersity In Primary Angiopla… | Phase4 | Acute Myocardial Infarction | Completed | 2011-01-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01492452 | The Anxiety of Parents of Children Undergoing Cardiac Surgery | Na | Anxiety | Completed | 2010-12-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT01404507 | Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombe… | Phase4 | Acute Myocardial Infarction | Completed | 2010-12-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01252407 | Acute Effect of Transcutaneous Electrical Nerve Stimulation in Heart Failure | Na | Improvement of Cardiovascular Autonomic Control | Unknown | 2010-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01237418 | French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010 | — | Myocardial Infarction | Completed | 2010-10-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT01120548 | Sleep Apnea Treatment During Cardiac Rehabilitation of Congestive Heart Failure… | Na | Heart Failure | Completed | 2010-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01030458 | Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NO… | Phase4 | Blood Pressure | Completed | 2010-09-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01233336 | Hepatocyte Growth Factor (HGF) Concentration in Myocardial Infarction | — | Acute Coronary Syndrome | Completed | 2010-07-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01157936 | Hyperuricemia on Hypertension and Metabolic Syndrome | Phase2 | Systolic and Diastolic Blood Pressure Levels | Completed | 2010-07-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT02782572 | Safety of Aerobic Exercise in Acute Heart Failure | Na | Heart Failure | Completed | 2010-07-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01319188 | Ranibizumab and the Risk of Arterial Thromboembolic Events | Phase4 | Age-related Macular Degeneration | Terminated | 2010-06-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02848339 | Aspirin Desensitization Registry in Patients With Aspirin Hypersensitivity | — | Aspirin Hypersensitivity | Completed | 2010-05-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01237717 | Relationship of Urine Sodium Excretion to Central Blood Pressure and Aortic Pul… | — | Hypertension | Completed | 2010-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01223443 | Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting … | Phase4 | Coronary Artery Bypass Grafting | Terminated | 2010-04-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01872299 | Studies Investigating Co-morbidities Aggravating Heart Failure | — | Heart Failure | Completed | 2010-03-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01667237 | Feasibility of a Short Home-based Rehabilitation Program for Cancer Patients Wa… | Early_Phase1 | Lung Cancer | Completed | 2010-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01096264 | Non-Invasive Quantitative Imaging of Human Local Arterial Wall Elasticity Using… | Na | Healthy Volunteers | Completed | 2010-03-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01325597 | Effects of Functional Electrical Stimulation and Inspiratory Muscle Training in… | Na | Heart Failure | Unknown | 2010-03-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01532167 | Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammat… | — | Takayasu Arteritis | Completed | 2010-02-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01023438 | Strategies to Improve Prescribing in Heart Failure Patients | Na | Chronic Heart Failure | Terminated | 2010-01-01 | 2017-04-01 | ClinicalTrials.gov |
| NCT01091480 | French Hypertrophic Cardiomyopathy Observatory | — | Hypertrophic Cardiomyopathy | Recruiting | 2010-01-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT01236157 | Monitoring of Nontraumatic Chest Pain Borne by the "Department of Emergency Hel… | — | Chest Pain | Completed | 2009-11-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01021943 | Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Trans… | Phase2 | Kidney Transplant | Suspended | 2009-11-01 | — | ClinicalTrials.gov |
| NCT01121679 | French Observatory on Hospitalizations in Cardiology of Patients of 80 Years an… | — | Cardiovascular Disease | Completed | 2009-10-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01265615 | Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Re… | Phase4 | Cardiorenal Syndrome | Completed | 2009-10-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT03870074 | CPET Predicts Long-term Survival and Positive Response to CRT | — | Heart Failure With Reduced Ejection Fraction | Completed | 2009-10-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT00968383 | Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treat… | Na | Cardiovascular Diseases | Terminated | 2009-09-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01551355 | Promoting Heart Health in Preschool Children | Phase3 | Cardiovascular Health | Completed | 2009-07-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT01267487 | Clinical Trial Comparing Heparin and Protamine Fixed and Titrated Doses in Card… | Phase4 | Cardiac Surgery | Completed | 2009-07-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00969735 | Cryoenergy Or Radiofrequency for Pulmonary Vein Isolation | Phase4 | Atrial Fibrillation | Completed | 2009-07-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT00930670 | Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogre… | Phase4 | Coronary Artery Disease | Completed | 2009-06-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00916695 | Everolimus-Eluting Stent for Bifurcation Coronary Lesions: Comparison of Simple… | Phase4 | Coronary Artery Disease | Unknown | 2009-06-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01398631 | A Comparison of the TIMI, GRACE and HEART Scores | — | Acute Coronary Syndrome | Completed | 2009-06-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00805311 | Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis | Phase4 | Carotid Artery Stenosis | Terminated | 2009-04-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01729702 | Neurohormonal Parameters in Hypertrophic Cardiomyopathies | Na | 1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | Completed | 2009-04-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01720121 | Digital Videos Disc and Printed Guidelines and Improve the Knowledge of Patient… | Na | Health Behavior | Completed | 2009-04-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00868673 | The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic … | Na | Overweight and Obesity | Completed | 2009-03-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT01080937 | French Observatory of Acute Heart Failure | — | Acute Heart Failure | Completed | 2009-03-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01342666 | Tomato Consumption and High Density Lipoprotein-cholesterol | Na | Hypoalphalipoproteinemia | Completed | 2009-03-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01567592 | Extracorporeal Shockwave Therapy for the Treatment of Chronic Angina Pectoris | Phase1 | Refractory Angina Pectoris | Suspended | 2009-03-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01250444 | Effects of Inspiratory Muscle Training on Cardiovascular Function in Hypertensi… | Na | Reduction of Blood Pressure in Hypertensive Patients. | Unknown | 2009-03-01 | — | ClinicalTrials.gov |
| NCT01274676 | Carotid Stenting in Patients With High Risk Carotid Stenosis ("Soft Plaque") | Na | Carotid Stenosis | Completed | 2009-02-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00822536 | Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implanta… | Phase4 | Coronary Artery Disease | Completed | 2009-01-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00791050 | Examine the Effects of Maintaining Body Core Temperature During CABGs | Na | Anesthesia | Unknown | 2009-01-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00821353 | Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hype… | Phase3 | Atrial Fibrillation | Completed | 2009-01-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00799565 | Mitral Valve Prolapse (MVP) - France Study | Na | Mitral Valve Prolapse | Completed | 2008-12-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT02366104 | Brasília Study on Healthy Aging | — | Healthy | Completed | 2008-12-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT00769938 | WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients Wi… | Phase4 | Anticoagulants | Completed | 2008-12-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00780156 | The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontin… | — | Restenosis | Terminated | 2008-11-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01091467 | Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fra… | — | Congestive Heart Failure | Completed | 2008-10-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00774709 | Karolinska-Rennes (KaRen) Prospective Study of Exercise Stress Echocardiography… | — | Heart Failure | Completed | 2008-10-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00700856 | Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention … | Phase4 | Type 2 Diabetes Mellitus | Unknown | 2008-09-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT03432663 | Time-dependent Amiodarone Treatment in Atrial Fibrillation | Phase4 | Atrial Fibrillation | Completed | 2008-08-01 | 2009-11-30 | ClinicalTrials.gov |
| NCT01559610 | Preoperatively Orientation in Cardiac Surgery: Nurses Intervention on Patients … | Na | Coronary Artery Bypass Graft Triple Vessel | Completed | 2008-08-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT01259843 | French National Observatory of Aortic Syndromes | — | Acute Aortic Syndrome | Completed | 2008-08-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00865449 | Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis | Phase3 | End Stage Renal Disease | Completed | 2008-07-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01260519 | Effect of Heparin on Femoral Arterial Sheaths Thrombosis During Diagnostic Coro… | Phase3 | Diagnostic Coronary Angiography | Completed | 2008-07-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00702728 | Induced Diuresis With Matched Hydration Compared to Standard Hydration for Cont… | Phase3 | Contrast Induced Nephropathy | Unknown | 2008-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT01122810 | Scanner and Transplant Heart Patients Protocol | Na | Heart Transplant Patients | Completed | 2008-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01796093 | Digoxin Versus Ivabradine in Heart Failure With Preserved Systolic Function | — | Heart Failure | Completed | 2008-04-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00648089 | EPOMI Study: ErythroPOietin in Myocardial Infarction | Phase2 | Myocardial Infarction | Completed | 2008-04-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01699776 | Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure | Phase4 | Cardiac Failure | Completed | 2008-04-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00646243 | Echo Assessment of Intraventricular Dyssynchrony | — | Chronic Heart Failure | Unknown | 2008-03-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00846378 | Minimizing Reperfusion Injury in Patients With Acute Myocardial Infarction | Phase1 | Acute Myocardial Infarction | Suspended | 2008-03-01 | — | ClinicalTrials.gov |
| NCT02230293 | Assistance Multidisciplinary in Hypertensive Patient: Randomized Clinical Trial | Na | Hypertension | Completed | 2008-03-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00522704 | Correlation Between Access Blood Flow and Extracorporeal Blood Flow | — | Arteriovenous Fistula | Unknown | 2008-03-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01146301 | Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During … | Phase4 | Carotid Stenosis | Completed | 2008-03-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00766129 | Comparison of Safety and Efficacy of Two Different Drug Eluting Stents Implante… | Phase3 | Stenosis in Saphenous Vein Graft, Drug Eluting Stent | Unknown | 2008-02-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01154413 | Implementation of a Diabetes Management Protocol as Compared to Conventional Ma… | Na | Diabetes Mellitus Type 2 | Completed | 2007-12-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00551681 | Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contrac… | Na | Left Ventricular Dysfunction | Completed | 2007-11-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT00710775 | Heart Leaflet Technologies Valve Study | Na | Aortic Valve Stenosis | Unknown | 2007-11-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT01098591 | Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE | — | Ischemic Heart Disease | Completed | 2007-11-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT00744315 | Induced Angiogenesis by Genic Therapy in Advanced Ischemic Cardiomyopathy | Phase2 | Ischemic Cardiopathy | Unknown | 2007-11-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT01097031 | Continuous or Intermittent for Keeping Arterial Catheter in Children: A Randomi… | — | Blood Pressure | Completed | 2007-10-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00463294 | Coronary Artery Bypass Surgery (CABG) Off or On Pump Revascularization Study | Phase3 | the Efficacy and Safety of Off-pump CABG | Completed | 2007-10-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT00825279 | A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus … | Phase4 | Coronary Artery Disease | Completed | 2007-08-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00484380 | The Scanner in the Coronary Evaluation | Na | Valvular Disease | Completed | 2007-08-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00517426 | Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breath… | Phase4 | Chronic Heart Failure | Completed | 2007-07-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00517725 | Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure | Phase4 | Chronic Heart Failure | Completed | 2007-07-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00481377 | Ablation for ICD Intervention Reduction in Patients With CAD | Na | Ventricular Tachycardia | Terminated | 2007-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01270139 | Plasmonic Nanophotothermal Therapy of Atherosclerosis | Na | Stable Angina | Completed | 2007-04-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT00430820 | Discovery of New Circulating Biomarkers of Coronary Atherosclerosis | — | Coronary Artery Disease | Completed | 2007-03-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00421239 | Risk Factors of Hypertensive Urgencies | — | Hypertensive Urgency | Completed | 2007-01-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00844987 | Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF… | — | Acute Coronary Syndrome | Completed | 2007-01-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00449488 | Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Fun… | Phase2 | Myocardial Infarction | Completed | 2007-01-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00428454 | Sirolimus-eluting vs Zotarolimus-eluting Stents for Chronic Total Coronary Occl… | Phase3 | Coronary Artery Disease | Completed | 2007-01-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT00412802 | Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Cor… | Phase4 | Acute Coronary Syndrome | Completed | 2006-12-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00392639 | Clinical and Economical Interest of Endovascular Cooling in the Management of C… | Phase4 | Hypothermia | Completed | 2006-11-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00424320 | Clinical Trial of Sodium Bicarbonate to Prevent Contrast-Induced Nephropathy | Phase3 | Acute Kidney Failure | Unknown | 2006-10-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00333320 | Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction | Phase1 | Acute Myocardial Infarction | Completed | 2006-09-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT02207894 | A Survey on the Success of Inhibitor Elimination Using Individualized Concentra… | — | Haemophilia A | Recruiting | 2006-08-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT00752440 | Inspiratory Muscle Training in Patients With Autonomic Neuropathic | Phase4 | Diabetes Mellitus | Unknown | 2006-08-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00360958 | Treatment of Severe Heart Failure by Ultrafiltration | Phase4 | Severe Congestive Heart Failure | Completed | 2006-08-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00351364 | Does Montelukast Have an Affect on the Function of the Artery in Patients With … | Phase4 | Coronary Artery Disease | Terminated | 2006-07-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00350766 | Cell Therapy in Myocardial Infarction | Phase2 | Acute Myocardial Infarction | Terminated | 2006-07-01 | 2014-07-14 | ClinicalTrials.gov |
| NCT00334373 | Post Conditioning in PCI for Acute ST Elevation Myocardial Infarction | Phase4 | Myocardial Infarction | Completed | 2006-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01621464 | Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) | Phase4 | Syncope, Vasovagal | Unknown | 2006-05-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT00247052 | Non Steroidal Anti Inflammatory Treatment for Post Operative Pericardial Effusi… | Phase4 | Pericardial Effusion | Completed | 2006-03-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00352014 | Evaluation and Comparison of Several Point-of-care Platelet Function Tests in P… | — | Stable Angina Pectoris | Completed | 2006-01-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00224757 | Transesophageal Echocardiography to Identify pAtients With Low Risk of Stroke i… | Na | Atrial Fibrillation | Completed | 2005-09-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT01999140 | Implantable Cardioverter Defibrillator (ICD Registry) | — | Heart Failure | Recruiting | 2005-06-01 | 2030-06-01 | ClinicalTrials.gov |
| NCT00220558 | GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Cor… | Phase4 | Coronary Artery Disease | Unknown | 2005-05-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00202683 | Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness | — | Altitude Intolerance | Completed | 2005-03-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT02303652 | Biatrial Contractility Recovery After Maze | — | Atrial Fibrillation | Completed | 2005-01-01 | — | ClinicalTrials.gov |
| NCT00620217 | Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option… | Phase2 | Coronary Artery Disease | Completed | 2004-12-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00320229 | Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared… | Phase4 | Coronary Disease | Terminated | 2004-12-01 | 2005-07-01 | ClinicalTrials.gov |
| NCT00675480 | Thrombectomy in Acute Myocardial Infarction | Phase3 | Acute Myocardial Infarction | Completed | 2004-11-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00123916 | BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Trea… | Phase3 | Chagas Disease | Completed | 2004-11-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT00149422 | Effect of NT-proBNP Guided Treatment of Chronic Heart Failure | Na | Heart Failure, Congestive | Completed | 2004-06-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00288665 | Thrombectomy and Improvement of Left Ventricular Function in AMI | Phase4 | Acute Myocardial Infarction | Completed | 2004-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00953810 | Educational Intervention in Heart Failure Patients | Na | Heart Failure | Completed | 2004-04-01 | 2008-01-01 | ClinicalTrials.gov |
| NCT00202670 | Diagnosis of Coronary Artery Disease in High Risk Diabetic Patients | — | Diabetes Mellitus | Terminated | 2004-01-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00269659 | Evaluating Effects of a Left Bundle Branch Block | — | Mechanical Dyssynchrony | Completed | 2004-01-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00690157 | Registry of Patients Referred for Heart Transplantation | — | Advanced Heart Failure | Completed | 2003-10-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT01187992 | Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisa… | Phase3 | Acute Coronary Syndrome | Terminated | 2003-09-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00147797 | Influence of Pravastatin on Carotid Artery Structure and Function in HIV-infect… | — | HIV Infection | Completed | 2003-05-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT02803411 | Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiog… | — | Coronary Heart Disease | Unknown | 2003-03-01 | 2026-01-01 | ClinicalTrials.gov |
| NCT00552864 | Comparison of Ropivacaine and Levobupivacaine in High Thoracic Epidural Anesthe… | Phase4 | Coronary Artery Bypass | Completed | 2003-01-01 | 2005-06-01 | ClinicalTrials.gov |
| NCT02503865 | Development of Rational Ways of Medical and Non-medical Treatment Methods for M… | Phase1 | Metabolic Syndrome | Completed | 2003-01-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00258596 | Sirolimus-Eluting Stents for Chronic Total Coronary Occlusions | Phase3 | Coronary Artery Disease | Completed | 2003-01-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT01642329 | Portuguese Registry on Acute Coronary Syndromes | — | Acute Coronary Syndrome | Unknown | 2002-01-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT01867801 | Portuguese Registry on Interventional Cardiology | — | Coronary Artery Disease | Unknown | 2002-01-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT01173029 | Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension an… | — | Systemic Arterial Hypertension | Completed | 2001-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT01340963 | The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas … | — | Chagas Cardiomyopathy | Completed | 1995-06-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT03272724 | French National Observatory on Infective Endocarditis | — | Infective Endocarditis | Recruiting | 1991-01-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT04557345 | Evaluation of the Inflammatory Response in Post-operated Aortic Valve Replaceme… | — | Aortic Valve Disease | Completed | 1990-01-01 | 2020-08-01 | ClinicalTrials.gov |
| NCT03654222 | The Long-term Success of Cardiovascular Surgery in Takayasu Arteritis | — | Arteritis, Takayasu | Completed | 1977-01-01 | 2017-06-26 | ClinicalTrials.gov |
Total clinical trials: 826
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Tirzepatide | Other | Preclinical | Psoriatic Arthritis | NOT_YET_RECRUITING | NCT07567378 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Assessment of Global Cognitive Function | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Single-Leg Balance Test | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Sit-to-Stand Test (5-Times Sit-to-Stand - 5STS) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Handgrip Dynamometry (Muscle Strength) | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Laser Speckle Contrast Imaging | Other | Preclinical | Aging Problems | NOT_YET_RECRUITING | NCT07563725 |
| Mesh group | Other | Preclinical | Incisional Hernia | UNKNOWN | NCT03105895 |
| Mesh group | Other | Preclinical | Incisional Hernia | UNKNOWN | NCT03105895 |
| Colchicine | Other | Phase PHASE3 | Arrhythmia | COMPLETED | NCT03021343 |
| observation of current care | Other | Preclinical | Acute Coronary Syndrome | UNKNOWN | NCT03231449 |
| observation of current care | Other | Preclinical | Acute Coronary Syndrome | UNKNOWN | NCT03231449 |
| Placebo | Other | Phase PHASE4 | Arrhythmia | COMPLETED | NCT03273634 |
| Lansoprazole Pill | Other | Phase PHASE4 | Arrhythmia | COMPLETED | NCT03273634 |
| Placebo | Other | Phase PHASE4 | Arrhythmia | COMPLETED | NCT03273634 |
| Lansoprazole Pill | Other | Phase PHASE4 | Arrhythmia | COMPLETED | NCT03273634 |
| Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin. | Other | Preclinical | Atrial Fibrillations | UNKNOWN | NCT02635230 |
| Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin. | Other | Preclinical | Atrial Fibrillations | UNKNOWN | NCT02635230 |
| Percutaneous coronary intervention | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT03234348 |
| Percutaneous coronary intervention | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT03234348 |
| Percutaneous coronary intervention | Other | Phase PHASE3 | Acute Coronary Syndrome | COMPLETED | NCT03234348 |
| Hyperemic stimuli | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04646278 |
| Hyperemic stimuli | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04646278 |
| Drug Eluting Stents (DES) | Drug | Approved | High Bleeding Risk | TERMINATED | NCT04885816 |
| Drug Eluting Balloon (DEB) | Drug | Approved | High Bleeding Risk | TERMINATED | NCT04885816 |
| Drug Eluting Stents (DES) | Drug | Approved | High Bleeding Risk | TERMINATED | NCT04885816 |
| Drug Eluting Balloon (DEB) | Drug | Approved | High Bleeding Risk | TERMINATED | NCT04885816 |
| Drug Eluting Stents (DES) | Drug | Approved | High Bleeding Risk | TERMINATED | NCT04885816 |
| Drug Eluting Balloon (DEB) | Drug | Approved | High Bleeding Risk | TERMINATED | NCT04885816 |
| Any surgery/procedure | Procedure | Preclinical | Surgery | UNKNOWN | NCT05147623 |
| Any surgery/procedure | Procedure | Preclinical | Surgery | UNKNOWN | NCT05147623 |
| Beta blocker | Other | Phase PHASE4 | Takotsubo Cardiomyopathy | NOT_YET_RECRUITING | NCT06509074 |
| Hemostatic device for distal radial approach. | Device | Approved | Coronary Intervention | UNKNOWN | NCT05966376 |
| Observing cardiovascular risk factors | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT04975503 |
| Observing cardiovascular risk factors | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT04975503 |
| Resistance training | Other | Approved | Pulmonary Disease | COMPLETED | NCT03518723 |
| Non-linear Periodized Resistance Training | Other | Approved | Pulmonary Disease | COMPLETED | NCT03518723 |
| Resistance training | Other | Approved | Pulmonary Disease | COMPLETED | NCT03518723 |
| Non-linear Periodized Resistance Training | Other | Approved | Pulmonary Disease | COMPLETED | NCT03518723 |
| red wine without alcohol | Other | Phase PHASE1 | Healthy | NOT_YET_RECRUITING | NCT06535620 |
| red wine with alcohol | Other | Phase PHASE1 | Healthy | NOT_YET_RECRUITING | NCT06535620 |
| red wine without alcohol | Other | Phase PHASE1 | Healthy | NOT_YET_RECRUITING | NCT06535620 |
| red wine with alcohol | Other | Phase PHASE1 | Healthy | NOT_YET_RECRUITING | NCT06535620 |
| Beta blocker | Other | Phase PHASE4 | Takotsubo Cardiomyopathy | NOT_YET_RECRUITING | NCT06509074 |
| Beta blocker | Other | Phase PHASE4 | Takotsubo Cardiomyopathy | NOT_YET_RECRUITING | NCT06509074 |
| Diuretics maintenance | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT05964738 |
| Diuretics withdrawal | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT05964738 |
| Diuretics maintenance | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT05964738 |
| Diuretics withdrawal | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT05964738 |
| Iohexol | Other | Phase PHASE1 | Chronic Kidney Failure | COMPLETED | NCT05105009 |
| Creatinine Powder | Other | Phase PHASE1 | Chronic Kidney Failure | COMPLETED | NCT05105009 |
| Furosemide Injection | Other | Phase PHASE1 | Chronic Kidney Failure | COMPLETED | NCT05105009 |
| Transcatheter edge-to-edge repair | Other | Preclinical | Tricuspid Regurgitation | RECRUITING | NCT06838611 |
| Pharmacological cardioversion with Refralon | Other | Approved | Atrium; Fibrillation | COMPLETED | NCT05456204 |
| Pharmacological cardioversion with Refralon | Other | Approved | Atrium; Fibrillation | COMPLETED | NCT05456204 |
| Pharmacological cardioversion with Refralon | Other | Phase PHASE4 | Atrial Fibrillation Paroxysmal | COMPLETED | NCT05445297 |
| Pharmacological cardioversion with Amiodarone | Other | Phase PHASE4 | Atrial Fibrillation Paroxysmal | COMPLETED | NCT05445297 |
| Export catheter (Medtronic) | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT00288665 |
| Export catheter (Medtronic) | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT00288665 |
| abciximab | Other | Phase PHASE4 | Coronary Disease | TERMINATED | NCT00320229 |
| abciximab | Other | Phase PHASE4 | Coronary Disease | TERMINATED | NCT00320229 |
| abciximab | Other | Phase PHASE4 | Coronary Disease | TERMINATED | NCT00320229 |
| Sodium bicarbonate | Other | Phase PHASE3 | Acute Kidney Failure | UNKNOWN | NCT00424320 |
| Sodium bicarbonate | Other | Phase PHASE3 | Acute Kidney Failure | UNKNOWN | NCT00424320 |
| sirolimus-eluting stent | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT00258596 |
| sirolimus-eluting stent | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT00258596 |
| Levobupivacaine | Other | Phase PHASE4 | Coronary Artery Bypass | COMPLETED | NCT00552864 |
| Ropivacaine | Other | Phase PHASE4 | Coronary Artery Bypass | COMPLETED | NCT00552864 |
| Levobupivacaine | Other | Phase PHASE4 | Coronary Artery Bypass | COMPLETED | NCT00552864 |
| Ropivacaine | Other | Phase PHASE4 | Coronary Artery Bypass | COMPLETED | NCT00552864 |
| ablation | Other | Approved | Ventricular Tachycardia | TERMINATED | NCT00481377 |
| ablation | Other | Approved | Ventricular Tachycardia | TERMINATED | NCT00481377 |
| Inspiratory muscle training (IMT) | Other | Phase PHASE4 | Diabetes Mellitus | UNKNOWN | NCT00752440 |
| Inspiratory muscle training (IMT) | Other | Phase PHASE4 | Diabetes Mellitus | UNKNOWN | NCT00752440 |
| Coronary Artery Bypass Grafting | Other | Preclinical | Myocardial Revascularization | UNKNOWN | NCT00755248 |
| Mini-thoracotomy for intramyocardial injection of VEGF165 | Other | Phase PHASE2 | Ischemic Cardiopathy | UNKNOWN | NCT00744315 |
| Mini-thoracotomy for intramyocardial injection of VEGF165 | Other | Phase PHASE2 | Ischemic Cardiopathy | UNKNOWN | NCT00744315 |
| Allon Thermowrap. MTRE Advanced Technologies Ltd. | Other | Approved | Anesthesia | UNKNOWN | NCT00791050 |
| Allon Thermowrap. MTRE Advanced Technologies Ltd. | Other | Approved | Anesthesia | UNKNOWN | NCT00791050 |
| Primary angioplasty | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT00675480 |
| Thrombectomy | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT00675480 |
| Primary angioplasty | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT00675480 |
| Thrombectomy | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT00675480 |
| Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A. | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT00916695 |
| Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A. | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT00916695 |
| matching placebo | Other | Phase PHASE4 | Pericardial Effusion | COMPLETED | NCT00247052 |
| diclofenac | Other | Phase PHASE4 | Pericardial Effusion | COMPLETED | NCT00247052 |
| matching placebo | Other | Phase PHASE4 | Pericardial Effusion | COMPLETED | NCT00247052 |
| diclofenac | Other | Phase PHASE4 | Pericardial Effusion | COMPLETED | NCT00247052 |
| Educational training regarding heart failure | Other | Approved | Heart Failure | COMPLETED | NCT00953810 |
| Educational training regarding heart failure | Other | Approved | Heart Failure | COMPLETED | NCT00953810 |
| Educational training regarding heart failure | Other | Approved | Heart Failure | COMPLETED | NCT00953810 |
| surgical replacement of the aortic stenotic valve | Other | Approved | Aortic Valve Stenosis | UNKNOWN | NCT00710775 |
| surgical replacement of the aortic stenotic valve | Other | Approved | Aortic Valve Stenosis | UNKNOWN | NCT00710775 |
| isotonic saline solution | Other | Phase PHASE3 | Contrast Induced Nephropathy | UNKNOWN | NCT00702728 |
| Furosemide and matched saline hydration | Other | Phase PHASE3 | Contrast Induced Nephropathy | UNKNOWN | NCT00702728 |
| isotonic saline solution | Other | Phase PHASE3 | Contrast Induced Nephropathy | UNKNOWN | NCT00702728 |
| Furosemide and matched saline hydration | Other | Phase PHASE3 | Contrast Induced Nephropathy | UNKNOWN | NCT00702728 |
| intramyocardial injection of VEGF-A165/bFGF:placebo plasmid | Other | Phase PHASE2 | Coronary Artery Disease | COMPLETED | NCT00620217 |
| intramyocardial injection of VEGF-A165/bFGF:placebo plasmid | Other | Phase PHASE2 | Coronary Artery Disease | COMPLETED | NCT00620217 |
| Comparison of 2 cooling procedures | Procedure | Phase PHASE4 | Hypothermia | COMPLETED | NCT00392639 |
| Coronary placement of bare metal stent vs. drug eluting stent | Drug | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT00220558 |
| Coronary placement of bare metal stent vs. drug eluting stent | Drug | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT00220558 |
| Coronary placement of bare metal stent vs. drug eluting stent | Drug | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT00220558 |
| epoetin alfa | Other | Phase PHASE2 | Myocardial Infarction | COMPLETED | NCT00449488 |
| epoetin alfa | Other | Phase PHASE2 | Myocardial Infarction | COMPLETED | NCT00449488 |
| epoetin alfa | Other | Phase PHASE2 | Myocardial Infarction | COMPLETED | NCT00449488 |
| NT-proBNP measurements | Other | Approved | Heart Failure, Congestive | COMPLETED | NCT00149422 |
| NT-proBNP measurements | Other | Approved | Heart Failure, Congestive | COMPLETED | NCT00149422 |
| NT-proBNP measurements | Other | Approved | Heart Failure, Congestive | COMPLETED | NCT00149422 |
| Infusion Intermittent | Other | Preclinical | Blood Pressure | COMPLETED | NCT01097031 |
| Infusion Intermittent | Other | Preclinical | Blood Pressure | COMPLETED | NCT01097031 |
| Infusion Intermittent | Other | Preclinical | Blood Pressure | COMPLETED | NCT01097031 |
| Drug Eluting Stent | Drug | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00825279 |
| Bare Metal Stent | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00825279 |
| Drug Eluting Stent | Drug | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00825279 |
| Bare Metal Stent | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00825279 |
| Clopidogrel | Other | Phase PHASE4 | Carotid Stenosis | COMPLETED | NCT01146301 |
| Clopidogrel | Other | Phase PHASE4 | Carotid Stenosis | COMPLETED | NCT01146301 |
| Clopidogrel | Other | Phase PHASE4 | Carotid Stenosis | COMPLETED | NCT01146301 |
| Intensive education of the doctor/nursing team on the protocol | Other | Approved | Diabetes Mellitus Type 2 | COMPLETED | NCT01154413 |
| Intensive education of the doctor/nursing team on the protocol | Other | Approved | Diabetes Mellitus Type 2 | COMPLETED | NCT01154413 |
| Normal fructose arm | Other | Approved | Overweight and Obesity | COMPLETED | NCT00868673 |
| low fructose | Other | Approved | Overweight and Obesity | COMPLETED | NCT00868673 |
| Normal fructose arm | Other | Approved | Overweight and Obesity | COMPLETED | NCT00868673 |
| low fructose | Other | Approved | Overweight and Obesity | COMPLETED | NCT00868673 |
| Atorvastatin | Other | Phase PHASE3 | Acute Coronary Syndrome | TERMINATED | NCT01187992 |
| Atorvastatin | Other | Phase PHASE3 | Acute Coronary Syndrome | TERMINATED | NCT01187992 |
| Nebivolol | Other | Phase PHASE4 | Chronic Heart Failure | COMPLETED | NCT00517725 |
| bisoprolol | Other | Phase PHASE4 | Chronic Heart Failure | COMPLETED | NCT00517725 |
| carvedilol | Other | Phase PHASE4 | Chronic Heart Failure | COMPLETED | NCT00517725 |
| Nebivolol | Other | Phase PHASE4 | Chronic Heart Failure | COMPLETED | NCT00517725 |
| bisoprolol | Other | Phase PHASE4 | Chronic Heart Failure | COMPLETED | NCT00517725 |
| carvedilol | Other | Phase PHASE4 | Chronic Heart Failure | COMPLETED | NCT00517725 |
| Inspiratory Muscle Training | Other | Approved | Reduction of Blood Pressure in Hypertensive Patients. | UNKNOWN | NCT01250444 |
| Inspiratory Muscle Training | Other | Approved | Reduction of Blood Pressure in Hypertensive Patients. | UNKNOWN | NCT01250444 |
| per intervention | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT00430820 |
| per intervention | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT00430820 |
| per intervention | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT00430820 |
| Heparin | Other | Phase PHASE3 | Diagnostic Coronary Angiography | COMPLETED | NCT01260519 |
| Heparin | Other | Phase PHASE3 | Diagnostic Coronary Angiography | COMPLETED | NCT01260519 |
| Heparin and protamine titration | Other | Phase PHASE4 | Cardiac Surgery | COMPLETED | NCT01267487 |
| PO continuous infusion of Protamine | Other | Phase PHASE4 | Cardiac Surgery | COMPLETED | NCT01267487 |
| Heparin fixed doses | Other | Phase PHASE4 | Cardiac Surgery | COMPLETED | NCT01267487 |
| Heparin and protamine titration | Other | Phase PHASE4 | Cardiac Surgery | COMPLETED | NCT01267487 |
| PO continuous infusion of Protamine | Other | Phase PHASE4 | Cardiac Surgery | COMPLETED | NCT01267487 |
| Heparin fixed doses | Other | Phase PHASE4 | Cardiac Surgery | COMPLETED | NCT01267487 |
| Carotid stenting with filter wire EZ | Other | Approved | Carotid Stenosis | COMPLETED | NCT01274676 |
| carotid stenting with MOMA | Other | Approved | Carotid Stenosis | COMPLETED | NCT01274676 |
| Carotid stenting with filter wire EZ | Other | Approved | Carotid Stenosis | COMPLETED | NCT01274676 |
| carotid stenting with MOMA | Other | Approved | Carotid Stenosis | COMPLETED | NCT01274676 |
| EPO | Other | Phase PHASE2 | Myocardial Infarction | COMPLETED | NCT00648089 |
| EPO | Other | Phase PHASE2 | Myocardial Infarction | COMPLETED | NCT00648089 |
| Coronary scanner | Other | Approved | Heart Transplant Patients | COMPLETED | NCT01122810 |
| Coronary scanner | Other | Approved | Heart Transplant Patients | COMPLETED | NCT01122810 |
| Coronary scanner | Other | Approved | Heart Transplant Patients | COMPLETED | NCT01122810 |
| Coronary scanner | Other | Approved | Valvular Disease | COMPLETED | NCT00484380 |
| Coronary scanner | Other | Approved | Valvular Disease | COMPLETED | NCT00484380 |
| Coronary scanner | Other | Approved | Valvular Disease | COMPLETED | NCT00484380 |
| Aerobic and anaerobic capacity use aquatic exercises | Other | Phase PHASE2 | Congestive Heart Failure | UNKNOWN | NCT00989248 |
| Aerobic and anaerobic capacity use aquatic exercises | Other | Phase PHASE2 | Congestive Heart Failure | UNKNOWN | NCT00989248 |
| Luc-Chopin stent | Other | Phase PHASE3 | Stenosis in Saphenous Vein Graft, Drug Eluting Stent | UNKNOWN | NCT00766129 |
| Taxus stent implantation | Other | Phase PHASE3 | Stenosis in Saphenous Vein Graft, Drug Eluting Stent | UNKNOWN | NCT00766129 |
| Luc-Chopin stent | Other | Phase PHASE3 | Stenosis in Saphenous Vein Graft, Drug Eluting Stent | UNKNOWN | NCT00766129 |
| Taxus stent implantation | Other | Phase PHASE3 | Stenosis in Saphenous Vein Graft, Drug Eluting Stent | UNKNOWN | NCT00766129 |
| Luc-Chopin stent | Other | Phase PHASE3 | Stenosis in Saphenous Vein Graft, Drug Eluting Stent | UNKNOWN | NCT00766129 |
| Taxus stent implantation | Other | Phase PHASE3 | Stenosis in Saphenous Vein Graft, Drug Eluting Stent | UNKNOWN | NCT00766129 |
| Manual settings with FreeO2 system in collection mode | Other | Approved | COPD Exacerbation | UNKNOWN | NCT01393015 |
| Automated settings on the oxygen delivery device | Device | Approved | COPD Exacerbation | UNKNOWN | NCT01393015 |
| Manual settings with FreeO2 system in collection mode | Other | Approved | COPD Exacerbation | UNKNOWN | NCT01393015 |
| Automated settings on the oxygen delivery device | Device | Approved | COPD Exacerbation | UNKNOWN | NCT01393015 |
| catch of blood | Other | Approved | Mitral Valve Prolapse | COMPLETED | NCT00799565 |
| catch of blood | Other | Approved | Mitral Valve Prolapse | COMPLETED | NCT00799565 |
| normal injection of Enoxaparine | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT00412802 |
| dose adaptation of Enoxaparin | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT00412802 |
| normal injection of Enoxaparine | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT00412802 |
| dose adaptation of Enoxaparin | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT00412802 |
| Transoesophageal echocardiography | Other | Approved | Atrial Fibrillation | COMPLETED | NCT00224757 |
| Transoesophageal echocardiography | Other | Approved | Atrial Fibrillation | COMPLETED | NCT00224757 |
| Transoesophageal echocardiography | Other | Approved | Atrial Fibrillation | COMPLETED | NCT00224757 |
| Aspirin | Other | Phase PHASE2 | Coronary Arteriosclerosis | UNKNOWN | NCT01466452 |
| Aspirin | Other | Phase PHASE2 | Coronary Arteriosclerosis | UNKNOWN | NCT01466452 |
| Telemetric ECG monitoring | Other | Approved | Cardiac Arrhythmia | UNKNOWN | NCT01265290 |
| repeated 24 hours ECG Holter monitoring | Other | Approved | Cardiac Arrhythmia | UNKNOWN | NCT01265290 |
| Telemetric ECG monitoring | Other | Approved | Cardiac Arrhythmia | UNKNOWN | NCT01265290 |
| repeated 24 hours ECG Holter monitoring | Other | Approved | Cardiac Arrhythmia | UNKNOWN | NCT01265290 |
| standardized guidelines for nursing | Other | Approved | Anxiety | COMPLETED | NCT01492452 |
| standardized guidelines for nursing | Other | Approved | Anxiety | COMPLETED | NCT01492452 |
| standardized guidelines for nursing | Other | Approved | Anxiety | COMPLETED | NCT01492452 |
| Atorvastatin-ranitidine | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Atorvastatin-esomeprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Atorvastatin-pantoprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Atorvastatin-omeprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Rosuvastatin-ranitidine | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Rosuvastatin-esomeprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Rosuvastatin-pantoprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Rosuvastatin-omeprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Atorvastatin-ranitidine | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Atorvastatin-esomeprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Atorvastatin-pantoprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Atorvastatin-omeprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Rosuvastatin-ranitidine | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Rosuvastatin-esomeprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Rosuvastatin-pantoprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Rosuvastatin-omeprazole | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00930670 |
| Intervention Group | Other | Approved | Coronary Artery Bypass Graft Triple Vessel | COMPLETED | NCT01559610 |
| Intervention Group | Other | Approved | Coronary Artery Bypass Graft Triple Vessel | COMPLETED | NCT01559610 |
| Intervention Group | Other | Approved | Coronary Artery Bypass Graft Triple Vessel | COMPLETED | NCT01559610 |
| Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec) | Drug | Phase PHASE1 | Refractory Angina Pectoris | SUSPENDED | NCT01567592 |
| Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec) | Drug | Phase PHASE1 | Refractory Angina Pectoris | SUSPENDED | NCT01567592 |
| Oat bran | Other | Phase PHASE1 | Atherosclerosis | UNKNOWN | NCT01581697 |
| Oat bran | Other | Phase PHASE1 | Atherosclerosis | UNKNOWN | NCT01581697 |
| Medium field of view | Other | Phase PHASE3 | Exposure to Ionizing Radiation | COMPLETED | NCT01334931 |
| Large field of view arm | Other | Phase PHASE3 | Exposure to Ionizing Radiation | COMPLETED | NCT01334931 |
| Medium field of view | Other | Phase PHASE3 | Exposure to Ionizing Radiation | COMPLETED | NCT01334931 |
| Large field of view arm | Other | Phase PHASE3 | Exposure to Ionizing Radiation | COMPLETED | NCT01334931 |
| transcutaneous electrical nerve stimulation | Other | Approved | Improvement of Cardiovascular Autonomic Control | UNKNOWN | NCT01252407 |
| transcutaneous electrical nerve stimulation | Other | Approved | Improvement of Cardiovascular Autonomic Control | UNKNOWN | NCT01252407 |
| Control group | Other | Phase PHASE1 | Acute Myocardial Infarction | COMPLETED | NCT00333320 |
| postconditioning | Other | Phase PHASE1 | Acute Myocardial Infarction | COMPLETED | NCT00333320 |
| Control group | Other | Phase PHASE1 | Acute Myocardial Infarction | COMPLETED | NCT00333320 |
| postconditioning | Other | Phase PHASE1 | Acute Myocardial Infarction | COMPLETED | NCT00333320 |
| Placebo | Other | Phase PHASE3 | End Stage Renal Disease | COMPLETED | NCT00865449 |
| spironolactone | Other | Phase PHASE3 | End Stage Renal Disease | COMPLETED | NCT00865449 |
| Placebo | Other | Phase PHASE3 | End Stage Renal Disease | COMPLETED | NCT00865449 |
| spironolactone | Other | Phase PHASE3 | End Stage Renal Disease | COMPLETED | NCT00865449 |
| Placebo | Other | Phase PHASE3 | End Stage Renal Disease | COMPLETED | NCT00865449 |
| spironolactone | Other | Phase PHASE3 | End Stage Renal Disease | COMPLETED | NCT00865449 |
| Printed, digital video disc | Other | Approved | Health Behavior | COMPLETED | NCT01720121 |
| Printed, digital video disc | Other | Approved | Health Behavior | COMPLETED | NCT01720121 |
| Printed, digital video disc | Other | Approved | Health Behavior | COMPLETED | NCT01720121 |
| Home-based pulmonary rehabilitation program | Other | Phase EARLY_PHASE1 | Lung Cancer | COMPLETED | NCT01667237 |
| Home-based pulmonary rehabilitation program | Other | Phase EARLY_PHASE1 | Lung Cancer | COMPLETED | NCT01667237 |
| PCI (percutaneous coronary intervention) | Other | Phase PHASE4 | Anticoagulants | COMPLETED | NCT00769938 |
| PCI (percutaneous coronary intervention) | Other | Phase PHASE4 | Anticoagulants | COMPLETED | NCT00769938 |
| Both use | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT01404507 |
| aspiration thrombectomy | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT01404507 |
| Gp 2b 3a inhibitor | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT01404507 |
| Both use | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT01404507 |
| aspiration thrombectomy | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT01404507 |
| Gp 2b 3a inhibitor | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT01404507 |
| Antiarrhythmic drugs | Drug | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT00821353 |
| RF catheter ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT00821353 |
| Antiarrhythmic drugs | Drug | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT00821353 |
| RF catheter ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT00821353 |
| Prolonged telemetric Full Disclosure ECG recording. | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT01265758 |
| Prolonged telemetric Full Disclosure ECG recording. | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT01265758 |
| Cucumber consumption | Other | Approved | Hypoalphalipoproteinemia | COMPLETED | NCT01342666 |
| Tomato consumption | Other | Approved | Hypoalphalipoproteinemia | COMPLETED | NCT01342666 |
| Cucumber consumption | Other | Approved | Hypoalphalipoproteinemia | COMPLETED | NCT01342666 |
| Tomato consumption | Other | Approved | Hypoalphalipoproteinemia | COMPLETED | NCT01342666 |
| Pulmonary vein radiofrequency ablation | Other | Phase PHASE4 | Atrial Fibrillation | COMPLETED | NCT00969735 |
| Pulmonary vein cryoablation | Other | Phase PHASE4 | Atrial Fibrillation | COMPLETED | NCT00969735 |
| Pulmonary vein radiofrequency ablation | Other | Phase PHASE4 | Atrial Fibrillation | COMPLETED | NCT00969735 |
| Pulmonary vein cryoablation | Other | Phase PHASE4 | Atrial Fibrillation | COMPLETED | NCT00969735 |
| Riboflavin | Other | Phase PHASE2 | Myocardial Infarction | UNKNOWN | NCT01741558 |
| Methotrexate | Other | Phase PHASE2 | Myocardial Infarction | UNKNOWN | NCT01741558 |
| Riboflavin | Other | Phase PHASE2 | Myocardial Infarction | UNKNOWN | NCT01741558 |
| Methotrexate | Other | Phase PHASE2 | Myocardial Infarction | UNKNOWN | NCT01741558 |
| Primary PCI | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT01377207 |
| Primary PCI | Other | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT01377207 |
| Anti-hypertensive drug treatment | Drug | Preclinical | Systemic Arterial Hypertension | COMPLETED | NCT01173029 |
| Anti-hypertensive drug treatment | Drug | Preclinical | Systemic Arterial Hypertension | COMPLETED | NCT01173029 |
| Anti-hypertensive drug treatment | Drug | Preclinical | Systemic Arterial Hypertension | COMPLETED | NCT01173029 |
| Prolonged telemetric Full Disclosure ECG recording. | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT01265303 |
| Prolonged telemetric Full Disclosure ECG recording. | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT01265303 |
| measure of left ventricular and diastolic pressure at exercise | Other | Approved | Heart Failure With Preserved Ejection Fraction (HFPEF) | COMPLETED | NCT01714752 |
| measure of left ventricular and diastolic pressure at exercise | Other | Approved | Heart Failure With Preserved Ejection Fraction (HFPEF) | COMPLETED | NCT01714752 |
| measure of left ventricular and diastolic pressure at exercise | Other | Approved | Heart Failure With Preserved Ejection Fraction (HFPEF) | COMPLETED | NCT01714752 |
| RIPer + IPost | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01390142 |
| RIPer | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01390142 |
| Control | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01390142 |
| RIPer + IPost | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01390142 |
| RIPer | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01390142 |
| Control | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01390142 |
| Polymer-Free Amphilimus-Eluting Stent | Other | Phase PHASE3 | Coronary Artery Disease | UNKNOWN | NCT01710748 |
| Polymer-Based Everolimus-Eluting Stent | Other | Phase PHASE3 | Coronary Artery Disease | UNKNOWN | NCT01710748 |
| Polymer-Free Amphilimus-Eluting Stent | Other | Phase PHASE3 | Coronary Artery Disease | UNKNOWN | NCT01710748 |
| Polymer-Based Everolimus-Eluting Stent | Other | Phase PHASE3 | Coronary Artery Disease | UNKNOWN | NCT01710748 |
| Placebo | Other | Phase PHASE4 | Ischemic Mitral Regurgitation | UNKNOWN | NCT01979965 |
| Ranolazine (Active drug) | Drug | Phase PHASE4 | Ischemic Mitral Regurgitation | UNKNOWN | NCT01979965 |
| Placebo | Other | Phase PHASE4 | Ischemic Mitral Regurgitation | UNKNOWN | NCT01979965 |
| Ranolazine (Active drug) | Drug | Phase PHASE4 | Ischemic Mitral Regurgitation | UNKNOWN | NCT01979965 |
| Digoxin | Other | Phase PHASE4 | Cardiac Failure | COMPLETED | NCT01699776 |
| Ivabradine | Other | Phase PHASE4 | Cardiac Failure | COMPLETED | NCT01699776 |
| Digoxin | Other | Phase PHASE4 | Cardiac Failure | COMPLETED | NCT01699776 |
| Ivabradine | Other | Phase PHASE4 | Cardiac Failure | COMPLETED | NCT01699776 |
| Omnipaque | Other | Phase PHASE3 | Ischemic Heart Diseases | COMPLETED | NCT01984411 |
| Femoral Technical | Other | Phase PHASE3 | Ischemic Heart Diseases | COMPLETED | NCT01984411 |
| Radial Technical | Other | Phase PHASE3 | Ischemic Heart Diseases | COMPLETED | NCT01984411 |
| Omnipaque | Other | Phase PHASE3 | Ischemic Heart Diseases | COMPLETED | NCT01984411 |
| Femoral Technical | Other | Phase PHASE3 | Ischemic Heart Diseases | COMPLETED | NCT01984411 |
| Radial Technical | Other | Phase PHASE3 | Ischemic Heart Diseases | COMPLETED | NCT01984411 |
| Placebo (cassava flavored flour) | Other | Approved | Dyslipidemia | COMPLETED | NCT01990391 |
| Brazil nut flour | Other | Approved | Dyslipidemia | COMPLETED | NCT01990391 |
| hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day | Other | Phase PHASE4 | Blood Pressure | COMPLETED | NCT01030458 |
| amlodipine 5/10 mg per day plus valsartan 160 mg/day | Other | Phase PHASE4 | Blood Pressure | COMPLETED | NCT01030458 |
| hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day | Other | Phase PHASE4 | Blood Pressure | COMPLETED | NCT01030458 |
| amlodipine 5/10 mg per day plus valsartan 160 mg/day | Other | Phase PHASE4 | Blood Pressure | COMPLETED | NCT01030458 |
| Placebo | Other | Phase PHASE4 | Pericardial Effusion | COMPLETED | NCT01266694 |
| Colchicines | Other | Phase PHASE4 | Pericardial Effusion | COMPLETED | NCT01266694 |
| Placebo | Other | Phase PHASE4 | Pericardial Effusion | COMPLETED | NCT01266694 |
| Colchicines | Other | Phase PHASE4 | Pericardial Effusion | COMPLETED | NCT01266694 |
| Usual Care for STEMI | Other | Phase PHASE1 | Acute Myocardial Infarction | SUSPENDED | NCT00846378 |
| Post conditioning | Other | Phase PHASE1 | Acute Myocardial Infarction | SUSPENDED | NCT00846378 |
| Usual Care for STEMI | Other | Phase PHASE1 | Acute Myocardial Infarction | SUSPENDED | NCT00846378 |
| Post conditioning | Other | Phase PHASE1 | Acute Myocardial Infarction | SUSPENDED | NCT00846378 |
| Usual Care for STEMI | Other | Phase PHASE1 | Acute Myocardial Infarction | SUSPENDED | NCT00846378 |
| Post conditioning | Other | Phase PHASE1 | Acute Myocardial Infarction | SUSPENDED | NCT00846378 |
| Noninvasive ventilation | Other | Approved | Heart Failure | COMPLETED | NCT02073253 |
| Noninvasive ventilation | Other | Approved | Heart Failure | COMPLETED | NCT02073253 |
| Noninvasive ventilation | Other | Approved | Heart Failure | COMPLETED | NCT02073253 |
| blood sample collection | Other | Approved | 1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | COMPLETED | NCT01729702 |
| blood sample collection | Other | Approved | 1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | COMPLETED | NCT01729702 |
| Conventional Physiotherapy | Drug | Approved | Cardiovascular Diseases | UNKNOWN | NCT02109055 |
| Pilates | Other | Approved | Cardiovascular Diseases | UNKNOWN | NCT02109055 |
| Conventional Physiotherapy | Drug | Approved | Cardiovascular Diseases | UNKNOWN | NCT02109055 |
| Pilates | Other | Approved | Cardiovascular Diseases | UNKNOWN | NCT02109055 |
| Pacemaker with Closed Loop Stimulation (CLS sensor) | Other | Phase PHASE4 | Syncope, Vasovagal | UNKNOWN | NCT01621464 |
| Pacemaker with Closed Loop Stimulation (CLS sensor) | Other | Phase PHASE4 | Syncope, Vasovagal | UNKNOWN | NCT01621464 |
| Separately drugs, simvastatin, aspirin and ramipril | Drug | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01321255 |
| FDC | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01321255 |
| Separately drugs, simvastatin, aspirin and ramipril | Drug | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01321255 |
| FDC | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01321255 |
| Curcumin | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT01831193 |
| Curcumin | Other | Phase PHASE3 | Proteinuria | COMPLETED | NCT01831193 |
| placebo | Other | Phase PHASE2 | Systolic and Diastolic Blood Pressure Levels | COMPLETED | NCT01157936 |
| Allopurinol | Other | Phase PHASE2 | Systolic and Diastolic Blood Pressure Levels | COMPLETED | NCT01157936 |
| placebo | Other | Phase PHASE2 | Systolic and Diastolic Blood Pressure Levels | COMPLETED | NCT01157936 |
| Allopurinol | Other | Phase PHASE2 | Systolic and Diastolic Blood Pressure Levels | COMPLETED | NCT01157936 |
| Placebo | Other | Phase PHASE2 | Kidney Transplant | SUSPENDED | NCT01021943 |
| spironolactone | Other | Phase PHASE2 | Kidney Transplant | SUSPENDED | NCT01021943 |
| Placebo | Other | Phase PHASE2 | Kidney Transplant | SUSPENDED | NCT01021943 |
| spironolactone | Other | Phase PHASE2 | Kidney Transplant | SUSPENDED | NCT01021943 |
| PCI of CTO | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT02022878 |
| PCI of CTO | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT02022878 |
| PCI of CTO | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT02022878 |
| GSV Radiofrequency | Other | Phase PHASE2 | Venous Disease | UNKNOWN | NCT02139085 |
| GSV Electrocoagulation | Other | Phase PHASE2 | Venous Disease | UNKNOWN | NCT02139085 |
| GSV Radiofrequency | Other | Phase PHASE2 | Venous Disease | UNKNOWN | NCT02139085 |
| GSV Electrocoagulation | Other | Phase PHASE2 | Venous Disease | UNKNOWN | NCT02139085 |
| Conventional treatment and follow up | Drug | Approved | Hypertension | COMPLETED | NCT02230293 |
| Multidisciplinary assistance | Other | Approved | Hypertension | COMPLETED | NCT02230293 |
| Conventional treatment and follow up | Drug | Approved | Hypertension | COMPLETED | NCT02230293 |
| Multidisciplinary assistance | Other | Approved | Hypertension | COMPLETED | NCT02230293 |
| Customized choice for the oral P2Y12 receptor blocker | Other | Phase PHASE4 | Acute Coronary Syndrome | UNKNOWN | NCT01477775 |
| Oral P2Y12 receptor blocker | Other | Phase PHASE4 | Acute Coronary Syndrome | UNKNOWN | NCT01477775 |
| Customized choice for the oral P2Y12 receptor blocker | Other | Phase PHASE4 | Acute Coronary Syndrome | UNKNOWN | NCT01477775 |
| Oral P2Y12 receptor blocker | Other | Phase PHASE4 | Acute Coronary Syndrome | UNKNOWN | NCT01477775 |
| Customized choice for the oral P2Y12 receptor blocker | Other | Phase PHASE4 | Acute Coronary Syndrome | UNKNOWN | NCT01477775 |
| Oral P2Y12 receptor blocker | Other | Phase PHASE4 | Acute Coronary Syndrome | UNKNOWN | NCT01477775 |
| Trans-femoral | Other | Approved | Exposure to Ionizing Radiation | COMPLETED | NCT01794325 |
| Trans-radial | Other | Approved | Exposure to Ionizing Radiation | COMPLETED | NCT01794325 |
| Trans-femoral | Other | Approved | Exposure to Ionizing Radiation | COMPLETED | NCT01794325 |
| Trans-radial | Other | Approved | Exposure to Ionizing Radiation | COMPLETED | NCT01794325 |
| Aspirin | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00822536 |
| Aspirin and Clopidogrel | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00822536 |
| Aspirin | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00822536 |
| Aspirin and Clopidogrel | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT00822536 |
| Dynamic Arterial line Pressure (DALP) | Other | Preclinical | Arteriovenous Fistula | UNKNOWN | NCT00522704 |
| Dynamic Arterial line Pressure (DALP) | Other | Preclinical | Arteriovenous Fistula | UNKNOWN | NCT00522704 |
| Dynamic Arterial line Pressure (DALP) | Other | Preclinical | Arteriovenous Fistula | UNKNOWN | NCT00522704 |
| TENS Placebo | Other | Approved | Cardiovascular Diseases | UNKNOWN | NCT02292199 |
| TENS Low Frequency | Other | Approved | Cardiovascular Diseases | UNKNOWN | NCT02292199 |
| TENS High Frequency | Other | Approved | Cardiovascular Diseases | UNKNOWN | NCT02292199 |
| Transthoracic echocardiography | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT02303652 |
| Radiofrequency maze procedure | Procedure | Preclinical | Atrial Fibrillation | COMPLETED | NCT02303652 |
| Transthoracic echocardiography | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT02303652 |
| Radiofrequency maze procedure | Procedure | Preclinical | Atrial Fibrillation | COMPLETED | NCT02303652 |
| Montelukast Sodium | Other | Phase PHASE4 | Coronary Artery Disease | TERMINATED | NCT00351364 |
| Montelukast Sodium | Other | Phase PHASE4 | Coronary Artery Disease | TERMINATED | NCT00351364 |
| Transfemoral PCI | Other | Approved | Percutaneous Coronary Intervention | TERMINATED | NCT01406236 |
| Transradial PCI | Other | Approved | Percutaneous Coronary Intervention | TERMINATED | NCT01406236 |
| trans-femoral and standard of care pharmacology | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| trans-femoral and long-term bivalirudin infusion | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| Trans-femoral and Short-term bivalirudin | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| trans-radial and standard of care pharmacology | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| trans-radial and long-term bivalirudin infusion | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| trans-radial and short-term bivalirudin | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| trans-femoral and standard of care pharmacology | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| trans-femoral and long-term bivalirudin infusion | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| Trans-femoral and Short-term bivalirudin | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| trans-radial and standard of care pharmacology | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| trans-radial and long-term bivalirudin infusion | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| trans-radial and short-term bivalirudin | Other | Phase PHASE3 | Acute Coronary Syndromes | UNKNOWN | NCT01433627 |
| Low electrical myostimulation | Other | Approved | Chronic Heart Failure | COMPLETED | NCT01408875 |
| Low electrical myostimulation | Other | Approved | Chronic Heart Failure | COMPLETED | NCT01408875 |
| ventilation therapy | Drug | Approved | Heart Failure | COMPLETED | NCT01120548 |
| SSI and SphygmoCor® evaluations | Other | Approved | Healthy Volunteers | COMPLETED | NCT01096264 |
| SSI and SphygmoCor® evaluations | Other | Approved | Healthy Volunteers | COMPLETED | NCT01096264 |
| Atrioventricular junction ablation (AVJA) | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT01850277 |
| Pharmacotherapy to slow and control ventricular rate | Drug | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT01850277 |
| External electrical cardioversion (EEC) | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT01850277 |
| Amiodarone | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT01850277 |
| Atrioventricular junction ablation (AVJA) | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT01850277 |
| Pharmacotherapy to slow and control ventricular rate | Drug | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT01850277 |
| External electrical cardioversion (EEC) | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT01850277 |
| Amiodarone | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT01850277 |
| Control group | Other | Approved | Heart Failure | UNKNOWN | NCT01325597 |
| Inspiratory muscle training | Other | Approved | Heart Failure | UNKNOWN | NCT01325597 |
| Electrical stimulation | Other | Approved | Heart Failure | UNKNOWN | NCT01325597 |
| Combined training | Other | Approved | Heart Failure | UNKNOWN | NCT01325597 |
| Heat Retention Head Wrap | Other | Phase PHASE1 | Impaired Thermoregulation | COMPLETED | NCT01675830 |
| Heat Retention Head Wrap | Other | Phase PHASE1 | Impaired Thermoregulation | COMPLETED | NCT01675830 |
| Stress MPI SPECT | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01368770 |
| Coronary CTA | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01368770 |
| Stress MPI SPECT | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01368770 |
| Coronary CTA | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01368770 |
| Stress MPI SPECT | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01368770 |
| Coronary CTA | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT01368770 |
| Furosemide | Other | Phase PHASE3 | Chronic Kidney Disease | UNKNOWN | NCT02417883 |
| Extended Lymphadenectomy | Other | Preclinical | Secondary Malignant Neoplasm of Lymph Node | COMPLETED | NCT02156414 |
| Radical Prostatectomy | Other | Preclinical | Secondary Malignant Neoplasm of Lymph Node | COMPLETED | NCT02156414 |
| Extended Lymphadenectomy | Other | Preclinical | Secondary Malignant Neoplasm of Lymph Node | COMPLETED | NCT02156414 |
| Radical Prostatectomy | Other | Preclinical | Secondary Malignant Neoplasm of Lymph Node | COMPLETED | NCT02156414 |
| Low intensity Exercise | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02441504 |
| Low intensity Exercise | Other | Approved | Diabetes Mellitus, Type 1 | COMPLETED | NCT02441504 |
| PCI with stenting | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| ACE inhibitors and/or ARB and/or AA | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| Statins | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| Platelet inhibitors | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| Beta adrenergic blockers | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| PCI with stenting | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| ACE inhibitors and/or ARB and/or AA | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| Statins | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| Platelet inhibitors | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| Beta adrenergic blockers | Other | Approved | Cardiovascular Diseases | TERMINATED | NCT00968383 |
| Sham injection | Other | Phase PHASE4 | Age-related Macular Degeneration | TERMINATED | NCT01319188 |
| 0.5 mg of ranibizumab + photodynamic therapy | Drug | Phase PHASE4 | Age-related Macular Degeneration | TERMINATED | NCT01319188 |
| 0.5 mg of ranibizumab | Other | Phase PHASE4 | Age-related Macular Degeneration | TERMINATED | NCT01319188 |
| Sham injection | Other | Phase PHASE4 | Age-related Macular Degeneration | TERMINATED | NCT01319188 |
| 0.5 mg of ranibizumab + photodynamic therapy | Drug | Phase PHASE4 | Age-related Macular Degeneration | TERMINATED | NCT01319188 |
| 0.5 mg of ranibizumab | Other | Phase PHASE4 | Age-related Macular Degeneration | TERMINATED | NCT01319188 |
| 0.9% saline | Other | Phase PHASE4 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT01527279 |
| antazoline | Other | Phase PHASE4 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT01527279 |
| 0.9% saline | Other | Phase PHASE4 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT01527279 |
| antazoline | Other | Phase PHASE4 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT01527279 |
| Fractional flow reserve (St. Jude Medical pressure-wire) | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT01835808 |
| Fractional flow reserve (St. Jude Medical pressure-wire) | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT01835808 |
| Fractional flow reserve (St. Jude Medical pressure-wire) | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT01835808 |
| PET CT | Other | Preclinical | Complications | UNKNOWN | NCT02196753 |
| Post conditioning | Other | Phase PHASE4 | Myocardial Infarction | COMPLETED | NCT00334373 |
| Post conditioning | Other | Phase PHASE4 | Myocardial Infarction | COMPLETED | NCT00334373 |
| sirolimus-eluting stent, zotarolimus-eluting stent | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT00428454 |
| sirolimus-eluting stent, zotarolimus-eluting stent | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT00428454 |
| sirolimus-eluting stent, zotarolimus-eluting stent | Other | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT00428454 |
| Supplemental | Other | Phase PHASE4 | Cardiorenal Syndrome | COMPLETED | NCT01265615 |
| Cholecalciferol | Other | Phase PHASE4 | Cardiorenal Syndrome | COMPLETED | NCT01265615 |
| Calcitriol | Other | Phase PHASE4 | Cardiorenal Syndrome | COMPLETED | NCT01265615 |
| Paricalcitol | Other | Phase PHASE4 | Cardiorenal Syndrome | COMPLETED | NCT01265615 |
| Supplemental | Other | Phase PHASE4 | Cardiorenal Syndrome | COMPLETED | NCT01265615 |
| Cholecalciferol | Other | Phase PHASE4 | Cardiorenal Syndrome | COMPLETED | NCT01265615 |
| Calcitriol | Other | Phase PHASE4 | Cardiorenal Syndrome | COMPLETED | NCT01265615 |
| Paricalcitol | Other | Phase PHASE4 | Cardiorenal Syndrome | COMPLETED | NCT01265615 |
| Fractional flow reserve measurement | Other | Approved | Stable Angina | COMPLETED | NCT02144090 |
| Fractional flow reserve measurement | Other | Approved | Stable Angina | COMPLETED | NCT02144090 |
| Fractional flow reserve measurement | Other | Approved | Stable Angina | COMPLETED | NCT02144090 |
| add-on sulphonylurea | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | UNKNOWN | NCT00700856 |
| add-on pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | UNKNOWN | NCT00700856 |
| add-on sulphonylurea | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | UNKNOWN | NCT00700856 |
| add-on pioglitazone | Other | Phase PHASE4 | Type 2 Diabetes Mellitus | UNKNOWN | NCT00700856 |
| periodontal treatment | Drug | Approved | Periodontitis | COMPLETED | NCT02543502 |
| periodontal treatment | Drug | Approved | Periodontitis | COMPLETED | NCT02543502 |
| Soy Oil | Other | Approved | Pregnancy | UNKNOWN | NCT02565290 |
| Omega 3 | Other | Approved | Pregnancy | UNKNOWN | NCT02565290 |
| Soy Oil | Other | Approved | Pregnancy | UNKNOWN | NCT02565290 |
| Omega 3 | Other | Approved | Pregnancy | UNKNOWN | NCT02565290 |
| Placebo controlled | Other | Phase PHASE2 | Inflammatory Disorder of the Cardiovascular System | COMPLETED | NCT02567617 |
| Polyphenols | Other | Phase PHASE2 | Inflammatory Disorder of the Cardiovascular System | COMPLETED | NCT02567617 |
| Placebo controlled | Other | Phase PHASE2 | Inflammatory Disorder of the Cardiovascular System | COMPLETED | NCT02567617 |
| Polyphenols | Other | Phase PHASE2 | Inflammatory Disorder of the Cardiovascular System | COMPLETED | NCT02567617 |
| atorvastatin, aspirin, losartan, amlodipine | Other | Phase PHASE4 | Carotid Artery Stenosis | TERMINATED | NCT00805311 |
| Carotid Endarterectomy | Other | Phase PHASE4 | Carotid Artery Stenosis | TERMINATED | NCT00805311 |
| atorvastatin, aspirin, losartan, amlodipine | Other | Phase PHASE4 | Carotid Artery Stenosis | TERMINATED | NCT00805311 |
| Carotid Endarterectomy | Other | Phase PHASE4 | Carotid Artery Stenosis | TERMINATED | NCT00805311 |
| Placebo | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT02261948 |
| Levosimendan | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT02261948 |
| Placebo | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT02261948 |
| Levosimendan | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT02261948 |
| Transcatheter closure of ASD II | Other | Preclinical | Ostium Secundum Atrial Septal Defect | UNKNOWN | NCT02601768 |
| Transcatheter closure of ASD II | Other | Preclinical | Ostium Secundum Atrial Septal Defect | UNKNOWN | NCT02601768 |
| Transcatheter closure of ASD II | Other | Preclinical | Ostium Secundum Atrial Septal Defect | UNKNOWN | NCT02601768 |
| Optimal Medical Treatment | Drug | Approved | Coronary Artery Disease | UNKNOWN | NCT02571803 |
| Dietary And Lifestyle Counseling | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02571803 |
| Optimal Medical Treatment | Drug | Approved | Coronary Artery Disease | UNKNOWN | NCT02571803 |
| Dietary And Lifestyle Counseling | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02571803 |
| "Analimentary detoxication" | Other | Phase PHASE1 | Metabolic Syndrome | COMPLETED | NCT02503865 |
| Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin | Other | Phase PHASE1 | Metabolic Syndrome | COMPLETED | NCT02503865 |
| "Analimentary detoxication" | Other | Phase PHASE1 | Metabolic Syndrome | COMPLETED | NCT02503865 |
| Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin | Other | Phase PHASE1 | Metabolic Syndrome | COMPLETED | NCT02503865 |
| Rate control | Other | Phase PHASE4 | Persistent Atrial Fibrillation | UNKNOWN | NCT02509754 |
| Atrial fibrillation catheter ablation | Other | Phase PHASE4 | Persistent Atrial Fibrillation | UNKNOWN | NCT02509754 |
| Rate control | Other | Phase PHASE4 | Persistent Atrial Fibrillation | UNKNOWN | NCT02509754 |
| Atrial fibrillation catheter ablation | Other | Phase PHASE4 | Persistent Atrial Fibrillation | UNKNOWN | NCT02509754 |
| low-intensity group | Other | Approved | Chronic Heart Failure | COMPLETED | NCT02263482 |
| moderate-intensity group | Other | Approved | Chronic Heart Failure | COMPLETED | NCT02263482 |
| control | Other | Approved | Chronic Heart Failure | COMPLETED | NCT02263482 |
| low-intensity group | Other | Approved | Chronic Heart Failure | COMPLETED | NCT02263482 |
| moderate-intensity group | Other | Approved | Chronic Heart Failure | COMPLETED | NCT02263482 |
| control | Other | Approved | Chronic Heart Failure | COMPLETED | NCT02263482 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02450994 |
| Dexamethasone | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02450994 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02450994 |
| Dexamethasone | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02450994 |
| Placebo | Other | Phase PHASE2 | Tetralogy of Fallot | UNKNOWN | NCT02010905 |
| Losartan | Other | Phase PHASE2 | Tetralogy of Fallot | UNKNOWN | NCT02010905 |
| Placebo | Other | Phase PHASE2 | Tetralogy of Fallot | UNKNOWN | NCT02010905 |
| Losartan | Other | Phase PHASE2 | Tetralogy of Fallot | UNKNOWN | NCT02010905 |
| Cognitive fuction, quality of life | Other | Phase PHASE4 | Quality of Life | UNKNOWN | NCT02650388 |
| Cognitive fuction, quality of life | Other | Phase PHASE4 | Quality of Life | UNKNOWN | NCT02650388 |
| Cognitive fuction, quality of life | Other | Phase PHASE4 | Quality of Life | UNKNOWN | NCT02650388 |
| acetazolamide | Other | Phase PHASE4 | Chronic Heart Failure | COMPLETED | NCT00517426 |
| acetazolamide | Other | Phase PHASE4 | Chronic Heart Failure | COMPLETED | NCT00517426 |
| ultrafiltration | Other | Phase PHASE4 | Severe Congestive Heart Failure | COMPLETED | NCT00360958 |
| ultrafiltration | Other | Phase PHASE4 | Severe Congestive Heart Failure | COMPLETED | NCT00360958 |
| Invasive coronary angiography as indicated by the guidelines | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02591992 |
| Cardiac CT as the first diagnostic modality in suspected CAD | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02591992 |
| Invasive coronary angiography as indicated by the guidelines | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02591992 |
| Cardiac CT as the first diagnostic modality in suspected CAD | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02591992 |
| Invasive coronary angiography as indicated by the guidelines | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02591992 |
| Cardiac CT as the first diagnostic modality in suspected CAD | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02591992 |
| hand grip strength | Other | Phase PHASE4 | Cachexia | UNKNOWN | NCT02686866 |
| dual-energy X-ray absorptiometry (Hologic, Delphi QDR) | Other | Phase PHASE4 | Cachexia | UNKNOWN | NCT02686866 |
| bioelectrical impedance analysis (Bodystat, Quadscan 4000) | Other | Phase PHASE4 | Cachexia | UNKNOWN | NCT02686866 |
| hand grip strength | Other | Phase PHASE4 | Cachexia | UNKNOWN | NCT02686866 |
| dual-energy X-ray absorptiometry (Hologic, Delphi QDR) | Other | Phase PHASE4 | Cachexia | UNKNOWN | NCT02686866 |
| bioelectrical impedance analysis (Bodystat, Quadscan 4000) | Other | Phase PHASE4 | Cachexia | UNKNOWN | NCT02686866 |
| Control treatment | Drug | Approved | Cardiovascular Diseases | COMPLETED | NCT02732223 |
| Functional treatment | Drug | Approved | Cardiovascular Diseases | COMPLETED | NCT02732223 |
| Control treatment | Drug | Approved | Cardiovascular Diseases | COMPLETED | NCT02732223 |
| Functional treatment | Drug | Approved | Cardiovascular Diseases | COMPLETED | NCT02732223 |
| Clopidogrel | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT02457130 |
| Ticagrelor | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT02457130 |
| transvenous left ventricular lead placement | Other | Approved | Left Ventricular Dysfunction | COMPLETED | NCT00551681 |
| biventricular pacemaker with epicardial left ventricular lead | Other | Approved | Left Ventricular Dysfunction | COMPLETED | NCT00551681 |
| transvenous left ventricular lead placement | Other | Approved | Left Ventricular Dysfunction | COMPLETED | NCT00551681 |
| biventricular pacemaker with epicardial left ventricular lead | Other | Approved | Left Ventricular Dysfunction | COMPLETED | NCT00551681 |
| Exercise | Other | Approved | Heart Failure | COMPLETED | NCT02782572 |
| Exercise | Other | Approved | Heart Failure | COMPLETED | NCT02782572 |
| Exercise | Other | Approved | Heart Failure | COMPLETED | NCT02782572 |
| usual low-fat dietary advice | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02578329 |
| Intensively advised Mediterranean diet | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02578329 |
| usual low-fat dietary advice | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02578329 |
| Intensively advised Mediterranean diet | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02578329 |
| coronary angiography | Other | Approved | Coronary Angiography | UNKNOWN | NCT02818127 |
| coronary angiography | Other | Approved | Coronary Angiography | UNKNOWN | NCT02818127 |
| aspirin | Other | Preclinical | Aspirin Hypersensitivity | COMPLETED | NCT02848339 |
| aspirin | Other | Preclinical | Aspirin Hypersensitivity | COMPLETED | NCT02848339 |
| Coronary angioplasty with implant of bioresorbable device | Device | Preclinical | Coronary Stenosis Treated With Implant of Bioresorbable Devices | UNKNOWN | NCT02854007 |
| Coronary angioplasty with implant of bioresorbable device | Device | Preclinical | Coronary Stenosis Treated With Implant of Bioresorbable Devices | UNKNOWN | NCT02854007 |
| Coronary angioplasty with implant of bioresorbable device | Device | Preclinical | Coronary Stenosis Treated With Implant of Bioresorbable Devices | UNKNOWN | NCT02854007 |
| Pacemaker Biotronik: bifocal stimulation | Other | Approved | Heart Failure | UNKNOWN | NCT02186314 |
| Pacemaker Biotronik: apical stimulation | Other | Approved | Heart Failure | UNKNOWN | NCT02186314 |
| Pacemaker Biotronik: bifocal stimulation | Other | Approved | Heart Failure | UNKNOWN | NCT02186314 |
| Pacemaker Biotronik: apical stimulation | Other | Approved | Heart Failure | UNKNOWN | NCT02186314 |
| cardiopulmonary exercise test,hypoxia and hypercapnia test | Other | Approved | Pulmonary Hypertension | COMPLETED | NCT02892981 |
| cardiopulmonary exercise test,hypoxia and hypercapnia test | Other | Approved | Pulmonary Hypertension | COMPLETED | NCT02892981 |
| Coronary Artery Bypass Graft without the use of CPB | Other | Phase PHASE3 | the Efficacy and Safety of Off-pump CABG | COMPLETED | NCT00463294 |
| Coronary Artery Bypass Graft with the use of CPB | Other | Phase PHASE3 | the Efficacy and Safety of Off-pump CABG | COMPLETED | NCT00463294 |
| Coronary Artery Bypass Graft without the use of CPB | Other | Phase PHASE3 | the Efficacy and Safety of Off-pump CABG | COMPLETED | NCT00463294 |
| Coronary Artery Bypass Graft with the use of CPB | Other | Phase PHASE3 | the Efficacy and Safety of Off-pump CABG | COMPLETED | NCT00463294 |
| Carotid Wallstent | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| Stent Roadsaver® | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| MO.MA Ultra | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| Filterwire EZ™ | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| Carotid Wallstent | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| Stent Roadsaver® | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| MO.MA Ultra | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| Filterwire EZ™ | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| Carotid Wallstent | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| Stent Roadsaver® | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| MO.MA Ultra | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| Filterwire EZ™ | Other | Approved | Carotid Stenosis | UNKNOWN | NCT02915328 |
| Thyroid facing the cathode end of xray machine | Other | Approved | Radiation Absorption | COMPLETED | NCT02925936 |
| Thyroid facing the anode end of xray machine | Other | Approved | Radiation Absorption | COMPLETED | NCT02925936 |
| Thyroid facing the cathode end of xray machine | Other | Approved | Radiation Absorption | COMPLETED | NCT02925936 |
| Thyroid facing the anode end of xray machine | Other | Approved | Radiation Absorption | COMPLETED | NCT02925936 |
| Task Force® Monitor | Other | Preclinical | Dysautonomia | UNKNOWN | NCT02931773 |
| Task Force® Monitor | Other | Preclinical | Dysautonomia | UNKNOWN | NCT02931773 |
| usual information | Other | Preclinical | Cardiac Disease | COMPLETED | NCT02484144 |
| modern information | Other | Preclinical | Cardiac Disease | COMPLETED | NCT02484144 |
| usual information | Other | Preclinical | Cardiac Disease | COMPLETED | NCT02484144 |
| modern information | Other | Preclinical | Cardiac Disease | COMPLETED | NCT02484144 |
| Angio-guided surgical revascularization | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02173860 |
| FFR-guided surgical revascularization | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02173860 |
| Angio-guided surgical revascularization | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02173860 |
| FFR-guided surgical revascularization | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02173860 |
| Angio-guided surgical revascularization | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02173860 |
| FFR-guided surgical revascularization | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02173860 |
| rehabilitation program | Other | Approved | Effect of High Altitude | COMPLETED | NCT02741583 |
| altitude rehabilitation program | Other | Approved | Effect of High Altitude | COMPLETED | NCT02741583 |
| rehabilitation program | Other | Approved | Effect of High Altitude | COMPLETED | NCT02741583 |
| altitude rehabilitation program | Other | Approved | Effect of High Altitude | COMPLETED | NCT02741583 |
| Predilatation with cutting balloon (Flextome) | Other | Phase PHASE3 | Coronary Artery Stenosis | UNKNOWN | NCT02946320 |
| Predilatation with scoring balloon (Scoroflex) | Other | Phase PHASE3 | Coronary Artery Stenosis | UNKNOWN | NCT02946320 |
| Predilatation with non-compliant balloon | Other | Phase PHASE3 | Coronary Artery Stenosis | UNKNOWN | NCT02946320 |
| Predilatation with cutting balloon (Flextome) | Other | Phase PHASE3 | Coronary Artery Stenosis | UNKNOWN | NCT02946320 |
| Predilatation with scoring balloon (Scoroflex) | Other | Phase PHASE3 | Coronary Artery Stenosis | UNKNOWN | NCT02946320 |
| Predilatation with non-compliant balloon | Other | Phase PHASE3 | Coronary Artery Stenosis | UNKNOWN | NCT02946320 |
| Paclitaxel eluting stent | Other | Phase PHASE4 | Coronary Artery Bypass Grafting | TERMINATED | NCT01223443 |
| Capnothorax and CPAP | Other | Approved | One-Lung Ventilation | UNKNOWN | NCT02959515 |
| Capnothorax | Other | Approved | One-Lung Ventilation | UNKNOWN | NCT02959515 |
| Capnothorax and CPAP | Other | Approved | One-Lung Ventilation | UNKNOWN | NCT02959515 |
| Capnothorax | Other | Approved | One-Lung Ventilation | UNKNOWN | NCT02959515 |
| Transfemoral coronary angiography and intervention | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01803841 |
| Transradial coronary angiography and intervention | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01803841 |
| Transfemoral coronary angiography and intervention | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01803841 |
| Transradial coronary angiography and intervention | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT01803841 |
| Early mitral valve repair | Other | Approved | Heart; Disease, Mitral(Valve) | TERMINATED | NCT01708265 |
| Watchful waiting | Other | Approved | Heart; Disease, Mitral(Valve) | TERMINATED | NCT01708265 |
| Early mitral valve repair | Other | Approved | Heart; Disease, Mitral(Valve) | TERMINATED | NCT01708265 |
| Watchful waiting | Other | Approved | Heart; Disease, Mitral(Valve) | TERMINATED | NCT01708265 |
| contrast media | Other | Preclinical | Acute Kidney Failure | UNKNOWN | NCT02991742 |
| contrast media | Other | Preclinical | Acute Kidney Failure | UNKNOWN | NCT02991742 |
| contrast media | Other | Preclinical | Acute Kidney Failure | UNKNOWN | NCT02991742 |
| transcutaneous vagal nerve stimulation off | Other | Approved | Hypertension | UNKNOWN | NCT03000842 |
| transcutaneous vagal nerve stimulation on | Other | Approved | Hypertension | UNKNOWN | NCT03000842 |
| transcutaneous vagal nerve stimulation off | Other | Approved | Hypertension | UNKNOWN | NCT03000842 |
| transcutaneous vagal nerve stimulation on | Other | Approved | Hypertension | UNKNOWN | NCT03000842 |
| Placebo | Other | Phase EARLY_PHASE1 | Hypertension | UNKNOWN | NCT03001271 |
| Angiotensin 1-7 | Other | Phase EARLY_PHASE1 | Hypertension | UNKNOWN | NCT03001271 |
| Placebo | Other | Phase EARLY_PHASE1 | Hypertension | UNKNOWN | NCT03001271 |
| Angiotensin 1-7 | Other | Phase EARLY_PHASE1 | Hypertension | UNKNOWN | NCT03001271 |
| Telerehabilitation program | Other | Approved | Lung Cancer | UNKNOWN | NCT02716493 |
| Telerehabilitation program | Other | Approved | Lung Cancer | UNKNOWN | NCT02716493 |
| Telerehabilitation program | Other | Approved | Lung Cancer | UNKNOWN | NCT02716493 |
| Children-Multicomponent intervention | Other | Phase PHASE3 | Cardiovascular Health | COMPLETED | NCT01551355 |
| Children-Multicomponent intervention | Other | Phase PHASE3 | Cardiovascular Health | COMPLETED | NCT01551355 |
| Procedure: PCI | Procedure | Preclinical | Percutaneous Coronary Intervention | COMPLETED | NCT01841346 |
| Procedure: PCI | Procedure | Preclinical | Percutaneous Coronary Intervention | COMPLETED | NCT01841346 |
| Placebo | Other | Phase PHASE2 | Proteinuria | UNKNOWN | NCT03019848 |
| Curcumin | Other | Phase PHASE2 | Proteinuria | UNKNOWN | NCT03019848 |
| Placebo | Other | Phase PHASE2 | Proteinuria | UNKNOWN | NCT03019848 |
| Curcumin | Other | Phase PHASE2 | Proteinuria | UNKNOWN | NCT03019848 |
| Renal denervation with a catheter-based procedure (Symplicity® Catheter System) | Procedure | Approved | Hypertension | COMPLETED | NCT01366625 |
| Renal denervation with a catheter-based procedure (Symplicity® Catheter System) | Procedure | Approved | Hypertension | COMPLETED | NCT01366625 |
| Digoxin and ivabradine | Other | Preclinical | Heart Failure | COMPLETED | NCT01796093 |
| Digoxin and ivabradine | Other | Preclinical | Heart Failure | COMPLETED | NCT01796093 |
| saline solution | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT01186445 |
| morphine chlorhydrate | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT01186445 |
| saline solution | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT01186445 |
| morphine chlorhydrate | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT01186445 |
| saline solution | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT01186445 |
| morphine chlorhydrate | Other | Phase PHASE3 | Acute Myocardial Infarction | COMPLETED | NCT01186445 |
| Control | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02635477 |
| Intervention | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02635477 |
| Control | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02635477 |
| Intervention | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02635477 |
| Bioresorbable vascular scaffold | Other | Phase PHASE4 | Coronary In-stent Restenosis | UNKNOWN | NCT02672878 |
| Bioresorbable vascular scaffold | Other | Phase PHASE4 | Coronary In-stent Restenosis | UNKNOWN | NCT02672878 |
| superficial palpatory agreement | Other | Approved | Congenital Heart Disease | COMPLETED | NCT02710825 |
| Osteopathy | Other | Approved | Congenital Heart Disease | COMPLETED | NCT02710825 |
| superficial palpatory agreement | Other | Approved | Congenital Heart Disease | COMPLETED | NCT02710825 |
| Osteopathy | Other | Approved | Congenital Heart Disease | COMPLETED | NCT02710825 |
| Bioresorbable vascular scaffold. Absorb GT1 (Abbott) | Other | Phase PHASE4 | Coronary In-stent Restenosis | UNKNOWN | NCT03069066 |
| Bioresorbable vascular scaffold. Absorb GT1 (Abbott) | Other | Phase PHASE4 | Coronary In-stent Restenosis | UNKNOWN | NCT03069066 |
| Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME) | Other | Phase PHASE3 | Coronary Artery Disease | UNKNOWN | NCT01516723 |
| Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME) | Other | Phase PHASE3 | Coronary Artery Disease | UNKNOWN | NCT01516723 |
| Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Other | Phase PHASE2 | Acute Myocardial Infarction | TERMINATED | NCT00350766 |
| Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Other | Phase PHASE2 | Acute Myocardial Infarction | TERMINATED | NCT00350766 |
| Ultrafiltration | Other | Phase PHASE4 | Acute Decompensated Heart Failure | TERMINATED | NCT01140399 |
| Furosemide or Furosemide and Dopamine | Other | Phase PHASE4 | Acute Decompensated Heart Failure | TERMINATED | NCT01140399 |
| Ultrafiltration | Other | Phase PHASE4 | Acute Decompensated Heart Failure | TERMINATED | NCT01140399 |
| Furosemide or Furosemide and Dopamine | Other | Phase PHASE4 | Acute Decompensated Heart Failure | TERMINATED | NCT01140399 |
| cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software | Other | Preclinical | Cardiopulmonary Resuscitation | UNKNOWN | NCT03112460 |
| cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software | Other | Preclinical | Cardiopulmonary Resuscitation | UNKNOWN | NCT03112460 |
| Esophageal cooling device (and usual standard procedure) | Device | Approved | Cardiac Arrest | COMPLETED | NCT02327871 |
| Esophageal cooling device (and usual standard procedure) | Device | Approved | Cardiac Arrest | COMPLETED | NCT02327871 |
| Aspirin | Other | Phase PHASE4 | Aortic Valve Disease | COMPLETED | NCT01559298 |
| Aspirin (80 mg/d) + clopidogrel (75 mg/d) | Other | Phase PHASE4 | Aortic Valve Disease | COMPLETED | NCT01559298 |
| Normal saline | Other | Phase PHASE2 | Hypertension, Pulmonary | WITHDRAWN | NCT00960921 |
| Iron sucrose | Other | Phase PHASE2 | Hypertension, Pulmonary | WITHDRAWN | NCT00960921 |
| Normal saline | Other | Phase PHASE2 | Hypertension, Pulmonary | WITHDRAWN | NCT00960921 |
| Iron sucrose | Other | Phase PHASE2 | Hypertension, Pulmonary | WITHDRAWN | NCT00960921 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02450968 |
| Dexamethasone | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02450968 |
| Placebo | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02450968 |
| Dexamethasone | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT02450968 |
| Coronary Computed Tomographic Angiography (CCTA) | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT03168269 |
| Coronary Computed Tomographic Angiography (CCTA) | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT03168269 |
| MATCh AFib application | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT03174093 |
| MATCh AFib application | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT03174093 |
| MATCh AFib application | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT03174093 |
| Facebook group | Other | Approved | Kidney Transplantation | COMPLETED | NCT03214965 |
| Facebook group | Other | Approved | Kidney Transplantation | COMPLETED | NCT03214965 |
| Placebo | Other | Phase PHASE2 | Chagas Disease | UNKNOWN | NCT02369978 |
| Benznidazole | Other | Phase PHASE2 | Chagas Disease | UNKNOWN | NCT02369978 |
| Nifurtimox | Other | Phase PHASE2 | Chagas Disease | UNKNOWN | NCT02369978 |
| Placebo | Other | Phase PHASE2 | Chagas Disease | UNKNOWN | NCT02369978 |
| Benznidazole | Other | Phase PHASE2 | Chagas Disease | UNKNOWN | NCT02369978 |
| Nifurtimox | Other | Phase PHASE2 | Chagas Disease | UNKNOWN | NCT02369978 |
| Water aerobic exercise session (WATER) | Other | Approved | Postexercise Hypotension | COMPLETED | NCT03112070 |
| Water aerobic exercise session (WATER) | Other | Approved | Postexercise Hypotension | COMPLETED | NCT03112070 |
| Nutritional and pharmaceutical counceling | Other | Phase PHASE3 | Chagas Disease | COMPLETED | NCT02517632 |
| Exercise, nutritional and pharmaceutical counceling | Other | Phase PHASE3 | Chagas Disease | COMPLETED | NCT02517632 |
| Nutritional and pharmaceutical counceling | Other | Phase PHASE3 | Chagas Disease | COMPLETED | NCT02517632 |
| Exercise, nutritional and pharmaceutical counceling | Other | Phase PHASE3 | Chagas Disease | COMPLETED | NCT02517632 |
| placebo | Other | Approved | Endothelial Dysfunction | COMPLETED | NCT02961972 |
| monohydrate and micronized creatine | Other | Approved | Endothelial Dysfunction | COMPLETED | NCT02961972 |
| placebo | Other | Approved | Endothelial Dysfunction | COMPLETED | NCT02961972 |
| monohydrate and micronized creatine | Other | Approved | Endothelial Dysfunction | COMPLETED | NCT02961972 |
| observation | Other | Preclinical | Chronic Heart Failure | COMPLETED | NCT02790801 |
| observation | Other | Preclinical | Chronic Heart Failure | COMPLETED | NCT02790801 |
| Treatment of restenosis | Drug | Preclinical | Coronary In-stnent Restenosis | UNKNOWN | NCT03167424 |
| Treatment of restenosis | Drug | Preclinical | Coronary In-stnent Restenosis | UNKNOWN | NCT03167424 |
| Treatment of restenosis | Drug | Preclinical | Coronary In-stnent Restenosis | UNKNOWN | NCT03167424 |
| DO2i | Other | Preclinical | Multiorgan Failure | UNKNOWN | NCT03281707 |
| NIRS | Other | Preclinical | Multiorgan Failure | UNKNOWN | NCT03281707 |
| DO2i | Other | Preclinical | Multiorgan Failure | UNKNOWN | NCT03281707 |
| NIRS | Other | Preclinical | Multiorgan Failure | UNKNOWN | NCT03281707 |
| catheter ablation | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT03332862 |
| catheter ablation | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT03332862 |
| MRI | Other | Approved | Diastolic Heart Failure | COMPLETED | NCT02537041 |
| elastography function ShearWave Imaging | Other | Approved | Diastolic Heart Failure | COMPLETED | NCT02537041 |
| MRI | Other | Approved | Diastolic Heart Failure | COMPLETED | NCT02537041 |
| elastography function ShearWave Imaging | Other | Approved | Diastolic Heart Failure | COMPLETED | NCT02537041 |
| blood sampling | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT03361202 |
| blood sampling | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT03361202 |
| whey protein | Other | Approved | Heart Failure | UNKNOWN | NCT03142399 |
| whey protein | Other | Approved | Heart Failure | UNKNOWN | NCT03142399 |
| whey protein | Other | Approved | Heart Failure | UNKNOWN | NCT03142399 |
| Colchicine | Other | Phase PHASE3 | Arrhythmia | COMPLETED | NCT03021343 |
| rosuvastatin | Other | Phase PHASE2 | Obstructive Coronary Artery Disease | COMPLETED | NCT01837823 |
| rosuvastatin | Other | Phase PHASE2 | Obstructive Coronary Artery Disease | COMPLETED | NCT01837823 |
| rosuvastatin | Other | Phase PHASE2 | Obstructive Coronary Artery Disease | COMPLETED | NCT01837823 |
| Intravenous amiodarone(2) | Other | Phase PHASE4 | Atrial Fibrillation | COMPLETED | NCT03432663 |
| Intravenous amiodarone(1) | Other | Phase PHASE4 | Atrial Fibrillation | COMPLETED | NCT03432663 |
| Intravenous amiodarone(2) | Other | Phase PHASE4 | Atrial Fibrillation | COMPLETED | NCT03432663 |
| Intravenous amiodarone(1) | Other | Phase PHASE4 | Atrial Fibrillation | COMPLETED | NCT03432663 |
| Cryoballoon ablation | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT03365700 |
| Radiofrequency Ablation | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT03365700 |
| Cryoballoon ablation | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT03365700 |
| Radiofrequency Ablation | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT03365700 |
| comparator group | Other | Phase PHASE4 | Arterial Hypertension | COMPLETED | NCT02620995 |
| sildenafil citrate | Other | Phase PHASE4 | Arterial Hypertension | COMPLETED | NCT02620995 |
| comparator group | Other | Phase PHASE4 | Arterial Hypertension | COMPLETED | NCT02620995 |
| sildenafil citrate | Other | Phase PHASE4 | Arterial Hypertension | COMPLETED | NCT02620995 |
| Comparison between two groups | Other | Preclinical | Vasovagal Syncope | COMPLETED | NCT02949804 |
| Comparison between two groups | Other | Preclinical | Vasovagal Syncope | COMPLETED | NCT02949804 |
| Pacebo | Other | Approved | Signs and Symptoms | COMPLETED | NCT02826408 |
| Rabeprazole sodium | Other | Approved | Signs and Symptoms | COMPLETED | NCT02826408 |
| Pacebo | Other | Approved | Signs and Symptoms | COMPLETED | NCT02826408 |
| Rabeprazole sodium | Other | Approved | Signs and Symptoms | COMPLETED | NCT02826408 |
| Pacebo | Other | Approved | Signs and Symptoms | COMPLETED | NCT02826408 |
| Rabeprazole sodium | Other | Approved | Signs and Symptoms | COMPLETED | NCT02826408 |
| home-based telerehabilitation | Other | Approved | Chronic Heart Failure | COMPLETED | NCT02523560 |
| home-based telerehabilitation | Other | Approved | Chronic Heart Failure | COMPLETED | NCT02523560 |
| Dobutamine stress test with trans-esophageal echocardiography | Other | Approved | Mortality After Major Non Cardiac Surgery | UNKNOWN | NCT03365726 |
| Dobutamine stress test with trans-esophageal echocardiography | Other | Approved | Mortality After Major Non Cardiac Surgery | UNKNOWN | NCT03365726 |
| Conventional care | Other | Approved | Non-cardiac Surgery | COMPLETED | NCT03213496 |
| Walk prescription | Other | Approved | Non-cardiac Surgery | COMPLETED | NCT03213496 |
| Conventional care | Other | Approved | Non-cardiac Surgery | COMPLETED | NCT03213496 |
| Walk prescription | Other | Approved | Non-cardiac Surgery | COMPLETED | NCT03213496 |
| Conventional care | Other | Approved | Non-cardiac Surgery | COMPLETED | NCT03213496 |
| Walk prescription | Other | Approved | Non-cardiac Surgery | COMPLETED | NCT03213496 |
| fractional flow reserve not performed | Other | Preclinical | Myocardial Ischemia | COMPLETED | NCT03082989 |
| fractional flow reserve performed | Other | Preclinical | Myocardial Ischemia | COMPLETED | NCT03082989 |
| fractional flow reserve not performed | Other | Preclinical | Myocardial Ischemia | COMPLETED | NCT03082989 |
| fractional flow reserve performed | Other | Preclinical | Myocardial Ischemia | COMPLETED | NCT03082989 |
| Standard Manual Compression | Other | Approved | Coronary Artery Disease | TERMINATED | NCT02061696 |
| Vascular Access Device | Device | Approved | Coronary Artery Disease | TERMINATED | NCT02061696 |
| Standard Manual Compression | Other | Approved | Coronary Artery Disease | TERMINATED | NCT02061696 |
| Vascular Access Device | Device | Approved | Coronary Artery Disease | TERMINATED | NCT02061696 |
| Canrenone | Other | Phase PHASE4 | Atrial Fibrillation, Paroxysmal | UNKNOWN | NCT03536806 |
| Saline 0.9% | Other | Phase PHASE4 | Atrial Fibrillation, Paroxysmal | UNKNOWN | NCT03536806 |
| Canrenone | Other | Phase PHASE4 | Atrial Fibrillation, Paroxysmal | UNKNOWN | NCT03536806 |
| Saline 0.9% | Other | Phase PHASE4 | Atrial Fibrillation, Paroxysmal | UNKNOWN | NCT03536806 |
| Usual care | Other | Approved | Chronic Heart Failure | TERMINATED | NCT01023438 |
| Strategy for assisted uptitration | Other | Approved | Chronic Heart Failure | TERMINATED | NCT01023438 |
| Usual care | Other | Approved | Chronic Heart Failure | TERMINATED | NCT01023438 |
| Strategy for assisted uptitration | Other | Approved | Chronic Heart Failure | TERMINATED | NCT01023438 |
| Usual care | Other | Approved | Chronic Heart Failure | TERMINATED | NCT01023438 |
| Strategy for assisted uptitration | Other | Approved | Chronic Heart Failure | TERMINATED | NCT01023438 |
| Placebos | Other | Approved | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT03071731 |
| Bronchodilators | Other | Approved | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT03071731 |
| Placebos | Other | Approved | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT03071731 |
| Bronchodilators | Other | Approved | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT03071731 |
| Aspirin | Other | Phase PHASE4 | Aortic Valve Disease | COMPLETED | NCT02640794 |
| Clopidogrel | Other | Phase PHASE4 | Aortic Valve Disease | COMPLETED | NCT02640794 |
| Aspirin | Other | Phase PHASE4 | Aortic Valve Disease | COMPLETED | NCT02640794 |
| Clopidogrel | Other | Phase PHASE4 | Aortic Valve Disease | COMPLETED | NCT02640794 |
| Control | Other | Approved | Cardiovascular Health | COMPLETED | NCT03579810 |
| Investigational | Other | Approved | Cardiovascular Health | COMPLETED | NCT03579810 |
| Control | Other | Approved | Cardiovascular Health | COMPLETED | NCT03579810 |
| Investigational | Other | Approved | Cardiovascular Health | COMPLETED | NCT03579810 |
| No intervention | Other | Phase PHASE4 | Decompensated Heart Failure | UNKNOWN | NCT02666651 |
| Tolvaptan | Other | Phase PHASE4 | Decompensated Heart Failure | UNKNOWN | NCT02666651 |
| No intervention | Other | Phase PHASE4 | Decompensated Heart Failure | UNKNOWN | NCT02666651 |
| Tolvaptan | Other | Phase PHASE4 | Decompensated Heart Failure | UNKNOWN | NCT02666651 |
| Arteries interruption before vein interruption | Other | Approved | Circulating Tumor Cell | UNKNOWN | NCT03645252 |
| Vein interruption before any other surgical manipulation | Other | Approved | Circulating Tumor Cell | UNKNOWN | NCT03645252 |
| Arteries interruption before vein interruption | Other | Approved | Circulating Tumor Cell | UNKNOWN | NCT03645252 |
| Vein interruption before any other surgical manipulation | Other | Approved | Circulating Tumor Cell | UNKNOWN | NCT03645252 |
| CARDIOENF | Other | Approved | Heart Failure | UNKNOWN | NCT03512782 |
| CARDIOENF | Other | Approved | Heart Failure | UNKNOWN | NCT03512782 |
| TAVR Implantation with SAPIEN | Other | Approved | Severe | COMPLETED | NCT02184442 |
| TAVR Implantation with SAPIEN XT | Other | Approved | Severe | COMPLETED | NCT02184442 |
| TAVR Implantation with SAPIEN | Other | Approved | Severe | COMPLETED | NCT02184442 |
| TAVR Implantation with SAPIEN XT | Other | Approved | Severe | COMPLETED | NCT02184442 |
| Blood sample and BNP measurement | Other | Preclinical | Reference Values of BNP in Healthy Newborn | COMPLETED | NCT02574806 |
| Blood sample and BNP measurement | Other | Preclinical | Reference Values of BNP in Healthy Newborn | COMPLETED | NCT02574806 |
| Right Heart Catheterization (RHC) | Other | Preclinical | Pulmonary Hypertension | UNKNOWN | NCT03707561 |
| Right Heart Catheterization (RHC) | Other | Preclinical | Pulmonary Hypertension | UNKNOWN | NCT03707561 |
| Right Heart Catheterization (RHC) | Other | Preclinical | Pulmonary Hypertension | UNKNOWN | NCT03707561 |
| Altitude exposure | Other | Approved | Effects of High Altitude | COMPLETED | NCT02451020 |
| Altitude exposure | Other | Approved | Effects of High Altitude | COMPLETED | NCT02451020 |
| Placebo | Other | Phase PHASE2 | Contrast-induced Nephropathy | UNKNOWN | NCT03767322 |
| Febuxostat | Other | Phase PHASE2 | Contrast-induced Nephropathy | UNKNOWN | NCT03767322 |
| Allopurinol | Other | Phase PHASE2 | Contrast-induced Nephropathy | UNKNOWN | NCT03767322 |
| Placebo | Other | Phase PHASE2 | Contrast-induced Nephropathy | UNKNOWN | NCT03767322 |
| Febuxostat | Other | Phase PHASE2 | Contrast-induced Nephropathy | UNKNOWN | NCT03767322 |
| Allopurinol | Other | Phase PHASE2 | Contrast-induced Nephropathy | UNKNOWN | NCT03767322 |
| In-Situ | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03753048 |
| Y-Graft | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03753048 |
| In-Situ | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03753048 |
| Y-Graft | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03753048 |
| Cooked diet with controlled amount of salt | Other | Approved | Heart Disease | COMPLETED | NCT03481322 |
| Cooked diet with controlled amount of salt | Other | Approved | Heart Disease | COMPLETED | NCT03481322 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177850 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177850 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177850 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177850 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03156231 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03156231 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03156231 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03156231 |
| Fractional Flow Reserve (FFR) | Other | Phase PHASE4 | Acute Coronary Syndrome | TERMINATED | NCT02000661 |
| Fractional Flow Reserve (FFR) | Other | Phase PHASE4 | Acute Coronary Syndrome | TERMINATED | NCT02000661 |
| Continous exercise training in the fasting state | Other | Approved | Obesity | WITHDRAWN | NCT03236285 |
| High-intensity interval exercise training in the fasting state | Other | Approved | Obesity | WITHDRAWN | NCT03236285 |
| Continous exercise training in the fed state | Other | Approved | Obesity | WITHDRAWN | NCT03236285 |
| High-intensity interval exercise training in the fed state | Other | Approved | Obesity | WITHDRAWN | NCT03236285 |
| Continous exercise training in the fasting state | Other | Approved | Obesity | WITHDRAWN | NCT03236285 |
| High-intensity interval exercise training in the fasting state | Other | Approved | Obesity | WITHDRAWN | NCT03236285 |
| Continous exercise training in the fed state | Other | Approved | Obesity | WITHDRAWN | NCT03236285 |
| High-intensity interval exercise training in the fed state | Other | Approved | Obesity | WITHDRAWN | NCT03236285 |
| Standard therapy | Drug | Approved | Cardiac Rehabilitation | UNKNOWN | NCT03178357 |
| Cardiac rehabilitation + standard therapy | Drug | Approved | Cardiac Rehabilitation | UNKNOWN | NCT03178357 |
| Standard therapy | Drug | Approved | Cardiac Rehabilitation | UNKNOWN | NCT03178357 |
| Cardiac rehabilitation + standard therapy | Drug | Approved | Cardiac Rehabilitation | UNKNOWN | NCT03178357 |
| No heart monitor | Other | Approved | Acute Myocardial Infarction | UNKNOWN | NCT03494751 |
| Heart monitor | Other | Approved | Acute Myocardial Infarction | UNKNOWN | NCT03494751 |
| No heart monitor | Other | Approved | Acute Myocardial Infarction | UNKNOWN | NCT03494751 |
| Heart monitor | Other | Approved | Acute Myocardial Infarction | UNKNOWN | NCT03494751 |
| Low glycemic load diet | Other | Approved | Glycemic Index | UNKNOWN | NCT03918005 |
| Low glycemic load diet | Other | Approved | Glycemic Index | UNKNOWN | NCT03918005 |
| Milled chia seeds | Other | Approved | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT03942822 |
| Milled chia seeds | Other | Approved | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT03942822 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03165890 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03165890 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03165890 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | NCT03165890 |
| Elective Cardiac Surgery | Procedure | Preclinical | Frailty Syndrome | COMPLETED | NCT03949439 |
| Elective Cardiac Surgery | Procedure | Preclinical | Frailty Syndrome | COMPLETED | NCT03949439 |
| Placebo | Other | Phase PHASE3 | Cardiac Catheterisation | COMPLETED | NCT02343276 |
| Nitroglycerin | Other | Phase PHASE3 | Cardiac Catheterisation | COMPLETED | NCT02343276 |
| Placebo | Other | Phase PHASE3 | Cardiac Catheterisation | COMPLETED | NCT02343276 |
| Nitroglycerin | Other | Phase PHASE3 | Cardiac Catheterisation | COMPLETED | NCT02343276 |
| Standard of care approach | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03976921 |
| Integration of CCTA with stress CTP when indicated | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03976921 |
| Standard of care approach | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03976921 |
| Integration of CCTA with stress CTP when indicated | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03976921 |
| Standard of care approach | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03976921 |
| Integration of CCTA with stress CTP when indicated | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT03976921 |
| No intervention | Other | Preclinical | Statins | TERMINATED | NCT03485742 |
| No intervention | Other | Preclinical | Statins | TERMINATED | NCT03485742 |
| No intervention | Other | Preclinical | Statins | TERMINATED | NCT03485742 |
| polygraphy and ECG | Other | Approved | Sleep Apnea Syndrome | COMPLETED | NCT02317848 |
| Isometric Handgrip Training (ISO) | Other | Approved | Coronary Artery Bypass Grafting | COMPLETED | NCT03096158 |
| Aerobic Training (AERO) | Other | Approved | Coronary Artery Bypass Grafting | COMPLETED | NCT03096158 |
| Ventilatory Muscle Training (TREMVEN) | Other | Approved | Coronary Artery Bypass Grafting | COMPLETED | NCT03096158 |
| Isometric Handgrip Training (ISO) | Other | Approved | Coronary Artery Bypass Grafting | COMPLETED | NCT03096158 |
| Aerobic Training (AERO) | Other | Approved | Coronary Artery Bypass Grafting | COMPLETED | NCT03096158 |
| Ventilatory Muscle Training (TREMVEN) | Other | Approved | Coronary Artery Bypass Grafting | COMPLETED | NCT03096158 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03173508 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03173508 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03173508 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03173508 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03167034 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03167034 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03167034 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03167034 |
| There is no intervention | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT03511885 |
| There is no intervention | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT03511885 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177837 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177837 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177837 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177837 |
| Statin intolerance test | Other | Preclinical | Statin Adverse Reaction | UNKNOWN | NCT04069598 |
| Statin intolerance test | Other | Preclinical | Statin Adverse Reaction | UNKNOWN | NCT04069598 |
| metacholine test | Other | Approved | Health, Subjective | UNKNOWN | NCT04137029 |
| Tiotropium Bromide | Other | Approved | Health, Subjective | UNKNOWN | NCT04137029 |
| Formoterol | Other | Approved | Health, Subjective | UNKNOWN | NCT04137029 |
| metacholine test | Other | Approved | Health, Subjective | UNKNOWN | NCT04137029 |
| Tiotropium Bromide | Other | Approved | Health, Subjective | UNKNOWN | NCT04137029 |
| Formoterol | Other | Approved | Health, Subjective | UNKNOWN | NCT04137029 |
| Placebo oral tablet | Other | Phase PHASE4 | Cardiovascular Diseases | UNKNOWN | NCT04161339 |
| Hydroxychloroquine | Other | Phase PHASE4 | Cardiovascular Diseases | UNKNOWN | NCT04161339 |
| Placebo oral tablet | Other | Phase PHASE4 | Cardiovascular Diseases | UNKNOWN | NCT04161339 |
| Hydroxychloroquine | Other | Phase PHASE4 | Cardiovascular Diseases | UNKNOWN | NCT04161339 |
| Placebo PA | Other | Phase PHASE1 | Infections, Respiratory | COMPLETED | NCT04174937 |
| Potentiator of antibiotics (PA) | Other | Phase PHASE1 | Infections, Respiratory | COMPLETED | NCT04174937 |
| Placebo PA | Other | Phase PHASE1 | Infections, Respiratory | COMPLETED | NCT04174937 |
| Potentiator of antibiotics (PA) | Other | Phase PHASE1 | Infections, Respiratory | COMPLETED | NCT04174937 |
| Clopidogrel | Other | Phase PHASE4 | Periprocedural Myocardial Infarction | COMPLETED | NCT04174261 |
| Remote Ischemic Preconditioning | Other | Phase PHASE4 | Periprocedural Myocardial Infarction | COMPLETED | NCT04174261 |
| Ticagrelor | Other | Phase PHASE4 | Periprocedural Myocardial Infarction | COMPLETED | NCT04174261 |
| Clopidogrel | Other | Phase PHASE4 | Periprocedural Myocardial Infarction | COMPLETED | NCT04174261 |
| Remote Ischemic Preconditioning | Other | Phase PHASE4 | Periprocedural Myocardial Infarction | COMPLETED | NCT04174261 |
| Ticagrelor | Other | Phase PHASE4 | Periprocedural Myocardial Infarction | COMPLETED | NCT04174261 |
| Clopidogrel | Other | Phase PHASE4 | Periprocedural Myocardial Infarction | COMPLETED | NCT04174261 |
| Remote Ischemic Preconditioning | Other | Phase PHASE4 | Periprocedural Myocardial Infarction | COMPLETED | NCT04174261 |
| Ticagrelor | Other | Phase PHASE4 | Periprocedural Myocardial Infarction | COMPLETED | NCT04174261 |
| Amiloride 10 mg | Other | Phase PHASE3 | Hypertension | UNKNOWN | NCT03928145 |
| Amiloride 20 mg | Other | Phase PHASE3 | Hypertension | UNKNOWN | NCT03928145 |
| Hydrochlorothiazide 50 mg | Other | Phase PHASE3 | Hypertension | UNKNOWN | NCT03928145 |
| Chlorthalidone 25 mg | Other | Phase PHASE3 | Hypertension | UNKNOWN | NCT03928145 |
| Amiloride 10 mg | Other | Phase PHASE3 | Hypertension | UNKNOWN | NCT03928145 |
| Amiloride 20 mg | Other | Phase PHASE3 | Hypertension | UNKNOWN | NCT03928145 |
| Hydrochlorothiazide 50 mg | Other | Phase PHASE3 | Hypertension | UNKNOWN | NCT03928145 |
| Chlorthalidone 25 mg | Other | Phase PHASE3 | Hypertension | UNKNOWN | NCT03928145 |
| Standard of Care | Other | Approved | Heart Failure | COMPLETED | NCT03613779 |
| LUS-guided therapy | Drug | Approved | Heart Failure | COMPLETED | NCT03613779 |
| Standard of Care | Other | Approved | Heart Failure | COMPLETED | NCT03613779 |
| LUS-guided therapy | Drug | Approved | Heart Failure | COMPLETED | NCT03613779 |
| Steps goal setting and supporting phone calls | Other | Approved | Sedentary Behavior | COMPLETED | NCT04235647 |
| Nurse led tutorial on lifestyle management and pedometer hand-out | Other | Approved | Sedentary Behavior | COMPLETED | NCT04235647 |
| Steps goal setting and supporting phone calls | Other | Approved | Sedentary Behavior | COMPLETED | NCT04235647 |
| Nurse led tutorial on lifestyle management and pedometer hand-out | Other | Approved | Sedentary Behavior | COMPLETED | NCT04235647 |
| Steps goal setting and supporting phone calls | Other | Approved | Sedentary Behavior | COMPLETED | NCT04235647 |
| Nurse led tutorial on lifestyle management and pedometer hand-out | Other | Approved | Sedentary Behavior | COMPLETED | NCT04235647 |
| Allopurinol Pill | Other | Phase PHASE3 | Musculoskeletal Degeneration | UNKNOWN | NCT04012294 |
| Allopurinol Pill | Other | Phase PHASE3 | Musculoskeletal Degeneration | UNKNOWN | NCT04012294 |
| Florence device | Device | Approved | Cardiac Failure | COMPLETED | NCT03799133 |
| Florence device | Device | Approved | Cardiac Failure | COMPLETED | NCT03799133 |
| Florence device | Device | Approved | Cardiac Failure | COMPLETED | NCT03799133 |
| Probiotic supplementation | Other | Approved | Systemic Arterial Hypertension | UNKNOWN | NCT03955159 |
| Probiotic supplementation | Other | Approved | Systemic Arterial Hypertension | UNKNOWN | NCT03955159 |
| Placebo | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT02598505 |
| Indacaterol | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT02598505 |
| no intervention | Other | Preclinical | Acute Myocardial Infarction | UNKNOWN | NCT04241770 |
| no intervention | Other | Preclinical | Acute Myocardial Infarction | UNKNOWN | NCT04241770 |
| Placebo | Other | Phase PHASE3 | Chagas Disease | COMPLETED | NCT00123916 |
| Benznidazole | Other | Phase PHASE3 | Chagas Disease | COMPLETED | NCT00123916 |
| Quality of life questionnaire | Other | Preclinical | Congenital Heart Disease | COMPLETED | NCT03931096 |
| Quality of life questionnaire | Other | Preclinical | Congenital Heart Disease | COMPLETED | NCT03931096 |
| Quality of life questionnaire | Other | Preclinical | Congenital Heart Disease | COMPLETED | NCT03931096 |
| Quality of life questionnaire | Other | Preclinical | Congenital Heart Disease | COMPLETED | NCT03931096 |
| Prophylactic administration of antithyroid drugs before iodinated contrast media exposure | Drug | Preclinical | Hyperthyroidism/Thyrotoxicosis | COMPLETED | NCT04304794 |
| Administration of iodinated contrast media | Other | Preclinical | Hyperthyroidism/Thyrotoxicosis | COMPLETED | NCT04304794 |
| Prophylactic administration of antithyroid drugs before iodinated contrast media exposure | Drug | Preclinical | Hyperthyroidism/Thyrotoxicosis | COMPLETED | NCT04304794 |
| Administration of iodinated contrast media | Other | Preclinical | Hyperthyroidism/Thyrotoxicosis | COMPLETED | NCT04304794 |
| FxCordiax 120 membrane | Other | Approved | Hemodiafiltration | UNKNOWN | NCT03938285 |
| Theranova 400 membrane | Other | Approved | Hemodiafiltration | UNKNOWN | NCT03938285 |
| PCI on left main | Other | Preclinical | Coronary Arteriosclerosis | UNKNOWN | NCT04321473 |
| PCI on left main | Other | Preclinical | Coronary Arteriosclerosis | UNKNOWN | NCT04321473 |
| PCI on left main | Other | Preclinical | Coronary Arteriosclerosis | UNKNOWN | NCT04321473 |
| Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions | Other | Phase PHASE1 | Spinal Cord Contusion | COMPLETED | NCT04331405 |
| sugar reduction | Other | Approved | Students of the 6. Grade | TERMINATED | NCT04165304 |
| sugar reduction | Other | Approved | Students of the 6. Grade | TERMINATED | NCT04165304 |
| sevoflurane | Other | Phase PHASE4 | Myocardial Infarction | TERMINATED | NCT02671084 |
| sevoflurane | Other | Phase PHASE4 | Myocardial Infarction | TERMINATED | NCT02671084 |
| COMBINED | Other | Approved | Hypertension | COMPLETED | NCT02937922 |
| RESISTANCE | Other | Approved | Hypertension | COMPLETED | NCT02937922 |
| AEROBIC | Other | Approved | Hypertension | COMPLETED | NCT02937922 |
| COMBINED | Other | Approved | Hypertension | COMPLETED | NCT02937922 |
| RESISTANCE | Other | Approved | Hypertension | COMPLETED | NCT02937922 |
| AEROBIC | Other | Approved | Hypertension | COMPLETED | NCT02937922 |
| COMBINED | Other | Approved | Hypertension | COMPLETED | NCT02937922 |
| RESISTANCE | Other | Approved | Hypertension | COMPLETED | NCT02937922 |
| AEROBIC | Other | Approved | Hypertension | COMPLETED | NCT02937922 |
| Placebo | Other | Approved | Autonomic Nervous System | UNKNOWN | NCT04371757 |
| α1-adrenergic block | Other | Approved | Autonomic Nervous System | UNKNOWN | NCT04371757 |
| Placebo | Other | Approved | Autonomic Nervous System | UNKNOWN | NCT04371757 |
| α1-adrenergic block | Other | Approved | Autonomic Nervous System | UNKNOWN | NCT04371757 |
| Placebo Oral Tablet | Other | Phase PHASE3 | Atrial Fibrillation | TERMINATED | NCT03015831 |
| Colchicine | Other | Phase PHASE3 | Atrial Fibrillation | TERMINATED | NCT03015831 |
| Placebo Oral Tablet | Other | Phase PHASE3 | Atrial Fibrillation | TERMINATED | NCT03015831 |
| Colchicine | Other | Phase PHASE3 | Atrial Fibrillation | TERMINATED | NCT03015831 |
| Aerobic Training | Other | Approved | Heart Failure | COMPLETED | NCT03013270 |
| Aerobic-Inspiratory | Other | Approved | Heart Failure | COMPLETED | NCT03013270 |
| Aerobic-Resistance | Other | Approved | Heart Failure | COMPLETED | NCT03013270 |
| Aerobic-Resistance-Inspiratory | Other | Approved | Heart Failure | COMPLETED | NCT03013270 |
| Aerobic Training | Other | Approved | Heart Failure | COMPLETED | NCT03013270 |
| Aerobic-Inspiratory | Other | Approved | Heart Failure | COMPLETED | NCT03013270 |
| Aerobic-Resistance | Other | Approved | Heart Failure | COMPLETED | NCT03013270 |
| Aerobic-Resistance-Inspiratory | Other | Approved | Heart Failure | COMPLETED | NCT03013270 |
| Clinical data | Other | Preclinical | COVID | UNKNOWN | NCT04374110 |
| Clinical data | Other | Preclinical | COVID | UNKNOWN | NCT04374110 |
| Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction | Other | Preclinical | Heart Failure, Left Sided | COMPLETED | NCT04397302 |
| Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction | Other | Preclinical | Heart Failure, Left Sided | COMPLETED | NCT04397302 |
| Resistance Training | Other | Phase PHASE4 | Resistance Training | UNKNOWN | NCT04443777 |
| Resistance Training | Other | Phase PHASE4 | Resistance Training | UNKNOWN | NCT04443777 |
| Sevoflurane | Other | Preclinical | Inflammatory Response | COMPLETED | NCT02672345 |
| Sevoflurane | Other | Preclinical | Inflammatory Response | COMPLETED | NCT02672345 |
| CCTA | Other | Approved | Management/Treatment of Coronary Artery Disease | COMPLETED | NCT04448691 |
| CCTA | Other | Approved | Management/Treatment of Coronary Artery Disease | COMPLETED | NCT04448691 |
| Distal radial artery approach | Other | Approved | Radial Artery Occlusion | COMPLETED | NCT04238026 |
| Distal radial artery approach | Other | Approved | Radial Artery Occlusion | COMPLETED | NCT04238026 |
| positioning | Other | Approved | Post-thoracotomy Pain Syndrome | UNKNOWN | NCT04415242 |
| positioning | Other | Approved | Post-thoracotomy Pain Syndrome | UNKNOWN | NCT04415242 |
| Pharmacoinvasive strategy | Other | Preclinical | Myocardial Infarction, Acute | COMPLETED | NCT03974581 |
| Primary percutaneous coronary intervention | Other | Preclinical | Myocardial Infarction, Acute | COMPLETED | NCT03974581 |
| Pharmacoinvasive strategy | Other | Preclinical | Myocardial Infarction, Acute | COMPLETED | NCT03974581 |
| Primary percutaneous coronary intervention | Other | Preclinical | Myocardial Infarction, Acute | COMPLETED | NCT03974581 |
| Pharmacoinvasive strategy | Other | Preclinical | Myocardial Infarction, Acute | COMPLETED | NCT03974581 |
| Primary percutaneous coronary intervention | Other | Preclinical | Myocardial Infarction, Acute | COMPLETED | NCT03974581 |
| without App hypercross group | Other | Approved | Blood Pressure | UNKNOWN | NCT04475367 |
| App hypercross group | Other | Approved | Blood Pressure | UNKNOWN | NCT04475367 |
| without App hypercross group | Other | Approved | Blood Pressure | UNKNOWN | NCT04475367 |
| App hypercross group | Other | Approved | Blood Pressure | UNKNOWN | NCT04475367 |
| Cannabidiol | Other | Phase PHASE1 | Heart Failure | UNKNOWN | NCT03634189 |
| Cannabidiol | Other | Phase PHASE1 | Heart Failure | UNKNOWN | NCT03634189 |
| Rituximab | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | UNKNOWN | NCT03332888 |
| Rituximab | Other | Phase PHASE2 | Heart Failure With Reduced Ejection Fraction | UNKNOWN | NCT03332888 |
| Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) | Drug | Preclinical | Cardiovascular Diseases | UNKNOWN | NCT04508920 |
| Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) | Drug | Preclinical | Cardiovascular Diseases | UNKNOWN | NCT04508920 |
| femoral artery access for complex PCI | Other | Approved | Complex Coronary Lesions | COMPLETED | NCT03846752 |
| radial artery access for complex PCI | Other | Approved | Complex Coronary Lesions | COMPLETED | NCT03846752 |
| femoral artery access for complex PCI | Other | Approved | Complex Coronary Lesions | COMPLETED | NCT03846752 |
| radial artery access for complex PCI | Other | Approved | Complex Coronary Lesions | COMPLETED | NCT03846752 |
| skin laser speckle contrast imaging and video-capillaroscopy | Other | Preclinical | Chagas Cardiomyopathy | COMPLETED | NCT03524768 |
| skin laser speckle contrast imaging and video-capillaroscopy | Other | Preclinical | Chagas Cardiomyopathy | COMPLETED | NCT03524768 |
| convalescent plasma | Other | Phase PHASE2 | COVID-19 | UNKNOWN | NCT04388410 |
| convalescent plasma | Other | Phase PHASE2 | COVID-19 | UNKNOWN | NCT04388410 |
| Internet-based education | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT03763500 |
| Internet-based education | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT03763500 |
| Internet-based education | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT03763500 |
| Cryoballoon ablation without contrast | Other | Approved | Paroxysmal Atrial Fibrillation | UNKNOWN | NCT04344743 |
| Cryoballoon ablation without contrast | Other | Approved | Paroxysmal Atrial Fibrillation | UNKNOWN | NCT04344743 |
| Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement | Other | Approved | Hypertension | COMPLETED | NCT03732924 |
| Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement | Other | Approved | Hypertension | COMPLETED | NCT03732924 |
| Control diet | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02202265 |
| Nuts | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02202265 |
| Olive oil | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02202265 |
| Control diet | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02202265 |
| Nuts | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02202265 |
| Olive oil | Other | Approved | Coronary Artery Disease | UNKNOWN | NCT02202265 |
| Two-dimensional transthoracic echocardiogram | Other | Preclinical | Aortic Valve Disease | COMPLETED | NCT04557345 |
| Determination of cytokines | Other | Preclinical | Aortic Valve Disease | COMPLETED | NCT04557345 |
| Two-dimensional transthoracic echocardiogram | Other | Preclinical | Aortic Valve Disease | COMPLETED | NCT04557345 |
| Determination of cytokines | Other | Preclinical | Aortic Valve Disease | COMPLETED | NCT04557345 |
| Feedback mannequim | Other | Approved | Simulation Training | COMPLETED | NCT04338490 |
| Feedback mannequim | Other | Approved | Simulation Training | COMPLETED | NCT04338490 |
| Placebo | Other | Approved | Chronic Thromboembolic Pulmonary Hypertension | UNKNOWN | NCT04081012 |
| N-acetyl cysteine | Other | Approved | Chronic Thromboembolic Pulmonary Hypertension | UNKNOWN | NCT04081012 |
| Placebo | Other | Approved | Chronic Thromboembolic Pulmonary Hypertension | UNKNOWN | NCT04081012 |
| N-acetyl cysteine | Other | Approved | Chronic Thromboembolic Pulmonary Hypertension | UNKNOWN | NCT04081012 |
| Simple chest tomography | Other | Preclinical | Covid19 | COMPLETED | NCT04577105 |
| Simple chest tomography | Other | Preclinical | Covid19 | COMPLETED | NCT04577105 |
| MECHANICAL PULMONARY HYPERINFLUATION | Other | Approved | Heart Diseases | UNKNOWN | NCT04583371 |
| MECHANICAL PULMONARY HYPERINFLUATION | Other | Approved | Heart Diseases | UNKNOWN | NCT04583371 |
| Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction | Other | Phase PHASE4 | Endothelial Dysfunction | COMPLETED | NCT04202172 |
| Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction | Other | Phase PHASE4 | Endothelial Dysfunction | COMPLETED | NCT04202172 |
| Pulmonary tele-rehabilitation | Other | Approved | Chronic Pulmonary Disease | UNKNOWN | NCT04658979 |
| Pulmonary tele-rehabilitation | Other | Approved | Chronic Pulmonary Disease | UNKNOWN | NCT04658979 |
| Pulmonary tele-rehabilitation | Other | Approved | Chronic Pulmonary Disease | UNKNOWN | NCT04658979 |
| Pressure guidewire, optimal coherence tomography | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT04674475 |
| Pressure guidewire, optimal coherence tomography | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT04674475 |
| Pressure guidewire, optimal coherence tomography | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT04674475 |
| ELISPOT IFN-γ assay | Other | Phase PHASE4 | Heart Transplant Infection | UNKNOWN | NCT04278547 |
| ELISPOT IFN-γ assay | Other | Phase PHASE4 | Heart Transplant Infection | UNKNOWN | NCT04278547 |
| ELISPOT IFN-γ assay | Other | Phase PHASE4 | Heart Transplant Infection | UNKNOWN | NCT04278547 |
| Vessel Fractional Flow Reserve | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT03791320 |
| Vessel Fractional Flow Reserve | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT03791320 |
| Specific blood sample of women under 50 years with acute MI | Other | Approved | Acute Myocardial Infarction | COMPLETED | NCT03073447 |
| Biolinx Polymer-based zotarolimus-eluting stents | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT03321032 |
| Polymer-free amphilimus-eluting stents | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT03321032 |
| Biolinx Polymer-based zotarolimus-eluting stents | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT03321032 |
| Polymer-free amphilimus-eluting stents | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT03321032 |
| Biolinx Polymer-based zotarolimus-eluting stents | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT03321032 |
| Polymer-free amphilimus-eluting stents | Other | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT03321032 |
| Placebo | Other | Phase PHASE3 | COVID-19 | UNKNOWN | NCT04403100 |
| Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets | Other | Phase PHASE3 | COVID-19 | UNKNOWN | NCT04403100 |
| Lopinavir/ Ritonavir Oral Tablet | Other | Phase PHASE3 | COVID-19 | UNKNOWN | NCT04403100 |
| Hydroxychloroquine Sulfate Tablets | Other | Phase PHASE3 | COVID-19 | UNKNOWN | NCT04403100 |
| Placebo | Other | Phase PHASE3 | COVID-19 | UNKNOWN | NCT04403100 |
| Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets | Other | Phase PHASE3 | COVID-19 | UNKNOWN | NCT04403100 |
| Lopinavir/ Ritonavir Oral Tablet | Other | Phase PHASE3 | COVID-19 | UNKNOWN | NCT04403100 |
| Hydroxychloroquine Sulfate Tablets | Other | Phase PHASE3 | COVID-19 | UNKNOWN | NCT04403100 |
| Percutaneous Left Atrial Appendage Closure in routine care | Other | Preclinical | Atrial Fibrillation and Other Dysrhythmias | Patient | COMPLETED | NCT02252861 |
| Percutaneous Left Atrial Appendage Closure in routine care | Other | Preclinical | Atrial Fibrillation and Other Dysrhythmias | Patient | COMPLETED | NCT02252861 |
| Stenting | Other | Approved | Stable Angina | COMPLETED | NCT01270139 |
| Transplantation of iron-bearing nanoparticles | Other | Approved | Stable Angina | COMPLETED | NCT01270139 |
| Transplantation of nanoparticles | Other | Approved | Stable Angina | COMPLETED | NCT01270139 |
| Stenting | Other | Approved | Stable Angina | COMPLETED | NCT01270139 |
| Transplantation of iron-bearing nanoparticles | Other | Approved | Stable Angina | COMPLETED | NCT01270139 |
| Transplantation of nanoparticles | Other | Approved | Stable Angina | COMPLETED | NCT01270139 |
| Continuation of ARB/ACEI | Other | Approved | COVID-19 | COMPLETED | NCT04338009 |
| Discontinuation of ARB/ACEI | Other | Approved | COVID-19 | COMPLETED | NCT04338009 |
| Continuation of ARB/ACEI | Other | Approved | COVID-19 | COMPLETED | NCT04338009 |
| Discontinuation of ARB/ACEI | Other | Approved | COVID-19 | COMPLETED | NCT04338009 |
| Continuation of ARB/ACEI | Other | Approved | COVID-19 | COMPLETED | NCT04338009 |
| Discontinuation of ARB/ACEI | Other | Approved | COVID-19 | COMPLETED | NCT04338009 |
| Beta blocker, aspirin, clopidogrel | Other | Phase PHASE4 | Spontaneous Coronary Artery Dissection | NOT_YET_RECRUITING | NCT04850417 |
| Beta blocker, aspirin, clopidogrel | Other | Phase PHASE4 | Spontaneous Coronary Artery Dissection | NOT_YET_RECRUITING | NCT04850417 |
| Prasugrel (Integral tablets) | Other | Phase PHASE4 | Cardiovascular Diseases | COMPLETED | NCT03296540 |
| Prasugrel (Crushed tablets) | Other | Phase PHASE4 | Cardiovascular Diseases | COMPLETED | NCT03296540 |
| Prasugrel (Integral tablets) | Other | Phase PHASE4 | Cardiovascular Diseases | COMPLETED | NCT03296540 |
| Prasugrel (Crushed tablets) | Other | Phase PHASE4 | Cardiovascular Diseases | COMPLETED | NCT03296540 |
| Placebo oral capsule | Other | Phase PHASE4 | Acute Mountain Sickness | COMPLETED | NCT03561675 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Acute Mountain Sickness | COMPLETED | NCT03561675 |
| Placebo oral capsule | Other | Phase PHASE4 | Acute Mountain Sickness | COMPLETED | NCT03561675 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Acute Mountain Sickness | COMPLETED | NCT03561675 |
| Pentoxifylline | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| N-acetyl cysteine | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| Melatonin | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| Vitamin E | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| Vitamin C | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| Pentoxifylline | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| N-acetyl cysteine | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| Melatonin | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| Vitamin E | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| Vitamin C | Other | Approved | Pneumonia, Viral | COMPLETED | NCT04570254 |
| No intervention provided | Other | Preclinical | Chronic Venous Disease | UNKNOWN | NCT04901845 |
| No intervention provided | Other | Preclinical | Chronic Venous Disease | UNKNOWN | NCT04901845 |
| No intervention provided | Other | Preclinical | Chronic Venous Disease | UNKNOWN | NCT04901845 |
| Trans aortic valve implantation | Other | Preclinical | Conduction Disturbance | COMPLETED | NCT04906837 |
| Trans aortic valve implantation | Other | Preclinical | Conduction Disturbance | COMPLETED | NCT04906837 |
| Trans aortic valve implantation | Other | Preclinical | Conduction Disturbance | COMPLETED | NCT04906837 |
| Genetic sub-study | Other | Preclinical | Spontaneous Coronary Artery Dissection | RECRUITING | NCT04906356 |
| Genetic sub-study | Other | Preclinical | Spontaneous Coronary Artery Dissection | RECRUITING | NCT04906356 |
| Algorithm | Other | Preclinical | Cardiac Amyloidosis | UNKNOWN | NCT04915235 |
| Algorithm | Other | Preclinical | Cardiac Amyloidosis | UNKNOWN | NCT04915235 |
| Nitinol stenting | Other | Phase PHASE4 | Peripheral Arterial Disease | COMPLETED | NCT02212470 |
| Drug Eluting Balloon Angioplasty | Drug | Phase PHASE4 | Peripheral Arterial Disease | COMPLETED | NCT02212470 |
| Oral anti-coagulant | Other | Approved | COVID -19 | COMPLETED | NCT04935515 |
| Intravenous Antibiotics with Low dose steroid. | Other | Approved | COVID -19 | COMPLETED | NCT04935515 |
| Oral low dose steroid | Other | Approved | COVID -19 | COMPLETED | NCT04935515 |
| Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins | Other | Approved | COVID -19 | COMPLETED | NCT04935515 |
| Oral anti-coagulant | Other | Approved | COVID -19 | COMPLETED | NCT04935515 |
| Intravenous Antibiotics with Low dose steroid. | Other | Approved | COVID -19 | COMPLETED | NCT04935515 |
| Oral low dose steroid | Other | Approved | COVID -19 | COMPLETED | NCT04935515 |
| Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins | Other | Approved | COVID -19 | COMPLETED | NCT04935515 |
| Placebo | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04529525 |
| Ivermectin | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04529525 |
| Placebo | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04529525 |
| Ivermectin | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04529525 |
| Placebo | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04529525 |
| Ivermectin | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04529525 |
| cell therapy | Drug | Preclinical | Ischemic Heart Disease | COMPLETED | NCT01098591 |
| cell therapy | Drug | Preclinical | Ischemic Heart Disease | COMPLETED | NCT01098591 |
| Magmaris | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT03413813 |
| Magmaris | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT03413813 |
| isometric of the lower limbs | Other | Approved | Arterial Hypertension | UNKNOWN | NCT03982758 |
| isometric handgrip exercise | Other | Approved | Arterial Hypertension | UNKNOWN | NCT03982758 |
| isometric of the lower limbs | Other | Approved | Arterial Hypertension | UNKNOWN | NCT03982758 |
| isometric handgrip exercise | Other | Approved | Arterial Hypertension | UNKNOWN | NCT03982758 |
| UF-ultrasound | Other | Approved | Carotid Stenosis | COMPLETED | NCT03234257 |
| UF-ultrasound | Other | Approved | Carotid Stenosis | COMPLETED | NCT03234257 |
| Standard treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04359095 |
| Rosuvastatin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04359095 |
| Colchicine Pill | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04359095 |
| Emtricitabine/tenofovir | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04359095 |
| Standard treatment | Drug | Phase PHASE2 | COVID-19 | COMPLETED | NCT04359095 |
| Rosuvastatin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04359095 |
| Colchicine Pill | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04359095 |
| Emtricitabine/tenofovir | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04359095 |
| Propofol | Other | Approved | Hemodynamic Instability | UNKNOWN | NCT05004545 |
| Propofol | Other | Approved | Hemodynamic Instability | UNKNOWN | NCT05004545 |
| Theobroma Cocoa (TC) | Other | Approved | Sedentary Behavior | UNKNOWN | NCT04732754 |
| Aerobic Exercise (AE) | Other | Approved | Sedentary Behavior | UNKNOWN | NCT04732754 |
| Control Group (CG) | Other | Approved | Sedentary Behavior | UNKNOWN | NCT04732754 |
| Aerobic exercise + Theobroma cocoa (AETC) | Other | Approved | Sedentary Behavior | UNKNOWN | NCT04732754 |
| Theobroma Cocoa (TC) | Other | Approved | Sedentary Behavior | UNKNOWN | NCT04732754 |
| Aerobic Exercise (AE) | Other | Approved | Sedentary Behavior | UNKNOWN | NCT04732754 |
| Control Group (CG) | Other | Approved | Sedentary Behavior | UNKNOWN | NCT04732754 |
| Aerobic exercise + Theobroma cocoa (AETC) | Other | Approved | Sedentary Behavior | UNKNOWN | NCT04732754 |
| Stereotactic Body Radiation Therapy | Drug | Approved | Non-small Cell Lung Cancer Stage I | WITHDRAWN | NCT03431415 |
| Anatomical Segmentectomy, Lobectomy or Bilobectomy | Other | Approved | Non-small Cell Lung Cancer Stage I | WITHDRAWN | NCT03431415 |
| Stereotactic Body Radiation Therapy | Drug | Approved | Non-small Cell Lung Cancer Stage I | WITHDRAWN | NCT03431415 |
| Anatomical Segmentectomy, Lobectomy or Bilobectomy | Other | Approved | Non-small Cell Lung Cancer Stage I | WITHDRAWN | NCT03431415 |
| Cardiologs | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT04792905 |
| Cardiologs | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT04792905 |
| Blood collection | Other | Preclinical | Cardiac Surgery | COMPLETED | NCT03309839 |
| Blood collection | Other | Preclinical | Cardiac Surgery | COMPLETED | NCT03309839 |
| Hemofiltration | Other | Approved | Dialysis; Complications | COMPLETED | NCT05060159 |
| Hemofiltration | Other | Approved | Dialysis; Complications | COMPLETED | NCT05060159 |
| Coronary flow reserve SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Pulmonary hemodynamics SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Mitral regurgitation SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Diastolic function SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Left ventricular outflow tract gradient SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| B-lines SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Left ventricular contractile reserve SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Coronary flow reserve SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Pulmonary hemodynamics SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Mitral regurgitation SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Diastolic function SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Left ventricular outflow tract gradient SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| B-lines SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Left ventricular contractile reserve SE | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536520 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536520 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536520 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536520 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536455 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536455 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536455 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536455 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536429 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536429 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536429 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536429 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177811 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177811 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177811 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03177811 |
| Eplerenone | Other | Phase PHASE3 | Phospholamban R14del Mutation-related Cardiomyopathy | COMPLETED | NCT01857856 |
| Eplerenone | Other | Phase PHASE3 | Phospholamban R14del Mutation-related Cardiomyopathy | COMPLETED | NCT01857856 |
| SE in heart donors | Other | Preclinical | Coronary Artery Disease | RECRUITING | NCT05081115 |
| SE Right ventricular function assessment | Other | Preclinical | Coronary Artery Disease | RECRUITING | NCT05081115 |
| SE diastolic assessment | Other | Preclinical | Coronary Artery Disease | RECRUITING | NCT05081115 |
| ABCDE-Stress Echo | Other | Preclinical | Coronary Artery Disease | RECRUITING | NCT05081115 |
| SE in heart donors | Other | Preclinical | Coronary Artery Disease | RECRUITING | NCT05081115 |
| SE Right ventricular function assessment | Other | Preclinical | Coronary Artery Disease | RECRUITING | NCT05081115 |
| SE diastolic assessment | Other | Preclinical | Coronary Artery Disease | RECRUITING | NCT05081115 |
| ABCDE-Stress Echo | Other | Preclinical | Coronary Artery Disease | RECRUITING | NCT05081115 |
| Healthy lifestyle intervention | Other | Phase PHASE4 | Metabolic Syndrome | NOT_YET_RECRUITING | NCT05105321 |
| Berberine | Other | Phase PHASE4 | Metabolic Syndrome | NOT_YET_RECRUITING | NCT05105321 |
| Healthy lifestyle intervention | Other | Phase PHASE4 | Metabolic Syndrome | NOT_YET_RECRUITING | NCT05105321 |
| Berberine | Other | Phase PHASE4 | Metabolic Syndrome | NOT_YET_RECRUITING | NCT05105321 |
| Clopidogrel | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT04695106 |
| Aspirin | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT04695106 |
| Dabigatran Etexilate | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT04695106 |
| Ticagrelor | Other | Phase PHASE4 | Atrial Fibrillation | UNKNOWN | NCT04695106 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03540901 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03540901 |
| Placebo oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03540901 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Chronic Obstructive Pulmonary Disease | COMPLETED | NCT03540901 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536507 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536507 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536507 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | COMPLETED | NCT03536507 |
| iFR/ FFR/ IVUS/ OCT | Other | Approved | Coronary Artery Disease Left Main | UNKNOWN | NCT04531007 |
| iFR/ FFR/ IVUS/ OCT | Other | Approved | Coronary Artery Disease Left Main | UNKNOWN | NCT04531007 |
| Any surgery/procedure | Procedure | Preclinical | Surgery | UNKNOWN | NCT05147623 |
| Permanent dual chamber pacemaker implantation | Other | Approved | Sinus Node Dysfunction | UNKNOWN | NCT05186220 |
| Cardioneuroablation | Other | Approved | Sinus Node Dysfunction | UNKNOWN | NCT05186220 |
| Permanent dual chamber pacemaker implantation | Other | Approved | Sinus Node Dysfunction | UNKNOWN | NCT05186220 |
| Cardioneuroablation | Other | Approved | Sinus Node Dysfunction | UNKNOWN | NCT05186220 |
| Standard care | Other | Phase PHASE4 | Heart Failure, Diastolic | COMPLETED | NCT03753087 |
| Empagliflozin | Other | Phase PHASE4 | Heart Failure, Diastolic | COMPLETED | NCT03753087 |
| Standard care | Other | Phase PHASE4 | Heart Failure, Diastolic | COMPLETED | NCT03753087 |
| Empagliflozin | Other | Phase PHASE4 | Heart Failure, Diastolic | COMPLETED | NCT03753087 |
| Transthoracic Echocardiography | Other | Preclinical | Functional Tricuspid Regurgitation | UNKNOWN | NCT05209919 |
| Transthoracic Echocardiography | Other | Preclinical | Functional Tricuspid Regurgitation | UNKNOWN | NCT05209919 |
| evaluation of skin microvascular flow and reactivity | Other | Preclinical | Coronavirus Infection | COMPLETED | NCT04406545 |
| evaluation of skin microvascular flow and reactivity | Other | Preclinical | Coronavirus Infection | COMPLETED | NCT04406545 |
| Dexmedetomidine alone | Other | Approved | Hemodynamic Instability | UNKNOWN | NCT05218161 |
| Dexmedetomidine alone | Other | Approved | Hemodynamic Instability | UNKNOWN | NCT05218161 |
| Index of Microvascular Resistance | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT05231161 |
| Index of Microvascular Resistance | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT05231161 |
| Clopidogrel 75 Mg Oral Tablet | Other | Phase PHASE2 | Acute Coronary Syndrome | UNKNOWN | NCT05233124 |
| Acetylsalicylic acid 100mg | Other | Phase PHASE2 | Acute Coronary Syndrome | UNKNOWN | NCT05233124 |
| Rivaroxaban 15 MG | Other | Phase PHASE2 | Acute Coronary Syndrome | UNKNOWN | NCT05233124 |
| Clopidogrel 75 Mg Oral Tablet | Other | Phase PHASE2 | Acute Coronary Syndrome | UNKNOWN | NCT05233124 |
| Acetylsalicylic acid 100mg | Other | Phase PHASE2 | Acute Coronary Syndrome | UNKNOWN | NCT05233124 |
| Rivaroxaban 15 MG | Other | Phase PHASE2 | Acute Coronary Syndrome | UNKNOWN | NCT05233124 |
| observational | Other | Preclinical | Cardiogenic Shock | UNKNOWN | NCT05246683 |
| observational | Other | Preclinical | Cardiogenic Shock | UNKNOWN | NCT05246683 |
| Endothelial function biomarkers | Other | Approved | Hypertrophic Cardiomyopathy | COMPLETED | NCT04129905 |
| Upper member arterial Doppler echography with analysis of FMD | Other | Approved | Hypertrophic Cardiomyopathy | COMPLETED | NCT04129905 |
| Air venous plethysmography | Other | Approved | Hypertrophic Cardiomyopathy | COMPLETED | NCT04129905 |
| Echocardiography | Other | Approved | Hypertrophic Cardiomyopathy | COMPLETED | NCT04129905 |
| Holter ECG | Other | Approved | Hypertrophic Cardiomyopathy | COMPLETED | NCT04129905 |
| Electrocardiogram | Other | Approved | Hypertrophic Cardiomyopathy | COMPLETED | NCT04129905 |
| BNP blood sample test | Other | Approved | Hypertrophic Cardiomyopathy | COMPLETED | NCT04129905 |
| Cardiologs Platform | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT05045456 |
| Cardiologs Platform | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT05045456 |
| Midazolam | Other | Approved | Coronary Artery Disease | COMPLETED | NCT05290324 |
| Midazolam | Other | Approved | Coronary Artery Disease | COMPLETED | NCT05290324 |
| Autologous bone marrow derived-CD133+ cells | Other | Phase PHASE1 | Chronic Myocardial Ischemia | COMPLETED | NCT02059681 |
| Autologous bone marrow derived-CD133+ cells | Other | Phase PHASE1 | Chronic Myocardial Ischemia | COMPLETED | NCT02059681 |
| UltraFast ultrasound | Other | Approved | Takayasu Arteritis | COMPLETED | NCT03956394 |
| UltraFast ultrasound | Other | Approved | Takayasu Arteritis | COMPLETED | NCT03956394 |
| Conservative | Other | Approved | Non-ST Elevation Myocardial Infarction | COMPLETED | NCT03208153 |
| Invasive | Other | Approved | Non-ST Elevation Myocardial Infarction | COMPLETED | NCT03208153 |
| Conservative | Other | Approved | Non-ST Elevation Myocardial Infarction | COMPLETED | NCT03208153 |
| Invasive | Other | Approved | Non-ST Elevation Myocardial Infarction | COMPLETED | NCT03208153 |
| mobile application "M-Cardio" based on android | Other | Phase EARLY_PHASE1 | CHF | UNKNOWN | NCT04591964 |
| mobile application "M-Cardio" based on android | Other | Phase EARLY_PHASE1 | CHF | UNKNOWN | NCT04591964 |
| Dilatation | Other | Approved | Tracheal Stenosis | UNKNOWN | NCT04719845 |
| Endoscopic laser resection | Other | Approved | Tracheal Stenosis | UNKNOWN | NCT04719845 |
| Dilatation | Other | Approved | Tracheal Stenosis | UNKNOWN | NCT04719845 |
| Endoscopic laser resection | Other | Approved | Tracheal Stenosis | UNKNOWN | NCT04719845 |
| Dilatation | Other | Approved | Tracheal Stenosis | UNKNOWN | NCT04719845 |
| Endoscopic laser resection | Other | Approved | Tracheal Stenosis | UNKNOWN | NCT04719845 |
| S-ICD | Other | Preclinical | Sudden Cardiac Death | UNKNOWN | NCT05302115 |
| S-ICD | Other | Preclinical | Sudden Cardiac Death | UNKNOWN | NCT05302115 |
| S-ICD | Other | Preclinical | Sudden Cardiac Death | UNKNOWN | NCT05302115 |
| Somnocheck | Other | Preclinical | Arterial Hypertension | UNKNOWN | NCT05436730 |
| VaSera-VS | Other | Preclinical | Arterial Hypertension | UNKNOWN | NCT05436730 |
| Sphygmocor | Other | Preclinical | Arterial Hypertension | UNKNOWN | NCT05436730 |
| Ambulatory blood pressure measurement device | Device | Preclinical | Arterial Hypertension | UNKNOWN | NCT05436730 |
| Somnocheck | Other | Preclinical | Arterial Hypertension | UNKNOWN | NCT05436730 |
| VaSera-VS | Other | Preclinical | Arterial Hypertension | UNKNOWN | NCT05436730 |
| Sphygmocor | Other | Preclinical | Arterial Hypertension | UNKNOWN | NCT05436730 |
| Ambulatory blood pressure measurement device | Device | Preclinical | Arterial Hypertension | UNKNOWN | NCT05436730 |
| CARTO-Finder-guided ablation plus PVI | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT05454111 |
| Multiscale entropy-guided ablation plus PVI | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT05454111 |
| CARTO-Finder-guided ablation plus PVI | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT05454111 |
| Multiscale entropy-guided ablation plus PVI | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT05454111 |
| Control | Other | Approved | Congenital Heart Defects | UNKNOWN | NCT05457712 |
| protocol | Other | Approved | Congenital Heart Defects | UNKNOWN | NCT05457712 |
| Control | Other | Approved | Congenital Heart Defects | UNKNOWN | NCT05457712 |
| protocol | Other | Approved | Congenital Heart Defects | UNKNOWN | NCT05457712 |
| Removal or leaving of LAA occluders | Other | Preclinical | Left Atrial Appendage Occluder | UNKNOWN | NCT05014477 |
| Removal or leaving of LAA occluders | Other | Preclinical | Left Atrial Appendage Occluder | UNKNOWN | NCT05014477 |
| Valve replacement | Other | Preclinical | Valvular Heart Disease | COMPLETED | NCT04509479 |
| Valve replacement | Other | Preclinical | Valvular Heart Disease | COMPLETED | NCT04509479 |
| optimizer smart | Other | Approved | Heart Failure | COMPLETED | NCT05550792 |
| Muscle building training | Other | Approved | Marfan Syndrome | COMPLETED | NCT04553094 |
| Endurance training | Other | Approved | Marfan Syndrome | COMPLETED | NCT04553094 |
| Muscle building training | Other | Approved | Marfan Syndrome | COMPLETED | NCT04553094 |
| Endurance training | Other | Approved | Marfan Syndrome | COMPLETED | NCT04553094 |
| Referral | Other | Approved | Heart Failure | UNKNOWN | NCT05572814 |
| Decision Support | Other | Approved | Heart Failure | UNKNOWN | NCT05572814 |
| Referral | Other | Approved | Heart Failure | UNKNOWN | NCT05572814 |
| Decision Support | Other | Approved | Heart Failure | UNKNOWN | NCT05572814 |
| Physioflow® | Other | Approved | Congenital Heart Diseases | TERMINATED | NCT03437148 |
| Innocor® | Other | Approved | Congenital Heart Diseases | TERMINATED | NCT03437148 |
| Physioflow® | Other | Approved | Congenital Heart Diseases | TERMINATED | NCT03437148 |
| Innocor® | Other | Approved | Congenital Heart Diseases | TERMINATED | NCT03437148 |
| Ingestion of mineral water | Other | Preclinical | Endothelial Function | COMPLETED | NCT05575895 |
| Ingestion of the energy drink (Red Bull®) | Other | Preclinical | Endothelial Function | COMPLETED | NCT05575895 |
| Ingestion of mineral water | Other | Preclinical | Endothelial Function | COMPLETED | NCT05575895 |
| Ingestion of the energy drink (Red Bull®) | Other | Preclinical | Endothelial Function | COMPLETED | NCT05575895 |
| Ingestion of mineral water | Other | Preclinical | Endothelial Function | COMPLETED | NCT05575895 |
| Ingestion of the energy drink (Red Bull®) | Other | Preclinical | Endothelial Function | COMPLETED | NCT05575895 |
| Placebo | Other | Phase PHASE3 | Right Heart Function | UNKNOWN | NCT04915365 |
| Acetazolamide | Other | Phase PHASE3 | Right Heart Function | UNKNOWN | NCT04915365 |
| Placebo | Other | Phase PHASE3 | Right Heart Function | UNKNOWN | NCT04915365 |
| Acetazolamide | Other | Phase PHASE3 | Right Heart Function | UNKNOWN | NCT04915365 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | UNKNOWN | NCT03537924 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | UNKNOWN | NCT03537924 |
| Placebo oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | UNKNOWN | NCT03537924 |
| ACETAZOLAMIDE oral capsule | Other | Phase PHASE4 | Altitude Hypoxia | UNKNOWN | NCT03537924 |
| Paint Night | Other | Approved | Stress | COMPLETED | NCT05252507 |
| Paint Night | Other | Approved | Stress | COMPLETED | NCT05252507 |
| Transcatheter mitral valve-in-valve implantation | Other | Preclinical | Mitral Insufficiency | RECRUITING | NCT05625607 |
| Transcatheter mitral valve-in-valve implantation | Other | Preclinical | Mitral Insufficiency | RECRUITING | NCT05625607 |
| Nasal Dexamethasone | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04513184 |
| IV Dexamethasone | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04513184 |
| Nasal Dexamethasone | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04513184 |
| IV Dexamethasone | Other | Phase PHASE2 | Covid19 | COMPLETED | NCT04513184 |
| Biological dosage from plasma | Other | Approved | Skin Restricted Lupus | COMPLETED | NCT03125083 |
| Biological dosage from plasma | Other | Approved | Skin Restricted Lupus | COMPLETED | NCT03125083 |
| Evaluation of systemic skin microvascular endothelial function | Other | Approved | Obesity | COMPLETED | NCT04233528 |
| Evaluation of systemic skin microvascular endothelial function | Other | Approved | Obesity | COMPLETED | NCT04233528 |
| Evaluation of systemic skin microvascular endothelial function | Other | Approved | Obesity | COMPLETED | NCT04233528 |
| Placebo comparator | Other | Phase PHASE3 | Cardiovascular Diseases | COMPLETED | NCT03837925 |
| Atorvastatin 40mg Tablet | Other | Phase PHASE3 | Cardiovascular Diseases | COMPLETED | NCT03837925 |
| Placebo comparator | Other | Phase PHASE3 | Cardiovascular Diseases | COMPLETED | NCT03837925 |
| Atorvastatin 40mg Tablet | Other | Phase PHASE3 | Cardiovascular Diseases | COMPLETED | NCT03837925 |
| Standard ablation power | Other | Approved | Ventricular Tachycardia | COMPLETED | NCT04657705 |
| High power ablation | Other | Approved | Ventricular Tachycardia | COMPLETED | NCT04657705 |
| Standard ablation power | Other | Approved | Ventricular Tachycardia | COMPLETED | NCT04657705 |
| High power ablation | Other | Approved | Ventricular Tachycardia | COMPLETED | NCT04657705 |
| Standard ablation power | Other | Approved | Ventricular Tachycardia | COMPLETED | NCT04657705 |
| High power ablation | Other | Approved | Ventricular Tachycardia | COMPLETED | NCT04657705 |
| PCI | Other | Preclinical | LMN Disease | UNKNOWN | NCT05701319 |
| PCI | Other | Preclinical | LMN Disease | UNKNOWN | NCT05701319 |
| Placebo | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT04913389 |
| Acetazolamide | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT04913389 |
| Placebo | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT04913389 |
| Acetazolamide | Other | Phase PHASE3 | Chronic Obstructive Pulmonary Disease | UNKNOWN | NCT04913389 |
| Exercise | Other | Approved | HIV/AIDS | COMPLETED | NCT03343522 |
| Exercise | Other | Approved | HIV/AIDS | COMPLETED | NCT03343522 |
| Blood pressure cuff inflation | Other | Approved | Aortic Valve Stenosis | UNKNOWN | NCT03305094 |
| Blood pressure cuff inflation | Other | Approved | Aortic Valve Stenosis | UNKNOWN | NCT03305094 |
| cardiopulmonary bypass pump flow rate | Other | Approved | Cardiopulmonary Bypass | RECRUITING | NCT03302195 |
| Heparin | Other | Approved | Cardiopulmonary Bypass | RECRUITING | NCT03302195 |
| cardiopulmonary bypass pump flow rate | Other | Approved | Cardiopulmonary Bypass | RECRUITING | NCT03302195 |
| Heparin | Other | Approved | Cardiopulmonary Bypass | RECRUITING | NCT03302195 |
| Digital empowerment | Other | Approved | Acute Myocardial Infarction | UNKNOWN | NCT05782023 |
| Digital empowerment | Other | Approved | Acute Myocardial Infarction | UNKNOWN | NCT05782023 |
| left atrial appendage occluder implantation | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT03867227 |
| Program for Teaching Self-Care in HF (PEAC-IC) | Other | Approved | Heart Failure | COMPLETED | NCT05081414 |
| Program for Teaching Self-Care in HF (PEAC-IC) | Other | Approved | Heart Failure | COMPLETED | NCT05081414 |
| Program for Teaching Self-Care in HF (PEAC-IC) | Other | Approved | Heart Failure | COMPLETED | NCT05081414 |
| GORE® CARDIOFORM ASD Occluder | Other | Approved | Atrial Septal Defect | UNKNOWN | NCT04291898 |
| Occlutech Figulla Flex II® | Other | Approved | Atrial Septal Defect | UNKNOWN | NCT04291898 |
| AMPLATZER™ Septal Occluder. | Other | Approved | Atrial Septal Defect | UNKNOWN | NCT04291898 |
| GORE® CARDIOFORM ASD Occluder | Other | Approved | Atrial Septal Defect | UNKNOWN | NCT04291898 |
| Occlutech Figulla Flex II® | Other | Approved | Atrial Septal Defect | UNKNOWN | NCT04291898 |
| AMPLATZER™ Septal Occluder. | Other | Approved | Atrial Septal Defect | UNKNOWN | NCT04291898 |
| RenalGuard device | Device | Approved | Acute Decompensated Heart Failure | UNKNOWN | NCT05807152 |
| RenalGuard device | Device | Approved | Acute Decompensated Heart Failure | UNKNOWN | NCT05807152 |
| CRP POCT (C-reactive protein point of care test) | Other | Approved | Antibiotic Resistance | COMPLETED | NCT05195866 |
| CRP POCT (C-reactive protein point of care test) | Other | Approved | Antibiotic Resistance | COMPLETED | NCT05195866 |
| Placebo oral tablet | Other | Phase PHASE2 | Myocardium; Injury | WITHDRAWN | NCT04218786 |
| Colchicine | Other | Phase PHASE2 | Myocardium; Injury | WITHDRAWN | NCT04218786 |
| Placebo oral tablet | Other | Phase PHASE2 | Myocardium; Injury | WITHDRAWN | NCT04218786 |
| Colchicine | Other | Phase PHASE2 | Myocardium; Injury | WITHDRAWN | NCT04218786 |
| There was no intervention, the study was a cross-sectional observational study | Other | Preclinical | Anxiety | COMPLETED | NCT05750420 |
| There was no intervention, the study was a cross-sectional observational study | Other | Preclinical | Anxiety | COMPLETED | NCT05750420 |
| There was no intervention, the study was a cross-sectional observational study | Other | Preclinical | Anxiety | COMPLETED | NCT05750420 |
| Thoracoabdominal rebalancing | Other | Approved | Respiratory Complication | COMPLETED | NCT04631198 |
| Thoracoabdominal rebalancing | Other | Approved | Respiratory Complication | COMPLETED | NCT04631198 |
| Brief behavioral sleep therapy, sleep hygiene education and mindfulness training | Drug | Approved | Sleep | COMPLETED | NCT05748496 |
| Brief behavioral sleep therapy, sleep hygiene education and mindfulness training | Drug | Approved | Sleep | COMPLETED | NCT05748496 |
| Vitls Tego Device | Device | Preclinical | Vital Signs | COMPLETED | NCT05245747 |
| Vitls Tego Device | Device | Preclinical | Vital Signs | COMPLETED | NCT05245747 |
| Ross Operation | Procedure | Preclinical | Ross Operation | WITHDRAWN | NCT03027804 |
| Ross Operation | Procedure | Preclinical | Ross Operation | WITHDRAWN | NCT03027804 |
| Biobanking | Other | Preclinical | Cancer | COMPLETED | NCT04586894 |
| Smart cloth | Other | Preclinical | Cancer | COMPLETED | NCT04586894 |
| Cardiac MRI | Other | Preclinical | Cancer | COMPLETED | NCT04586894 |
| Biobanking | Other | Preclinical | Cancer | COMPLETED | NCT04586894 |
| Smart cloth | Other | Preclinical | Cancer | COMPLETED | NCT04586894 |
| Cardiac MRI | Other | Preclinical | Cancer | COMPLETED | NCT04586894 |
| Biobanking | Other | Preclinical | Cancer | COMPLETED | NCT04586894 |
| Smart cloth | Other | Preclinical | Cancer | COMPLETED | NCT04586894 |
| Cardiac MRI | Other | Preclinical | Cancer | COMPLETED | NCT04586894 |
| CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative | Other | Approved | Post-operative Delirium | UNKNOWN | NCT05877326 |
| General anesthesia with propofol or sevoflurane | Other | Approved | Post-operative Delirium | UNKNOWN | NCT05877326 |
| CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative | Other | Approved | Post-operative Delirium | UNKNOWN | NCT05877326 |
| General anesthesia with propofol or sevoflurane | Other | Approved | Post-operative Delirium | UNKNOWN | NCT05877326 |
| PCI with support of Shockwave Intravascular Lithotripsy | Other | Preclinical | Safety Issues | RECRUITING | NCT05916898 |
| PCI with support of Shockwave Intravascular Lithotripsy | Other | Preclinical | Safety Issues | RECRUITING | NCT05916898 |
| Early stimulation protocol on neuropsychomotor development of children with congenital heart disease | Other | Approved | Congenital Heart Disease | COMPLETED | NCT04152330 |
| Early stimulation protocol on neuropsychomotor development of children with congenital heart disease | Other | Approved | Congenital Heart Disease | COMPLETED | NCT04152330 |
| Catheter ablation | Other | Approved | Ventricular Premature Beats | COMPLETED | NCT03845010 |
| Flecainide and verapamil | Other | Approved | Ventricular Premature Beats | COMPLETED | NCT03845010 |
| Sotalol | Other | Approved | Ventricular Premature Beats | COMPLETED | NCT03845010 |
| Catheter ablation | Other | Approved | Ventricular Premature Beats | COMPLETED | NCT03845010 |
| Flecainide and verapamil | Other | Approved | Ventricular Premature Beats | COMPLETED | NCT03845010 |
| Sotalol | Other | Approved | Ventricular Premature Beats | COMPLETED | NCT03845010 |
| anger management training | Other | Approved | Myocardial Infarction | COMPLETED | NCT02868216 |
| anger management training | Other | Approved | Myocardial Infarction | COMPLETED | NCT02868216 |
| 6 months treatment with a single antiplatelet agent | Drug | Phase PHASE4 | Atrial Fibrillation | RECRUITING | NCT03445949 |
| long-term treatment with a single antiplatelet agent | Drug | Phase PHASE4 | Atrial Fibrillation | RECRUITING | NCT03445949 |
| extended postimplantation dual antiplatelet therapy | Drug | Phase PHASE4 | Atrial Fibrillation | RECRUITING | NCT03445949 |
| short postimplantation dual antiplatelet therapy | Drug | Phase PHASE4 | Atrial Fibrillation | RECRUITING | NCT03445949 |
| 6 months treatment with a single antiplatelet agent | Drug | Phase PHASE4 | Atrial Fibrillation | RECRUITING | NCT03445949 |
| long-term treatment with a single antiplatelet agent | Drug | Phase PHASE4 | Atrial Fibrillation | RECRUITING | NCT03445949 |
| extended postimplantation dual antiplatelet therapy | Drug | Phase PHASE4 | Atrial Fibrillation | RECRUITING | NCT03445949 |
| short postimplantation dual antiplatelet therapy | Drug | Phase PHASE4 | Atrial Fibrillation | RECRUITING | NCT03445949 |
| Dapagliflozin | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT04707352 |
| Dapagliflozin | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT04707352 |
| Diet | Other | Approved | Diabetes Mellitus Type 2 in Obese | UNKNOWN | NCT05579561 |
| Diet | Other | Approved | Diabetes Mellitus Type 2 in Obese | UNKNOWN | NCT05579561 |
| Facilitated referral to a cardiometabolic team-based center | Other | Approved | Type 2 Diabetes | UNKNOWN | NCT05948969 |
| Decision support | Other | Approved | Type 2 Diabetes | UNKNOWN | NCT05948969 |
| Standard multidisciplinary care | Other | Approved | Heart Failure | UNKNOWN | NCT05948241 |
| Online psychological support group | Other | Approved | Heart Failure | UNKNOWN | NCT05948241 |
| Standard multidisciplinary care | Other | Approved | Heart Failure | UNKNOWN | NCT05948241 |
| Online psychological support group | Other | Approved | Heart Failure | UNKNOWN | NCT05948241 |
| List of any event | Other | Approved | Myocardial Infarction, Acute | UNKNOWN | NCT05955950 |
| Gratitude list | Other | Approved | Myocardial Infarction, Acute | UNKNOWN | NCT05955950 |
| List of any event | Other | Approved | Myocardial Infarction, Acute | UNKNOWN | NCT05955950 |
| Gratitude list | Other | Approved | Myocardial Infarction, Acute | UNKNOWN | NCT05955950 |
| Apixaban 5mg or 2.5mg oral tablet | Other | Phase PHASE4 | Left Ventricular Thrombus | UNKNOWN | NCT05973188 |
| Rivaroxaban 20 MG Oral Tablet | Other | Phase PHASE4 | Left Ventricular Thrombus | UNKNOWN | NCT05973188 |
| Warfarin | Other | Phase PHASE4 | Left Ventricular Thrombus | UNKNOWN | NCT05973188 |
| Apixaban 5mg or 2.5mg oral tablet | Other | Phase PHASE4 | Left Ventricular Thrombus | UNKNOWN | NCT05973188 |
| Rivaroxaban 20 MG Oral Tablet | Other | Phase PHASE4 | Left Ventricular Thrombus | UNKNOWN | NCT05973188 |
| Warfarin | Other | Phase PHASE4 | Left Ventricular Thrombus | UNKNOWN | NCT05973188 |
| Cardiac Implantable Electronic Devices | Device | Preclinical | Cardiac Implantable Electronic Devices | COMPLETED | NCT05361759 |
| Cardiac Implantable Electronic Devices | Device | Preclinical | Cardiac Implantable Electronic Devices | COMPLETED | NCT05361759 |
| 24 hours monitoring of BP | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| 24-hours monitoring of ECG | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| Cardio MRI | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| Echocardiography | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| Blood sampling | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| 24 hours monitoring of BP | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| 24-hours monitoring of ECG | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| Cardio MRI | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| Echocardiography | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| Blood sampling | Other | Preclinical | Cardiotoxicity | UNKNOWN | NCT05992337 |
| Laboratory Test | Other | Preclinical | Chronic Heart Failure | NOT_YET_RECRUITING | NCT06002321 |
| Echocardiography | Other | Preclinical | Chronic Heart Failure | NOT_YET_RECRUITING | NCT06002321 |
| Laboratory Test | Other | Preclinical | Chronic Heart Failure | NOT_YET_RECRUITING | NCT06002321 |
| Echocardiography | Other | Preclinical | Chronic Heart Failure | NOT_YET_RECRUITING | NCT06002321 |
| Plant-based diet for 14 days in patients with rheumatoid arthritis. | Other | Approved | Rheumatoid Arthritis | UNKNOWN | NCT05911880 |
| Plant-based diet for 14 days in patients with rheumatoid arthritis. | Other | Approved | Rheumatoid Arthritis | UNKNOWN | NCT05911880 |
| Breastfeeding | Other | Approved | Breastfeeding | UNKNOWN | NCT06025864 |
| Breastfeeding | Other | Approved | Breastfeeding | UNKNOWN | NCT06025864 |
| multidisciplinary guide | Other | Approved | Obesity, Morbid | COMPLETED | NCT06033690 |
| multidisciplinary guide | Other | Approved | Obesity, Morbid | COMPLETED | NCT06033690 |
| SBRT | Other | Approved | Refractory Ventricular Tachycardia | UNKNOWN | NCT04066517 |
| SBRT | Other | Approved | Refractory Ventricular Tachycardia | UNKNOWN | NCT04066517 |
| Placebo | Other | Phase PHASE2 | Xerostomia Following Radiotherapy | UNKNOWN | NCT04776538 |
| Stem cells | Other | Phase PHASE2 | Xerostomia Following Radiotherapy | UNKNOWN | NCT04776538 |
| Placebo | Other | Phase PHASE2 | Xerostomia Following Radiotherapy | UNKNOWN | NCT04776538 |
| Stem cells | Other | Phase PHASE2 | Xerostomia Following Radiotherapy | UNKNOWN | NCT04776538 |
| Hemostatic device for distal radial approach. | Device | Approved | Coronary Intervention | UNKNOWN | NCT05966376 |
| Hemostatic device for distal radial approach. | Device | Approved | Coronary Intervention | UNKNOWN | NCT05966376 |
| Recording of an extended high-resolution ECG | Other | Preclinical | Supraventricular Arrhythmia | RECRUITING | NCT06061120 |
| Recording of an extended high-resolution ECG | Other | Preclinical | Supraventricular Arrhythmia | RECRUITING | NCT06061120 |
| Cardiologs Platform | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT05167058 |
| Cardiologs Platform | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT05167058 |
| Cardiologs | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT05161065 |
| Cardiologs | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT05161065 |
| Placebo | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT02548364 |
| Calcifediol | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT02548364 |
| Placebo | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT02548364 |
| Calcifediol | Other | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT02548364 |
| Diuretic de/escalation based on clinical findings (CCS Score) | Other | Approved | Cardiorenal Syndrome Type 1 | UNKNOWN | NCT06065163 |
| Diuretic de/escalation based on ultrasound findings (VExUS Score) | Other | Approved | Cardiorenal Syndrome Type 1 | UNKNOWN | NCT06065163 |
| Diuretic de/escalation based on clinical findings (CCS Score) | Other | Approved | Cardiorenal Syndrome Type 1 | UNKNOWN | NCT06065163 |
| Diuretic de/escalation based on ultrasound findings (VExUS Score) | Other | Approved | Cardiorenal Syndrome Type 1 | UNKNOWN | NCT06065163 |
| CMR and blood collection | Other | Preclinical | STEMI | RECRUITING | NCT06070974 |
| CMR and blood collection | Other | Preclinical | STEMI | RECRUITING | NCT06070974 |
| CMR and blood collection | Other | Preclinical | STEMI | RECRUITING | NCT06070974 |
| CPET and related variables evaluation | Other | Approved | HF - Heart Failure | RECRUITING | NCT06070519 |
| CPET and related variables evaluation | Other | Approved | HF - Heart Failure | RECRUITING | NCT06070519 |
| DISCO Intervention | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT06031974 |
| DISCO Intervention | Other | Preclinical | Coronary Artery Disease | UNKNOWN | NCT06031974 |
| Refralon | Other | Preclinical | Paroxysmal Atrial Fibrillation | COMPLETED | NCT05773170 |
| Refralon | Other | Preclinical | Paroxysmal Atrial Fibrillation | COMPLETED | NCT05773170 |
| Data collection | Other | Preclinical | Atrial Fibrillation Paroxysmal | UNKNOWN | NCT06085014 |
| Standard of care | Other | Preclinical | Atrial Fibrillation Paroxysmal | UNKNOWN | NCT06085014 |
| Data collection | Other | Preclinical | Atrial Fibrillation Paroxysmal | UNKNOWN | NCT06085014 |
| Standard of care | Other | Preclinical | Atrial Fibrillation Paroxysmal | UNKNOWN | NCT06085014 |
| Baseline Quality of Life questionnaire | Other | Preclinical | Myocarditis | UNKNOWN | NCT06103123 |
| Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire | Other | Preclinical | Myocarditis | UNKNOWN | NCT06103123 |
| Baseline Quality of Life questionnaire | Other | Preclinical | Myocarditis | UNKNOWN | NCT06103123 |
| Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire | Other | Preclinical | Myocarditis | UNKNOWN | NCT06103123 |
| Baseline Quality of Life questionnaire | Other | Preclinical | Myocarditis | UNKNOWN | NCT06103123 |
| Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire | Other | Preclinical | Myocarditis | UNKNOWN | NCT06103123 |
| Intravenous furosemide | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT04533997 |
| Hypertonic saline solution plus intravenous furosemide | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT04533997 |
| Intravenous furosemide | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT04533997 |
| Hypertonic saline solution plus intravenous furosemide | Other | Phase PHASE3 | Heart Failure | COMPLETED | NCT04533997 |
| TOTUM-63 | Other | Approved | Prediabetic State | COMPLETED | NCT05369585 |
| TOTUM-63 | Other | Approved | Prediabetic State | COMPLETED | NCT05369585 |
| Radial Artery approach on percutaneous coronary intervention (PCI) | Other | Approved | STEMI - ST Elevation Myocardial Infarction | UNKNOWN | NCT06013813 |
| Radial Artery approach on percutaneous coronary intervention (PCI) | Other | Approved | STEMI - ST Elevation Myocardial Infarction | UNKNOWN | NCT06013813 |
| Combined Lipid-lowering Therapy | Drug | Approved | Dyslipidemias | UNKNOWN | NCT05624658 |
| Combined Lipid-lowering Therapy | Drug | Approved | Dyslipidemias | UNKNOWN | NCT05624658 |
| CONTROL | Other | Approved | Heart Failure | UNKNOWN | NCT05923138 |
| MULTIDOMAIN NUTRITIONAL INTERVENTION: DIET, EXERCISE AND NUTRITIONAL SUPPLEMENTS | Other | Approved | Heart Failure | UNKNOWN | NCT05923138 |
| CONTROL | Other | Approved | Heart Failure | UNKNOWN | NCT05923138 |
| MULTIDOMAIN NUTRITIONAL INTERVENTION: DIET, EXERCISE AND NUTRITIONAL SUPPLEMENTS | Other | Approved | Heart Failure | UNKNOWN | NCT05923138 |
| APPLI | Other | Approved | Heart Failure | TERMINATED | NCT04198779 |
| APPLI | Other | Approved | Heart Failure | TERMINATED | NCT04198779 |
| APPLI | Other | Approved | Heart Failure | TERMINATED | NCT04198779 |
| Placebos | Other | Phase PHASE4 | Heart Failure | UNKNOWN | NCT03783429 |
| Digoxin | Other | Phase PHASE4 | Heart Failure | UNKNOWN | NCT03783429 |
| No specific intervention | Other | Preclinical | ST Elevation Myocardial Infarction | UNKNOWN | NCT06048003 |
| No specific intervention | Other | Preclinical | ST Elevation Myocardial Infarction | UNKNOWN | NCT06048003 |
| No specific intervention | Other | Preclinical | ST Elevation Myocardial Infarction | UNKNOWN | NCT06048003 |
| Usual care for atrial fibrillation | Other | Phase PHASE3 | Acute Ischemic Stroke | NOT_YET_RECRUITING | NCT05293080 |
| Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version) | Drug | Phase PHASE3 | Acute Ischemic Stroke | NOT_YET_RECRUITING | NCT05293080 |
| Usual care for atrial fibrillation | Other | Phase PHASE3 | Acute Ischemic Stroke | NOT_YET_RECRUITING | NCT05293080 |
| Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version) | Drug | Phase PHASE3 | Acute Ischemic Stroke | NOT_YET_RECRUITING | NCT05293080 |
| Usual care for atrial fibrillation | Other | Phase PHASE3 | Acute Ischemic Stroke | NOT_YET_RECRUITING | NCT05293080 |
| Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version) | Drug | Phase PHASE3 | Acute Ischemic Stroke | NOT_YET_RECRUITING | NCT05293080 |
| Pacemaker implantation with conduction system pacing using Stylet-driven leads | Other | Approved | Left Bundle-Branch Pacing | UNKNOWN | NCT06049992 |
| Pacemaker implantation with conduction system pacing using Lumenless leads | Other | Approved | Left Bundle-Branch Pacing | UNKNOWN | NCT06049992 |
| Pacemaker implantation with conduction system pacing using Stylet-driven leads | Other | Approved | Left Bundle-Branch Pacing | UNKNOWN | NCT06049992 |
| Pacemaker implantation with conduction system pacing using Lumenless leads | Other | Approved | Left Bundle-Branch Pacing | UNKNOWN | NCT06049992 |
| Prevention events organized by participating centers | Other | Preclinical | Cardiovascular Diseases | UNKNOWN | NCT06190743 |
| Prevention events organized by participating centers | Other | Preclinical | Cardiovascular Diseases | UNKNOWN | NCT06190743 |
| Prevention events organized by participating centers | Other | Preclinical | Cardiovascular Diseases | UNKNOWN | NCT06190743 |
| circulating sex hormones levels sample | Other | Approved | Pregnancy | COMPLETED | NCT02931695 |
| evaluation of QT interval duration | Other | Approved | Pregnancy | COMPLETED | NCT02931695 |
| circulating sex hormones levels sample | Other | Approved | Pregnancy | COMPLETED | NCT02931695 |
| evaluation of QT interval duration | Other | Approved | Pregnancy | COMPLETED | NCT02931695 |
| Conventional care | Other | Approved | Critical Illness | COMPLETED | NCT04604665 |
| High frequency postural change | Other | Approved | Critical Illness | COMPLETED | NCT04604665 |
| Conventional care | Other | Approved | Critical Illness | COMPLETED | NCT04604665 |
| High frequency postural change | Other | Approved | Critical Illness | COMPLETED | NCT04604665 |
| CT scan and blood sample collection | Other | Approved | Breast Cancer | COMPLETED | NCT05775822 |
| CT scan and blood sample collection | Other | Approved | Breast Cancer | COMPLETED | NCT05775822 |
| observation | Other | Preclinical | Peripheral Atherosclerotic Disease | UNKNOWN | NCT06239415 |
| observation | Other | Preclinical | Peripheral Atherosclerotic Disease | UNKNOWN | NCT06239415 |
| observation | Other | Preclinical | Peripheral Atherosclerotic Disease | UNKNOWN | NCT06239415 |
| Orsiro Sirolimus Eluting Coronary Stent System (OSES) | Other | Approved | Diabetes Mellitus | UNKNOWN | NCT04660240 |
| Abluminus Sirolimus Eluting Stent System (ASES) | Other | Approved | Diabetes Mellitus | UNKNOWN | NCT04660240 |
| Orsiro Sirolimus Eluting Coronary Stent System (OSES) | Other | Approved | Diabetes Mellitus | UNKNOWN | NCT04660240 |
| Abluminus Sirolimus Eluting Stent System (ASES) | Other | Approved | Diabetes Mellitus | UNKNOWN | NCT04660240 |
| Unfractionated Heparin | Other | Approved | Radial Artery Occlusion | UNKNOWN | NCT04561648 |
| Unfractionated Heparin | Other | Approved | Radial Artery Occlusion | UNKNOWN | NCT04561648 |
| Standard of care | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04405102 |
| Ozanimod | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04405102 |
| Phase A: Confirmation of uncontrolled hypertension | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Phase B: Triplixam / Elestar HCT | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Phase C: Torasemide | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Phase C: Spironolactone | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Phase C: Eplerenone | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Phase A: Confirmation of uncontrolled hypertension | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Phase B: Triplixam / Elestar HCT | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Phase C: Torasemide | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Phase C: Spironolactone | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Phase C: Eplerenone | Other | Phase PHASE4 | Hypertension | UNKNOWN | NCT06275763 |
| Aerobic Exercise | Other | Approved | Hypertension,Essential | UNKNOWN | NCT06282302 |
| Isometric Exercise | Other | Approved | Hypertension,Essential | UNKNOWN | NCT06282302 |
| Group control | Other | Approved | Hypertension,Essential | UNKNOWN | NCT06282302 |
| Aerobic Exercise | Other | Approved | Hypertension,Essential | UNKNOWN | NCT06282302 |
| Isometric Exercise | Other | Approved | Hypertension,Essential | UNKNOWN | NCT06282302 |
| Group control | Other | Approved | Hypertension,Essential | UNKNOWN | NCT06282302 |
| Electrophysiological study | Other | Approved | Bradycardia | RECRUITING | NCT06288633 |
| Ganglionated plexi ablation | Other | Approved | Bradycardia | RECRUITING | NCT06288633 |
| Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte | Other | Preclinical | Safety Issues | RECRUITING | NCT06284057 |
| Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte | Other | Preclinical | Safety Issues | RECRUITING | NCT06284057 |
| Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte | Other | Preclinical | Safety Issues | RECRUITING | NCT06284057 |
| AI platform to detect ST elevation in ECG | Other | Preclinical | STEMI - ST Elevation Myocardial Infarction | UNKNOWN | NCT05689970 |
| AI platform to detect ST elevation in ECG | Other | Preclinical | STEMI - ST Elevation Myocardial Infarction | UNKNOWN | NCT05689970 |
| Cardiovascular physical examination | Other | Approved | Heart Failure | RECRUITING | NCT05859048 |
| electrocardiogram | Other | Approved | Heart Failure | RECRUITING | NCT05859048 |
| AI echocardiogram | Other | Approved | Heart Failure | RECRUITING | NCT05859048 |
| NT-proBNP | Other | Approved | Heart Failure | RECRUITING | NCT05859048 |
| Cardiovascular physical examination | Other | Approved | Heart Failure | RECRUITING | NCT05859048 |
| electrocardiogram | Other | Approved | Heart Failure | RECRUITING | NCT05859048 |
| AI echocardiogram | Other | Approved | Heart Failure | RECRUITING | NCT05859048 |
| NT-proBNP | Other | Approved | Heart Failure | RECRUITING | NCT05859048 |
| Revascularization | Other | Approved | Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients | RECRUITING | NCT06279663 |
| TGFBR2 | Other | Preclinical | Thoracic Aortic Aneurysm | UNKNOWN | NCT05146375 |
| TGFBR2 | Other | Preclinical | Thoracic Aortic Aneurysm | UNKNOWN | NCT05146375 |
| Placebo | Other | Approved | Atrial Fibrillation | COMPLETED | NCT04272762 |
| Cryoablation | Other | Approved | Atrial Fibrillation | COMPLETED | NCT04272762 |
| a basal LV septum biopsy | Other | Approved | Heart Disease | UNKNOWN | NCT02260466 |
| a basal LV septum biopsy | Other | Approved | Heart Disease | UNKNOWN | NCT02260466 |
| Coronary angiography with physiological lesion assessment by fractional flow reserve (FFR) and contrast fractional flow reserve (cFFR). | Other | Approved | Myocardial Ischemia | COMPLETED | NCT05864729 |
| Coronary angiography with physiological lesion assessment by fractional flow reserve (FFR) and contrast fractional flow reserve (cFFR). | Other | Approved | Myocardial Ischemia | COMPLETED | NCT05864729 |
| sugar and fat oral load | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03515460 |
| fat oral load | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03515460 |
| sugar oral load | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03515460 |
| sugar and fat oral load | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03515460 |
| fat oral load | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03515460 |
| sugar oral load | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03515460 |
| Left Atrial Appendage Occlusion | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT02699957 |
| Left Atrial Appendage Occlusion | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT02699957 |
| Esmolol Hcl 10Mg/Ml Inj | Other | Approved | Myocardial Infarction | RECRUITING | NCT06376630 |
| Esmolol Hcl 10Mg/Ml Inj | Other | Approved | Myocardial Infarction | RECRUITING | NCT06376630 |
| Esmolol Hcl 10Mg/Ml Inj | Other | Approved | Myocardial Infarction | RECRUITING | NCT06376630 |
| Progression and structured surgical training. | Other | Approved | Vascular Diseases | NOT_YET_RECRUITING | NCT06452901 |
| Progression and structured surgical training. | Other | Approved | Vascular Diseases | NOT_YET_RECRUITING | NCT06452901 |
| Food craving induction | Other | Preclinical | Bulimia Nervosa | RECRUITING | NCT05879679 |
| Food craving induction | Other | Preclinical | Bulimia Nervosa | RECRUITING | NCT05879679 |
| Food craving induction | Other | Preclinical | Bulimia Nervosa | RECRUITING | NCT05879679 |
| Education | Other | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT04396418 |
| Education | Other | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT04396418 |
| Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet) | Other | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT04676880 |
| Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet) | Other | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT04676880 |
| IMT PowerBreath Placebo | Other | Approved | Postmenopausal Disorder | RECRUITING | NCT03672760 |
| IMT PowerBreath | Other | Approved | Postmenopausal Disorder | RECRUITING | NCT03672760 |
| CardioBreathApp | Other | Approved | Postmenopausal Disorder | RECRUITING | NCT03672760 |
| IMT PowerBreath Placebo | Other | Approved | Postmenopausal Disorder | RECRUITING | NCT03672760 |
| IMT PowerBreath | Other | Approved | Postmenopausal Disorder | RECRUITING | NCT03672760 |
| CardioBreathApp | Other | Approved | Postmenopausal Disorder | RECRUITING | NCT03672760 |
| Mineral Oil | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT06494566 |
| Omega-3 | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT06494566 |
| Mineral Oil | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT06494566 |
| Omega-3 | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT06494566 |
| Mineral Oil | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT06494566 |
| Omega-3 | Other | Phase EARLY_PHASE1 | Obesity | COMPLETED | NCT06494566 |
| Schultz Autogenic Training | Other | Approved | Cardiovascular Diseases | COMPLETED | NCT06241534 |
| Virtual reality therapy | Drug | Approved | Cardiovascular Diseases | COMPLETED | NCT06241534 |
| Relaxation-therapeutic recordings | Other | Approved | Cardiovascular Diseases | COMPLETED | NCT06241534 |
| Cardiac rehabilitation | Other | Approved | Cardiovascular Diseases | COMPLETED | NCT06241534 |
| Schultz Autogenic Training | Other | Approved | Cardiovascular Diseases | COMPLETED | NCT06241534 |
| Virtual reality therapy | Drug | Approved | Cardiovascular Diseases | COMPLETED | NCT06241534 |
| Relaxation-therapeutic recordings | Other | Approved | Cardiovascular Diseases | COMPLETED | NCT06241534 |
| Cardiac rehabilitation | Other | Approved | Cardiovascular Diseases | COMPLETED | NCT06241534 |
| No intervention | Other | Preclinical | Aortic Aneurysm | RECRUITING | NCT06514170 |
| No intervention | Other | Preclinical | Aortic Aneurysm | RECRUITING | NCT06514170 |
| Placebo | Other | Approved | Acute Kidney Injury | NOT_YET_RECRUITING | NCT06521307 |
| Nicotinamide riboside | Other | Approved | Acute Kidney Injury | NOT_YET_RECRUITING | NCT06521307 |
| Placebo | Other | Approved | Acute Kidney Injury | NOT_YET_RECRUITING | NCT06521307 |
| Nicotinamide riboside | Other | Approved | Acute Kidney Injury | NOT_YET_RECRUITING | NCT06521307 |
| Anticoagulant | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Nitrates | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| CCB | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| ACEi/ARB | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Beta blocker | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Statin | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Antiplatelet Drug | Drug | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Circulating biomarkers | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Cardiac magnetic resonance | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| TE/contrast echocardiography | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| TT-Echocardiography | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Acetylcholine provocative test | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Percutaneous coronary intervention (PCI): | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| OCT imaging | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Coronary angiography | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Anticoagulant | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Nitrates | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| CCB | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| ACEi/ARB | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Beta blocker | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Statin | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Antiplatelet Drug | Drug | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Circulating biomarkers | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Cardiac magnetic resonance | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| TE/contrast echocardiography | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| TT-Echocardiography | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Acetylcholine provocative test | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Percutaneous coronary intervention (PCI): | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| OCT imaging | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Coronary angiography | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Anticoagulant | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Nitrates | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| CCB | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| ACEi/ARB | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Beta blocker | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Statin | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Antiplatelet Drug | Drug | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Circulating biomarkers | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Cardiac magnetic resonance | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| TE/contrast echocardiography | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| TT-Echocardiography | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Acetylcholine provocative test | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Percutaneous coronary intervention (PCI): | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| OCT imaging | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Coronary angiography | Other | Phase PHASE4 | Myocardial Infarction With Non-Obstructive Coronary Arteries | ACTIVE_NOT_RECRUITING | NCT05122780 |
| Standard-of-care | Other | Approved | Heart Failure | RECRUITING | NCT06400927 |
| HF-guided VA | Other | Approved | Heart Failure | RECRUITING | NCT06400927 |
| Standard-of-care | Other | Approved | Heart Failure | RECRUITING | NCT06400927 |
| HF-guided VA | Other | Approved | Heart Failure | RECRUITING | NCT06400927 |
| Myocardial Infarction | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT03015064 |
| Myocardial Infarction | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT03015064 |
| Single Anastomosis Duodenal Switch | Other | Approved | Obesity | RECRUITING | NCT04767490 |
| Standard Duodenal Switch | Other | Approved | Obesity | RECRUITING | NCT04767490 |
| Single Anastomosis Duodenal Switch | Other | Approved | Obesity | RECRUITING | NCT04767490 |
| Standard Duodenal Switch | Other | Approved | Obesity | RECRUITING | NCT04767490 |
| PCI Facilitated with Orbital Atherectomy Device | Device | Preclinical | Safety Issues | RECRUITING | NCT06451146 |
| PCI Facilitated with Orbital Atherectomy Device | Device | Preclinical | Safety Issues | RECRUITING | NCT06451146 |
| Catheter ablation | Other | Preclinical | Atrial Fibrillation and Flutter | RECRUITING | NCT06584266 |
| Transoesophageal echocardiography | Other | Preclinical | Atrial Fibrillation and Flutter | RECRUITING | NCT06584266 |
| Catheter ablation | Other | Preclinical | Atrial Fibrillation and Flutter | RECRUITING | NCT06584266 |
| Transoesophageal echocardiography | Other | Preclinical | Atrial Fibrillation and Flutter | RECRUITING | NCT06584266 |
| Catheter ablation | Other | Preclinical | Atrial Fibrillation and Flutter | RECRUITING | NCT06584266 |
| Transoesophageal echocardiography | Other | Preclinical | Atrial Fibrillation and Flutter | RECRUITING | NCT06584266 |
| Respiratory protective mask | Other | Approved | Heart Failure | COMPLETED | NCT05762406 |
| Respiratory protective mask | Other | Approved | Heart Failure | COMPLETED | NCT05762406 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | ACTIVE_NOT_RECRUITING | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | ACTIVE_NOT_RECRUITING | NCT06584734 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | ACTIVE_NOT_RECRUITING | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | ACTIVE_NOT_RECRUITING | NCT06584734 |
| Home sleep study device | Device | Preclinical | Obstructive Sleep Apnea | RECRUITING | NCT06331819 |
| Continuous positive airway pressure | Other | Preclinical | Obstructive Sleep Apnea | RECRUITING | NCT06331819 |
| In-lab polysomnography | Other | Preclinical | Obstructive Sleep Apnea | RECRUITING | NCT06331819 |
| Home sleep study device | Device | Preclinical | Obstructive Sleep Apnea | RECRUITING | NCT06331819 |
| Continuous positive airway pressure | Other | Preclinical | Obstructive Sleep Apnea | RECRUITING | NCT06331819 |
| In-lab polysomnography | Other | Preclinical | Obstructive Sleep Apnea | RECRUITING | NCT06331819 |
| Multiple intervention program | Other | Approved | Heart Decompensation | TERMINATED | NCT04703504 |
| Multiple intervention program | Other | Approved | Heart Decompensation | TERMINATED | NCT04703504 |
| CTO PCI without the first-choice Gladius guidewire | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04691778 |
| CTO PCI with the first-choice Gladius guidewire | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04691778 |
| CTO PCI without the first-choice Gladius guidewire | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04691778 |
| CTO PCI with the first-choice Gladius guidewire | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04691778 |
| CTO PCI without the first-choice Gladius guidewire | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04691778 |
| CTO PCI with the first-choice Gladius guidewire | Other | Approved | Coronary Artery Disease | COMPLETED | NCT04691778 |
| MitraClip | Other | Preclinical | Mitral Regurgitation | RECRUITING | NCT06633159 |
| MitraClip | Other | Preclinical | Mitral Regurgitation | RECRUITING | NCT06633159 |
| Observational | Other | Preclinical | Binge-Eating Disorder | RECRUITING | NCT05149859 |
| Observational | Other | Preclinical | Binge-Eating Disorder | RECRUITING | NCT05149859 |
| Standard imaging | Other | Approved | Atrial Fibrillation | RECRUITING | NCT04800913 |
| Multimodal imaging | Other | Approved | Atrial Fibrillation | RECRUITING | NCT04800913 |
| Standard imaging | Other | Approved | Atrial Fibrillation | RECRUITING | NCT04800913 |
| Multimodal imaging | Other | Approved | Atrial Fibrillation | RECRUITING | NCT04800913 |
| A conventional device | Device | Approved | Cardiac Arrhythmia | COMPLETED | NCT04723355 |
| An innovative 3-lead wireless water resistant Holter device | Device | Approved | Cardiac Arrhythmia | COMPLETED | NCT04723355 |
| A conventional device | Device | Approved | Cardiac Arrhythmia | COMPLETED | NCT04723355 |
| An innovative 3-lead wireless water resistant Holter device | Device | Approved | Cardiac Arrhythmia | COMPLETED | NCT04723355 |
| A conventional device | Device | Approved | Cardiac Arrhythmia | COMPLETED | NCT04723355 |
| An innovative 3-lead wireless water resistant Holter device | Device | Approved | Cardiac Arrhythmia | COMPLETED | NCT04723355 |
| There are no interventions as the study is purely observational. | Other | Preclinical | Spontaneous Coronary Artery Dissection | RECRUITING | NCT06601270 |
| There are no interventions as the study is purely observational. | Other | Preclinical | Spontaneous Coronary Artery Dissection | RECRUITING | NCT06601270 |
| HealthReveal | Other | Approved | Heart Failure, Systolic | WITHDRAWN | NCT04872959 |
| HealthReveal | Other | Approved | Heart Failure, Systolic | WITHDRAWN | NCT04872959 |
| Evolocumab | Other | Phase PHASE2 | ST-elevation Myocardial Infarction | WITHDRAWN | NCT04303377 |
| Evolocumab | Other | Phase PHASE2 | ST-elevation Myocardial Infarction | WITHDRAWN | NCT04303377 |
| Evolocumab | Other | Phase PHASE2 | ST-elevation Myocardial Infarction | WITHDRAWN | NCT04303377 |
| Placebo | Other | Approved | Non-Alcoholic Fatty Liver Disease | RECRUITING | NCT06704321 |
| TOTUM-448 | Other | Approved | Non-Alcoholic Fatty Liver Disease | RECRUITING | NCT06704321 |
| Placebo | Other | Approved | Non-Alcoholic Fatty Liver Disease | RECRUITING | NCT06704321 |
| TOTUM-448 | Other | Approved | Non-Alcoholic Fatty Liver Disease | RECRUITING | NCT06704321 |
| Amiodarone (Antiarrhythmic drug) | Drug | Phase PHASE4 | Atrial Fibrillation (AF) | NOT_YET_RECRUITING | NCT06645249 |
| Amiodarone (Antiarrhythmic drug) | Drug | Phase PHASE4 | Atrial Fibrillation (AF) | NOT_YET_RECRUITING | NCT06645249 |
| Amiodarone (Antiarrhythmic drug) | Drug | Phase PHASE4 | Atrial Fibrillation (AF) | NOT_YET_RECRUITING | NCT06645249 |
| Dapagliflozin (DAPA) | Other | Phase PHASE4 | Arrhythmias, Cardiac | COMPLETED | NCT06721442 |
| Dapagliflozin (DAPA) | Other | Phase PHASE4 | Arrhythmias, Cardiac | COMPLETED | NCT06721442 |
| Placebo II | Other | Phase PHASE3 | Injury of Radial Artery | COMPLETED | NCT03158532 |
| Nitroglycerin II | Other | Phase PHASE3 | Injury of Radial Artery | COMPLETED | NCT03158532 |
| Placebo I | Other | Phase PHASE3 | Injury of Radial Artery | COMPLETED | NCT03158532 |
| Nitroglycerin I | Other | Phase PHASE3 | Injury of Radial Artery | COMPLETED | NCT03158532 |
| Placebo II | Other | Phase PHASE3 | Injury of Radial Artery | COMPLETED | NCT03158532 |
| Nitroglycerin II | Other | Phase PHASE3 | Injury of Radial Artery | COMPLETED | NCT03158532 |
| Placebo I | Other | Phase PHASE3 | Injury of Radial Artery | COMPLETED | NCT03158532 |
| Nitroglycerin I | Other | Phase PHASE3 | Injury of Radial Artery | COMPLETED | NCT03158532 |
| late anticoagulation | Other | Phase PHASE4 | Mitral Regurgitation | ENROLLING_BY_INVITATION | NCT05305612 |
| early anticoagulation | Other | Phase PHASE4 | Mitral Regurgitation | ENROLLING_BY_INVITATION | NCT05305612 |
| late anticoagulation | Other | Phase PHASE4 | Mitral Regurgitation | ENROLLING_BY_INVITATION | NCT05305612 |
| early anticoagulation | Other | Phase PHASE4 | Mitral Regurgitation | ENROLLING_BY_INVITATION | NCT05305612 |
| Percutaneous coronary intervention with stent implantation | Other | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | Other | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Intravascular lithotripsy | Other | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Orbital atherectomy | Other | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Percutaneous coronary intervention with stent implantation | Other | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | Other | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Intravascular lithotripsy | Other | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Orbital atherectomy | Other | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Iohexol | Other | Phase PHASE1 | Chronic Kidney Failure | COMPLETED | NCT05105009 |
| Creatinine Powder | Other | Phase PHASE1 | Chronic Kidney Failure | COMPLETED | NCT05105009 |
| Furosemide Injection | Other | Phase PHASE1 | Chronic Kidney Failure | COMPLETED | NCT05105009 |
| Telematic intervention | Other | Approved | Aortic Stenosis | NOT_YET_RECRUITING | NCT06742970 |
| Telematic intervention | Other | Approved | Aortic Stenosis | NOT_YET_RECRUITING | NCT06742970 |
| heated tobacco - lifestyle intervention | Other | Approved | Coronary Artery Disease | RECRUITING | NCT05660798 |
| heated tobacco - lifestyle intervention | Other | Approved | Coronary Artery Disease | RECRUITING | NCT05660798 |
| Placebo | Other | Phase PHASE4 | Aortic Stenosis | RECRUITING | NCT04913870 |
| Angiotensin Receptor Blockers | Other | Phase PHASE4 | Aortic Stenosis | RECRUITING | NCT04913870 |
| Placebo | Other | Phase PHASE4 | Aortic Stenosis | RECRUITING | NCT04913870 |
| Angiotensin Receptor Blockers | Other | Phase PHASE4 | Aortic Stenosis | RECRUITING | NCT04913870 |
| Complex PCI | Other | Preclinical | Myocardial Infarction (MI) | NOT_YET_RECRUITING | NCT06565793 |
| Non Complex PCI | Other | Preclinical | Myocardial Infarction (MI) | NOT_YET_RECRUITING | NCT06565793 |
| Complex PCI | Other | Preclinical | Myocardial Infarction (MI) | NOT_YET_RECRUITING | NCT06565793 |
| Non Complex PCI | Other | Preclinical | Myocardial Infarction (MI) | NOT_YET_RECRUITING | NCT06565793 |
| Diet | Other | Approved | Metabolic Associated Fatty Liver Disease | NOT_YET_RECRUITING | NCT06764056 |
| semaglutide | Other | Approved | Metabolic Associated Fatty Liver Disease | NOT_YET_RECRUITING | NCT06764056 |
| Diet | Other | Approved | Metabolic Associated Fatty Liver Disease | NOT_YET_RECRUITING | NCT06764056 |
| semaglutide | Other | Approved | Metabolic Associated Fatty Liver Disease | NOT_YET_RECRUITING | NCT06764056 |
| CABG and SAVR | Other | Approved | Aortic Stenosis | COMPLETED | NCT03424941 |
| FFR-guided PCI and TAVI | Other | Approved | Aortic Stenosis | COMPLETED | NCT03424941 |
| Dapagliflozin 10 MG | Other | Phase PHASE4 | Aortic Stenosis | COMPLETED | NCT04696185 |
| Dapagliflozin 10 MG | Other | Phase PHASE4 | Aortic Stenosis | COMPLETED | NCT04696185 |
| Dapagliflozin 10 MG | Other | Phase PHASE4 | Aortic Stenosis | COMPLETED | NCT04696185 |
| Aortic Valve Replacement - Inspires Resilia prosthesis | Other | Approved | Aortic Regurgitation Disease | RECRUITING | NCT06688448 |
| Dafodil prosthesis | Other | Approved | Aortic Regurgitation Disease | RECRUITING | NCT06688448 |
| Aortic Valve Replacement - Inspires Resilia prosthesis | Other | Approved | Aortic Regurgitation Disease | RECRUITING | NCT06688448 |
| Dafodil prosthesis | Other | Approved | Aortic Regurgitation Disease | RECRUITING | NCT06688448 |
| PFO closure | Other | Preclinical | Patent Foramen Ovale | RECRUITING | NCT06156670 |
| PFO closure | Other | Preclinical | Patent Foramen Ovale | RECRUITING | NCT06156670 |
| Sodium-GLucose coTransporter-2 inhibitors | Other | Preclinical | Sodium-GLucose coTransporter-2 Inhibitors | COMPLETED | NCT05344963 |
| Sodium-GLucose coTransporter-2 inhibitors | Other | Preclinical | Sodium-GLucose coTransporter-2 Inhibitors | COMPLETED | NCT05344963 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | NOT_YET_RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | NOT_YET_RECRUITING | NCT06655480 |
| Transcatheter edge-to-edge repair | Other | Preclinical | Tricuspid Regurgitation | RECRUITING | NCT06838611 |
| Observation | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT06239402 |
| Observation | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT06239402 |
| Observation | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT06239402 |
| Evaluation of risk factors by direct interview with subjects who have atherosclerotic cardiovascular patients | Other | Preclinical | Cardiovascular Risk Factors | COMPLETED | NCT06199869 |
| Evaluation of risk factors by direct interview with subjects who have atherosclerotic cardiovascular patients | Other | Preclinical | Cardiovascular Risk Factors | COMPLETED | NCT06199869 |
| Performing blood thyroid test (TSH, FT4, FT3) | Other | Preclinical | Thyroid Dysfunction | WITHDRAWN | NCT05980923 |
| Performing blood thyroid test (TSH, FT4, FT3) | Other | Preclinical | Thyroid Dysfunction | WITHDRAWN | NCT05980923 |
| Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor. | Other | Preclinical | Blood Pressure | COMPLETED | NCT06627920 |
| Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor. | Other | Preclinical | Blood Pressure | COMPLETED | NCT06627920 |
| Extensive TAAD- R | Other | Preclinical | Aortic Dissection | ENROLLING_BY_INVITATION | NCT05912634 |
| Conservative TAAD-R | Other | Preclinical | Aortic Dissection | ENROLLING_BY_INVITATION | NCT05912634 |
| Extensive TAAD- R | Other | Preclinical | Aortic Dissection | ENROLLING_BY_INVITATION | NCT05912634 |
| Conservative TAAD-R | Other | Preclinical | Aortic Dissection | ENROLLING_BY_INVITATION | NCT05912634 |
| Restrictive Mitral Annuloplastie/Subvalvular Repair | Other | Preclinical | Severe Mitral Valve Regurgitation (Disorder) | ENROLLING_BY_INVITATION | NCT05090540 |
| Restrictive Mitral Annuloplastie | Other | Preclinical | Severe Mitral Valve Regurgitation (Disorder) | ENROLLING_BY_INVITATION | NCT05090540 |
| Mitral Valve Replacement | Other | Preclinical | Severe Mitral Valve Regurgitation (Disorder) | ENROLLING_BY_INVITATION | NCT05090540 |
| Trancatheter Edge to Edge Repair | Other | Preclinical | Severe Mitral Valve Regurgitation (Disorder) | ENROLLING_BY_INVITATION | NCT05090540 |
| Restrictive Mitral Annuloplastie/Subvalvular Repair | Other | Preclinical | Severe Mitral Valve Regurgitation (Disorder) | ENROLLING_BY_INVITATION | NCT05090540 |
| Restrictive Mitral Annuloplastie | Other | Preclinical | Severe Mitral Valve Regurgitation (Disorder) | ENROLLING_BY_INVITATION | NCT05090540 |
| Mitral Valve Replacement | Other | Preclinical | Severe Mitral Valve Regurgitation (Disorder) | ENROLLING_BY_INVITATION | NCT05090540 |
| Trancatheter Edge to Edge Repair | Other | Preclinical | Severe Mitral Valve Regurgitation (Disorder) | ENROLLING_BY_INVITATION | NCT05090540 |
| SuperSonic image | Other | Approved | Cardiovascular Diseases in Old Age | RECRUITING | NCT03895541 |
| SuperSonic image | Other | Approved | Cardiovascular Diseases in Old Age | RECRUITING | NCT03895541 |
| Surgery (Mastectomy or quadrantectomy) | Procedure | Preclinical | Breast Cancer | ENROLLING_BY_INVITATION | NCT06447532 |
| Surgery (Mastectomy or quadrantectomy) | Procedure | Preclinical | Breast Cancer | ENROLLING_BY_INVITATION | NCT06447532 |
| CardiolRx | Other | Phase PHASE2 | Acute Myocarditis | COMPLETED | NCT05180240 |
| Conventional full-face mask - dual-limb | Other | Approved | Acute Hypercapnic Respiratory Failure | RECRUITING | NCT06007495 |
| Conventional full-face mask - single-limb | Other | Approved | Acute Hypercapnic Respiratory Failure | RECRUITING | NCT06007495 |
| Investigational full-face mask with expiratory washout | Other | Approved | Acute Hypercapnic Respiratory Failure | RECRUITING | NCT06007495 |
| Conventional full-face mask - dual-limb | Other | Approved | Acute Hypercapnic Respiratory Failure | RECRUITING | NCT06007495 |
| Conventional full-face mask - single-limb | Other | Approved | Acute Hypercapnic Respiratory Failure | RECRUITING | NCT06007495 |
| Investigational full-face mask with expiratory washout | Other | Approved | Acute Hypercapnic Respiratory Failure | RECRUITING | NCT06007495 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| post-PCI FFR | Other | Approved | Coronary Artery Disease | ACTIVE_NOT_RECRUITING | NCT04929496 |
| post-PCI FFR | Other | Approved | Coronary Artery Disease | ACTIVE_NOT_RECRUITING | NCT04929496 |
| Implantable Loop Recorder implant | Other | Preclinical | Death, Sudden | ACTIVE_NOT_RECRUITING | NCT04765943 |
| Implantable Loop Recorder implant | Other | Preclinical | Death, Sudden | ACTIVE_NOT_RECRUITING | NCT04765943 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Biomarkers evaluation | Other | Approved | Heart Failure | COMPLETED | NCT06896461 |
| Lung function | Other | Approved | Heart Failure | COMPLETED | NCT06896461 |
| Cardiopulmonary exercise test | Other | Approved | Heart Failure | COMPLETED | NCT06896461 |
| Biomarkers evaluation | Other | Approved | Heart Failure | COMPLETED | NCT06896461 |
| Lung function | Other | Approved | Heart Failure | COMPLETED | NCT06896461 |
| Cardiopulmonary exercise test | Other | Approved | Heart Failure | COMPLETED | NCT06896461 |
| 3 whole eggs | Other | Approved | Obesity and Obesity-related Medical Conditions | RECRUITING | NCT06687122 |
| 3 whole eggs | Other | Approved | Obesity and Obesity-related Medical Conditions | RECRUITING | NCT06687122 |
| Pharmacological cardioversion with Refralon | Other | Phase PHASE4 | Atrial Fibrillation Paroxysmal | COMPLETED | NCT05445297 |
| Pharmacological cardioversion with Amiodarone | Other | Phase PHASE4 | Atrial Fibrillation Paroxysmal | COMPLETED | NCT05445297 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Therapeutic education | Other | Approved | Heart Failure | COMPLETED | NCT03035123 |
| Therapeutic education | Other | Approved | Heart Failure | COMPLETED | NCT03035123 |
| Mobile health application | Other | Approved | Healthy Population | ACTIVE_NOT_RECRUITING | NCT05339841 |
| Mobile health application | Other | Approved | Healthy Population | ACTIVE_NOT_RECRUITING | NCT05339841 |
| Mobile health application | Other | Approved | Healthy Population | ACTIVE_NOT_RECRUITING | NCT05339841 |
| Edwards SAPIEN Transcatheter Heart Valve | Other | Preclinical | Severe Symptomatic Aortic Stenosis | COMPLETED | NCT01787084 |
| Edwards SAPIEN Transcatheter Heart Valve | Other | Preclinical | Severe Symptomatic Aortic Stenosis | COMPLETED | NCT01787084 |
| CardioBreath | Other | Approved | Hypertension | NOT_YET_RECRUITING | NCT06917729 |
| CardioBreath | Other | Approved | Hypertension | NOT_YET_RECRUITING | NCT06917729 |
| whole blood flow cytometry analisys | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT06919731 |
| whole blood flow cytometry analisys | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT06919731 |
| whole blood flow cytometry analisys | Other | Preclinical | Cardiovascular Diseases | COMPLETED | NCT06919731 |
| Placebo | Other | Phase PHASE2 | Systemic Sclerosis With Lung Involvement | RECRUITING | NCT05785065 |
| Mycophenolate Mofetil | Other | Phase PHASE2 | Systemic Sclerosis With Lung Involvement | RECRUITING | NCT05785065 |
| Placebo | Other | Phase PHASE2 | Systemic Sclerosis With Lung Involvement | RECRUITING | NCT05785065 |
| Mycophenolate Mofetil | Other | Phase PHASE2 | Systemic Sclerosis With Lung Involvement | RECRUITING | NCT05785065 |
| DPP6 risk haplotype | Other | Preclinical | Short-coupled Ventricular Fibrillation | ENROLLING_BY_INVITATION | NCT06943365 |
| Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies | Other | Preclinical | Short-coupled Ventricular Fibrillation | ENROLLING_BY_INVITATION | NCT06943365 |
| DPP6 risk haplotype | Other | Preclinical | Short-coupled Ventricular Fibrillation | ENROLLING_BY_INVITATION | NCT06943365 |
| Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies | Other | Preclinical | Short-coupled Ventricular Fibrillation | ENROLLING_BY_INVITATION | NCT06943365 |
| DPP6 risk haplotype | Other | Preclinical | Short-coupled Ventricular Fibrillation | ENROLLING_BY_INVITATION | NCT06943365 |
| Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies | Other | Preclinical | Short-coupled Ventricular Fibrillation | ENROLLING_BY_INVITATION | NCT06943365 |
| Health self-assessment questionnaire | Other | Preclinical | Epidemiology of Cardiovascular Risk | COMPLETED | NCT03962309 |
| Health self-assessment questionnaire | Other | Preclinical | Epidemiology of Cardiovascular Risk | COMPLETED | NCT03962309 |
| Placebo | Other | Phase PHASE4 | Heart Failure New York Heart Association Class III | TERMINATED | NCT04705337 |
| Levosimendan | Other | Phase PHASE4 | Heart Failure New York Heart Association Class III | TERMINATED | NCT04705337 |
| Placebo | Other | Phase PHASE4 | Heart Failure New York Heart Association Class III | TERMINATED | NCT04705337 |
| Levosimendan | Other | Phase PHASE4 | Heart Failure New York Heart Association Class III | TERMINATED | NCT04705337 |
| Placebo | Other | Phase PHASE4 | Heart Failure New York Heart Association Class III | TERMINATED | NCT04705337 |
| Levosimendan | Other | Phase PHASE4 | Heart Failure New York Heart Association Class III | TERMINATED | NCT04705337 |
| Evaluation of sublingual microcirculation with side-stream dark field imaging (cytocam) | Other | Preclinical | Microvascular Rarefaction | COMPLETED | NCT05728047 |
| Evaluation of sublingual microcirculation with side-stream dark field imaging (cytocam) | Other | Preclinical | Microvascular Rarefaction | COMPLETED | NCT05728047 |
| THERE IS NOT A INTERVENTION | Other | Preclinical | Arrhythmia | NOT_YET_RECRUITING | NCT06985082 |
| THERE IS NOT A INTERVENTION | Other | Preclinical | Arrhythmia | NOT_YET_RECRUITING | NCT06985082 |
| Valsartan | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT03928158 |
| LCZ 696 | Other | Phase PHASE2 | Heart Failure | COMPLETED | NCT03928158 |
| Gemcitabine | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT03101995 |
| Gemcitabine | Other | Phase PHASE2 | Cervical Cancer | RECRUITING | NCT03101995 |
| Control | Other | Approved | Clinical Trial | COMPLETED | NCT07017296 |
| Active comparator | Other | Approved | Clinical Trial | COMPLETED | NCT07017296 |
| Positive control | Other | Approved | Clinical Trial | COMPLETED | NCT07017296 |
| Placebo | Other | Approved | Clinical Trial | COMPLETED | NCT07017296 |
| Control | Other | Approved | Clinical Trial | COMPLETED | NCT07017296 |
| Active comparator | Other | Approved | Clinical Trial | COMPLETED | NCT07017296 |
| Positive control | Other | Approved | Clinical Trial | COMPLETED | NCT07017296 |
| Placebo | Other | Approved | Clinical Trial | COMPLETED | NCT07017296 |
| Exposure to 3600 m | Other | Preclinical | Acute Mountain Sickness | RECRUITING | NCT06499714 |
| Exposure to 3600 m | Other | Preclinical | Acute Mountain Sickness | RECRUITING | NCT06499714 |
| Placebo | Other | Phase PHASE4 | High Altitude | RECRUITING | NCT06498505 |
| Acetazolamide | Other | Phase PHASE4 | High Altitude | RECRUITING | NCT06498505 |
| Placebo | Other | Phase PHASE4 | High Altitude | RECRUITING | NCT06498505 |
| Acetazolamide | Other | Phase PHASE4 | High Altitude | RECRUITING | NCT06498505 |
| Clopidogrel | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT01777503 |
| prasugrel | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT01777503 |
| Clopidogrel | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT01777503 |
| prasugrel | Other | Phase PHASE4 | Acute Coronary Syndrome | COMPLETED | NCT01777503 |
| Pulmonary vein isolation by percutaneous endocardial catheter ablation using a pentaspline pulsed high voltage electrical field system in patients with atrial fibrillation | Other | Approved | Atrial Fibrillation | RECRUITING | NCT07021313 |
| Pulmonary vein isolation by percutaneous endocardial catheter ablation using the FARAPULSE pulsed high voltage electrical field system in patients with atrial fibrillation | Other | Approved | Atrial Fibrillation | RECRUITING | NCT07021313 |
| Pulmonary vein isolation by percutaneous endocardial catheter ablation using a pentaspline pulsed high voltage electrical field system in patients with atrial fibrillation | Other | Approved | Atrial Fibrillation | RECRUITING | NCT07021313 |
| Pulmonary vein isolation by percutaneous endocardial catheter ablation using the FARAPULSE pulsed high voltage electrical field system in patients with atrial fibrillation | Other | Approved | Atrial Fibrillation | RECRUITING | NCT07021313 |
| Placebo atorvastatin | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06922994 |
| Atorvastatin 80 mg/day | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06922994 |
| Placebo atorvastatin | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06922994 |
| Atorvastatin 80 mg/day | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06922994 |
| Placebo atorvastatin | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06922994 |
| Atorvastatin 80 mg/day | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06922994 |
| Placebo atorvastatin | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06922994 |
| Atorvastatin 80 mg/day | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06922994 |
| Colchicine | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT04382443 |
| Colchicine | Other | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT04382443 |
| Cardiac resynchronization therapy | Drug | Approved | Left Bundle-Branch Block | ACTIVE_NOT_RECRUITING | NCT05434962 |
| Cardiac resynchronization therapy | Drug | Approved | Left Bundle-Branch Block | ACTIVE_NOT_RECRUITING | NCT05434962 |
| Catheter ablation | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT05432024 |
| Catheter ablation | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT05432024 |
| Quality of life and cognitive status questionnaire | Other | Approved | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT06278519 |
| Cardiac MRI | Other | Approved | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT06278519 |
| Blood, urinary and feces collection | Other | Approved | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT06278519 |
| Quality of life and cognitive status questionnaire | Other | Approved | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT06278519 |
| Cardiac MRI | Other | Approved | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT06278519 |
| Blood, urinary and feces collection | Other | Approved | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT06278519 |
| Angio guided revascularization | Other | Phase PHASE4 | ST Elevated Myocardial Infarction | RECRUITING | NCT05491200 |
| OCT guided revascularization | Other | Phase PHASE4 | ST Elevated Myocardial Infarction | RECRUITING | NCT05491200 |
| Prasugrel based standard DAPT | Other | Phase PHASE4 | ST Elevated Myocardial Infarction | RECRUITING | NCT05491200 |
| Prasugrel based short DAPT | Other | Phase PHASE4 | ST Elevated Myocardial Infarction | RECRUITING | NCT05491200 |
| Angio guided revascularization | Other | Phase PHASE4 | ST Elevated Myocardial Infarction | RECRUITING | NCT05491200 |
| OCT guided revascularization | Other | Phase PHASE4 | ST Elevated Myocardial Infarction | RECRUITING | NCT05491200 |
| Prasugrel based standard DAPT | Other | Phase PHASE4 | ST Elevated Myocardial Infarction | RECRUITING | NCT05491200 |
| Prasugrel based short DAPT | Other | Phase PHASE4 | ST Elevated Myocardial Infarction | RECRUITING | NCT05491200 |
| support garment | Other | Approved | Obesity | TERMINATED | NCT04938310 |
| sleeve gastrectomy | Other | Approved | Obesity | TERMINATED | NCT04938310 |
| support garment | Other | Approved | Obesity | TERMINATED | NCT04938310 |
| sleeve gastrectomy | Other | Approved | Obesity | TERMINATED | NCT04938310 |
| Moment 1: CardioBreath and moment 2: IMT. | Other | Approved | Congestive Heart Failure | COMPLETED | NCT06139653 |
| Moment 1: IMT. Moment 2 CardioBreath. | Other | Approved | Congestive Heart Failure | COMPLETED | NCT06139653 |
| Moment 1: CardioBreath and moment 2: IMT. | Other | Approved | Congestive Heart Failure | COMPLETED | NCT06139653 |
| Moment 1: IMT. Moment 2 CardioBreath. | Other | Approved | Congestive Heart Failure | COMPLETED | NCT06139653 |
| Exercise | Other | Approved | Cardiomyopathy, Hypertrophic | ACTIVE_NOT_RECRUITING | NCT07127640 |
| Exercise | Other | Approved | Cardiomyopathy, Hypertrophic | ACTIVE_NOT_RECRUITING | NCT07127640 |
| Exercise | Other | Approved | Cardiomyopathy, Hypertrophic | ACTIVE_NOT_RECRUITING | NCT07127640 |
| Control Group | Other | Approved | Depressive Symptoms | COMPLETED | NCT05956249 |
| Online group therapy | Drug | Approved | Depressive Symptoms | COMPLETED | NCT05956249 |
| Control Group | Other | Approved | Depressive Symptoms | COMPLETED | NCT05956249 |
| Online group therapy | Drug | Approved | Depressive Symptoms | COMPLETED | NCT05956249 |
| Acetyl cysteine | Other | Phase PHASE2 | Cardiac Arrhythmia | COMPLETED | NCT04154982 |
| Acetyl cysteine | Other | Phase PHASE2 | Cardiac Arrhythmia | COMPLETED | NCT04154982 |
| Acetyl cysteine | Other | Phase PHASE2 | Cardiac Arrhythmia | COMPLETED | NCT04154982 |
| FAITH! App | Other | Approved | Health Equity | RECRUITING | NCT06187077 |
| DHA-Enhanced FAITH! App | Other | Approved | Health Equity | RECRUITING | NCT06187077 |
| FAITH! App | Other | Approved | Health Equity | RECRUITING | NCT06187077 |
| DHA-Enhanced FAITH! App | Other | Approved | Health Equity | RECRUITING | NCT06187077 |
| Isometric knee extension exercise | Other | Approved | Hypertension (HTN) | COMPLETED | NCT07147595 |
| Isometric handgrip exercise | Other | Approved | Hypertension (HTN) | COMPLETED | NCT07147595 |
| Isometric knee extension exercise | Other | Approved | Hypertension (HTN) | COMPLETED | NCT07147595 |
| Isometric handgrip exercise | Other | Approved | Hypertension (HTN) | COMPLETED | NCT07147595 |
| Redo Mitral valve surgery | Procedure | Approved | Mitral Prosthetic Valve Stenosis and Regurgitation | COMPLETED | NCT04402931 |
| Transcatheter Valve-in-Valve Intervention | Other | Approved | Mitral Prosthetic Valve Stenosis and Regurgitation | COMPLETED | NCT04402931 |
| Redo Mitral valve surgery | Procedure | Approved | Mitral Prosthetic Valve Stenosis and Regurgitation | COMPLETED | NCT04402931 |
| Transcatheter Valve-in-Valve Intervention | Other | Approved | Mitral Prosthetic Valve Stenosis and Regurgitation | COMPLETED | NCT04402931 |
| Redo Mitral valve surgery | Procedure | Approved | Mitral Prosthetic Valve Stenosis and Regurgitation | COMPLETED | NCT04402931 |
| Transcatheter Valve-in-Valve Intervention | Other | Approved | Mitral Prosthetic Valve Stenosis and Regurgitation | COMPLETED | NCT04402931 |
| iVAC 2L | Other | Approved | Ischemic Cardiovascular Disease | RECRUITING | NCT07149714 |
| Colchicine 0.5 MG | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT06798714 |
| NSAID | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT06798714 |
| Colchicine 0.5 MG | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT06798714 |
| NSAID | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT06798714 |
| Conduction System Pacing (pacemaker implantation) | Other | Approved | Heart Failure | RECRUITING | NCT05029570 |
| Conduction System Pacing (pacemaker implantation) | Other | Approved | Heart Failure | RECRUITING | NCT05029570 |
| Observational Invasive Hemodynamic Assessment | Other | Preclinical | Heart Failure | RECRUITING | NCT07112391 |
| Observational Invasive Hemodynamic Assessment | Other | Preclinical | Heart Failure | RECRUITING | NCT07112391 |
| Pacemaker programming | Other | Approved | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT06833138 |
| atrioventricular node ablation | Other | Approved | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT06833138 |
| pacemaker implantation | Other | Approved | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT06833138 |
| Pacemaker programming | Other | Approved | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT06833138 |
| atrioventricular node ablation | Other | Approved | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT06833138 |
| pacemaker implantation | Other | Approved | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT06833138 |
| Pacemaker programming | Other | Approved | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT06833138 |
| atrioventricular node ablation | Other | Approved | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT06833138 |
| pacemaker implantation | Other | Approved | Heart Failure With Preserved Ejection Fraction | RECRUITING | NCT06833138 |
| Thoracic Aortic Surgery | Procedure | Approved | Ascending Aortic Aneurysm Enlargement | RECRUITING | NCT03536312 |
| Thoracic Aortic Surgery | Procedure | Approved | Ascending Aortic Aneurysm Enlargement | RECRUITING | NCT03536312 |
| Single-anastomosis duodenal switch | Other | Approved | Obesity | RECRUITING | NCT05242835 |
| Standard duodenal switch | Other | Approved | Obesity | RECRUITING | NCT05242835 |
| Single-anastomosis duodenal switch | Other | Approved | Obesity | RECRUITING | NCT05242835 |
| Standard duodenal switch | Other | Approved | Obesity | RECRUITING | NCT05242835 |
| Seerlinq Telemedical Monitoring System | Other | Approved | Heart Failure | COMPLETED | NCT06641921 |
| Seerlinq Telemedical Monitoring System | Other | Approved | Heart Failure | COMPLETED | NCT06641921 |
| Urinary test | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Vital signs | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Scales and questionnaire | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Blood sampling | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Arterial ultrasound | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Echocardiography | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| ECG monitoring | Other | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT03561805 |
| ECG monitoring | Other | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT03561805 |
| ECG monitoring | Other | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT03561805 |
| Ultrasound localization microscopy, coronary arteries | Other | Approved | Carotid Atherosclerosis | NOT_YET_RECRUITING | NCT07193225 |
| Ultrasound localization microscopy, circle of Willis | Other | Approved | Carotid Atherosclerosis | NOT_YET_RECRUITING | NCT07193225 |
| Ultrasound localization microscopy, coronary arteries | Other | Approved | Carotid Atherosclerosis | NOT_YET_RECRUITING | NCT07193225 |
| Ultrasound localization microscopy, circle of Willis | Other | Approved | Carotid Atherosclerosis | NOT_YET_RECRUITING | NCT07193225 |
| Medical imaging analysis via artificial intelligence algorithms | Other | Preclinical | Heart Valve Disease | RECRUITING | NCT07213531 |
| CardiolRx | Other | Phase PHASE2 | Recurrent Pericarditis | COMPLETED | NCT05494788 |
| Endo-epicardial VT ablation | Other | Approved | Ventricular Tachycardias | RECRUITING | NCT07240441 |
| Endocardial VT ablation | Other | Approved | Ventricular Tachycardias | RECRUITING | NCT07240441 |
| Endo-epicardial VT ablation | Other | Approved | Ventricular Tachycardias | RECRUITING | NCT07240441 |
| Endocardial VT ablation | Other | Approved | Ventricular Tachycardias | RECRUITING | NCT07240441 |
| Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin® | Other | Preclinical | Pulmonary Embolism Acute Massive | RECRUITING | NCT07245927 |
| Conventional Valve Surgery | Procedure | Approved | Heart Valve Diseases or Prosthesis | NOT_YET_RECRUITING | NCT07251660 |
| Minimally Invasive Valve Surgery | Procedure | Approved | Heart Valve Diseases or Prosthesis | NOT_YET_RECRUITING | NCT07251660 |
| Conventional Valve Surgery | Procedure | Approved | Heart Valve Diseases or Prosthesis | NOT_YET_RECRUITING | NCT07251660 |
| Minimally Invasive Valve Surgery | Procedure | Approved | Heart Valve Diseases or Prosthesis | NOT_YET_RECRUITING | NCT07251660 |
| Optimal Medical Therapy (OMT) And Lifestyle Intervention | Drug | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Metformin | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Dapagliflozin (Forxiga) | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Semaglutide 14 MG [Rybelsus] | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Optimal Medical Therapy (OMT) And Lifestyle Intervention | Drug | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Metformin | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Dapagliflozin (Forxiga) | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Semaglutide 14 MG [Rybelsus] | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Optimal Medical Therapy (OMT) And Lifestyle Intervention | Drug | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Metformin | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Dapagliflozin (Forxiga) | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Semaglutide 14 MG [Rybelsus] | Other | Phase PHASE4 | Coronary Artery Disease | RECRUITING | NCT07254572 |
| Aspirin monotherapy | Drug | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT04624854 |
| Clopidogrel and aspirin dual-antiplatelet therapy | Drug | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT04624854 |
| Aspirin monotherapy | Drug | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT04624854 |
| Clopidogrel and aspirin dual-antiplatelet therapy | Drug | Phase PHASE4 | Coronary Artery Disease | COMPLETED | NCT04624854 |
| AI diagnostic test for severe low-gradient aortic stenosis | Other | Preclinical | Low-gradient Aortic Stenosis | RECRUITING | NCT07144189 |
| AI diagnostic test for severe low-gradient aortic stenosis | Other | Preclinical | Low-gradient Aortic Stenosis | RECRUITING | NCT07144189 |
| AI diagnostic test for severe low-gradient aortic stenosis | Other | Preclinical | Low-gradient Aortic Stenosis | RECRUITING | NCT07144189 |
| 0.9%sodium chloride | Other | Approved | Laparoscopic Surgery | COMPLETED | NCT04946396 |
| dexmedetomidine intravenous infusion | Other | Approved | Laparoscopic Surgery | COMPLETED | NCT04946396 |
| 0.9%sodium chloride | Other | Approved | Laparoscopic Surgery | COMPLETED | NCT04946396 |
| dexmedetomidine intravenous infusion | Other | Approved | Laparoscopic Surgery | COMPLETED | NCT04946396 |
| self-expanding valve | Other | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT05454150 |
| balloon-expandable valve | Other | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT05454150 |
| self-expanding valve | Other | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT05454150 |
| balloon-expandable valve | Other | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT05454150 |
| Single-anastomosis duodenal switch | Other | Approved | Obesity, Morbid | ACTIVE_NOT_RECRUITING | NCT07115836 |
| Standard duodenal switch | Other | Approved | Obesity, Morbid | ACTIVE_NOT_RECRUITING | NCT07115836 |
| Single-anastomosis duodenal switch | Other | Approved | Obesity, Morbid | ACTIVE_NOT_RECRUITING | NCT07115836 |
| Standard duodenal switch | Other | Approved | Obesity, Morbid | ACTIVE_NOT_RECRUITING | NCT07115836 |
| Standard care | Other | Approved | Metabolic Disease | RECRUITING | NCT06952348 |
| Brisk walking | Other | Approved | Metabolic Disease | RECRUITING | NCT06952348 |
| Stair and brisk walking combined | Other | Approved | Metabolic Disease | RECRUITING | NCT06952348 |
| Standard care | Other | Approved | Metabolic Disease | RECRUITING | NCT06952348 |
| Brisk walking | Other | Approved | Metabolic Disease | RECRUITING | NCT06952348 |
| Stair and brisk walking combined | Other | Approved | Metabolic Disease | RECRUITING | NCT06952348 |
| Coronary artery bypass graft | Other | Approved | Cardiac Disease | RECRUITING | NCT06179329 |
| Coronary artery bypass graft | Other | Approved | Cardiac Disease | RECRUITING | NCT06179329 |
| Coronary artery bypass graft | Other | Approved | Cardiac Disease | RECRUITING | NCT06179329 |
| whole genome sequencing | Other | Preclinical | Cardiomyopathy, Hypertrophic | RECRUITING | NCT06546137 |
| whole genome sequencing | Other | Preclinical | Cardiomyopathy, Hypertrophic | RECRUITING | NCT06546137 |
| Right ventricular pacing | Other | Approved | Atrioventricular Block | COMPLETED | NCT04730921 |
| Left bundle branch area pacing | Other | Approved | Atrioventricular Block | COMPLETED | NCT04730921 |
| Right ventricular pacing | Other | Approved | Atrioventricular Block | COMPLETED | NCT04730921 |
| Left bundle branch area pacing | Other | Approved | Atrioventricular Block | COMPLETED | NCT04730921 |
| CTO PCI using retrograde strategy | Other | Approved | Coronary Artery Disease | RECRUITING | NCT06878729 |
| CTO PCI using ADR strategy | Other | Approved | Coronary Artery Disease | RECRUITING | NCT06878729 |
| CTO PCI using retrograde strategy | Other | Approved | Coronary Artery Disease | RECRUITING | NCT06878729 |
| CTO PCI using ADR strategy | Other | Approved | Coronary Artery Disease | RECRUITING | NCT06878729 |
| CTO PCI using DCB-only strategy | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT05977842 |
| CTO PCI using DCB-only strategy | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT05977842 |
| CTO PCI using DCB-only strategy | Other | Preclinical | Coronary Artery Disease | COMPLETED | NCT05977842 |
| Standard Cardiac Rehabilitation | Other | Approved | High Blood Pressure (& [Essential Hypertension]) | NOT_YET_RECRUITING | NCT07310992 |
| Meditation | Other | Approved | High Blood Pressure (& [Essential Hypertension]) | NOT_YET_RECRUITING | NCT07310992 |
| Standard Cardiac Rehabilitation | Other | Approved | High Blood Pressure (& [Essential Hypertension]) | NOT_YET_RECRUITING | NCT07310992 |
| Meditation | Other | Approved | High Blood Pressure (& [Essential Hypertension]) | NOT_YET_RECRUITING | NCT07310992 |
| Fecal Immunochemical Test (FIT) | Other | Preclinical | Gastrointestinal Bleeding | NOT_YET_RECRUITING | NCT07327853 |
| Fecal Immunochemical Test (FIT) | Other | Preclinical | Gastrointestinal Bleeding | NOT_YET_RECRUITING | NCT07327853 |
| Fecal Immunochemical Test (FIT) | Other | Preclinical | Gastrointestinal Bleeding | NOT_YET_RECRUITING | NCT07327853 |
| Major events | Other | Preclinical | Myocardial Infarction, Acute | RECRUITING | NCT07181317 |
| Questionnaires | Other | Preclinical | Myocardial Infarction, Acute | RECRUITING | NCT07181317 |
| Major events | Other | Preclinical | Myocardial Infarction, Acute | RECRUITING | NCT07181317 |
| Questionnaires | Other | Preclinical | Myocardial Infarction, Acute | RECRUITING | NCT07181317 |
| Lifestyle Management | Other | Approved | Cardiovascular Risk | RECRUITING | NCT06832644 |
| Lifestyle Management | Other | Approved | Cardiovascular Risk | RECRUITING | NCT06832644 |
| Macintosh group | Other | Approved | Echocardiography, Transesophageal | NOT_YET_RECRUITING | NCT07346898 |
| McGRATH group | Other | Approved | Echocardiography, Transesophageal | NOT_YET_RECRUITING | NCT07346898 |
| Macintosh group | Other | Approved | Echocardiography, Transesophageal | NOT_YET_RECRUITING | NCT07346898 |
| McGRATH group | Other | Approved | Echocardiography, Transesophageal | NOT_YET_RECRUITING | NCT07346898 |
| Myval THV series | Other | Preclinical | Aortic Valve Stenosis | RECRUITING | NCT06818435 |
| Myval THV series | Other | Preclinical | Aortic Valve Stenosis | RECRUITING | NCT06818435 |
| Myval THV series | Other | Preclinical | Aortic Valve Stenosis | RECRUITING | NCT06818435 |
| Gastric ultrasound | Other | Preclinical | Gastric Retention | COMPLETED | NCT06500143 |
| Gastric ultrasound | Other | Preclinical | Gastric Retention | COMPLETED | NCT06500143 |
| Endobronchial ultrasound | Other | Approved | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05560776 |
| Endobronchial ultrasound | Other | Approved | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05560776 |
| Endobronchial ultrasound | Other | Approved | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05560776 |
| Urinary test | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Vital signs | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Scales and questionnaire | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Blood sampling | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Arterial ultrasound | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Echocardiography | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Urinary test | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Vital signs | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Scales and questionnaire | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Blood sampling | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Arterial ultrasound | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Echocardiography | Other | Approved | Healthy Volunteer | NOT_YET_RECRUITING | NCT07372859 |
| Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions | Other | Approved | Cardiac Disease | COMPLETED | NCT04766554 |
| Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions | Other | Approved | Cardiac Disease | COMPLETED | NCT04766554 |
| Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter) and protocol-based interventions | Other | Approved | Cardiac Disease | COMPLETED | NCT04766554 |
| DASH diet | Other | Approved | Heart Failure | ACTIVE_NOT_RECRUITING | NCT05117086 |
| DASH diet | Other | Approved | Heart Failure | ACTIVE_NOT_RECRUITING | NCT05117086 |
| DASH diet | Other | Approved | Heart Failure | ACTIVE_NOT_RECRUITING | NCT05117086 |
| CDSS ("MedicBK") | Other | Approved | Atrial Fibrillation | COMPLETED | NCT05367141 |
| CDSS ("MedicBK") | Other | Approved | Atrial Fibrillation | COMPLETED | NCT05367141 |
| J-shaped mini-sternotomy | Other | Approved | Ascending Aortic Aneurysm | RECRUITING | NCT07386028 |
| Full sternotomy | Other | Approved | Ascending Aortic Aneurysm | RECRUITING | NCT07386028 |
| J-shaped mini-sternotomy | Other | Approved | Ascending Aortic Aneurysm | RECRUITING | NCT07386028 |
| Full sternotomy | Other | Approved | Ascending Aortic Aneurysm | RECRUITING | NCT07386028 |
| Nicotinic Acid | Other | Approved | Diabetes Mellitus Type 2 | RECRUITING | NCT05934409 |
| Bariatric surgery | Procedure | Approved | Diabetes Mellitus Type 2 | RECRUITING | NCT05934409 |
| Nicotinic Acid | Other | Approved | Diabetes Mellitus Type 2 | RECRUITING | NCT05934409 |
| Bariatric surgery | Procedure | Approved | Diabetes Mellitus Type 2 | RECRUITING | NCT05934409 |
| Incretin-Based Treatment | Drug | Approved | Obesity & Overweight | NOT_YET_RECRUITING | NCT07409831 |
| Intervention | Other | Approved | Obesity & Overweight | NOT_YET_RECRUITING | NCT07409831 |
| Incretin-Based Treatment | Drug | Approved | Obesity & Overweight | NOT_YET_RECRUITING | NCT07409831 |
| Intervention | Other | Approved | Obesity & Overweight | NOT_YET_RECRUITING | NCT07409831 |
| Incretin-Based Treatment | Drug | Approved | Obesity & Overweight | NOT_YET_RECRUITING | NCT07409831 |
| Intervention | Other | Approved | Obesity & Overweight | NOT_YET_RECRUITING | NCT07409831 |
| Coronary artery calcium score evaluation | Other | Preclinical | Diabetes Mellitus | WITHDRAWN | NCT05314140 |
| Theory-based motivational letter | Other | Approved | Cardiovascular Diseases (CVD) | COMPLETED | NCT07430644 |
| Theory-based motivational letter | Other | Approved | Cardiovascular Diseases (CVD) | COMPLETED | NCT07430644 |
| Theory-based motivational letter | Other | Approved | Cardiovascular Diseases (CVD) | COMPLETED | NCT07430644 |
| Fentanyl | Other | Phase PHASE4 | Laryngoscopy | RECRUITING | NCT07435337 |
| Nalbuphine | Other | Phase PHASE4 | Laryngoscopy | RECRUITING | NCT07435337 |
| Fentanyl | Other | Phase PHASE4 | Laryngoscopy | RECRUITING | NCT07435337 |
| Nalbuphine | Other | Phase PHASE4 | Laryngoscopy | RECRUITING | NCT07435337 |
| LAMBRE device implantation | Device | Preclinical | Atrial Fibrillation | RECRUITING | NCT06465459 |
| LAMBRE device implantation | Device | Preclinical | Atrial Fibrillation | RECRUITING | NCT06465459 |
| Observational Registry of Carcinoid Heart Disease | Other | Preclinical | Carcinoid Heart Disease | NOT_YET_RECRUITING | NCT07450287 |
| Observational Registry of Carcinoid Heart Disease | Other | Preclinical | Carcinoid Heart Disease | NOT_YET_RECRUITING | NCT07450287 |
| Observational Registry of Carcinoid Heart Disease | Other | Preclinical | Carcinoid Heart Disease | NOT_YET_RECRUITING | NCT07450287 |
| Dynamic fluoroscopy | Other | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT07462910 |
| Dynamic fluoroscopy | Other | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT07462910 |
| CardiolRx | Other | Phase PHASE3 | Recurrent Pericarditis | RECRUITING | NCT06708299 |
| atherectomy | Other | Preclinical | Peripheral Artery Disease | COMPLETED | NCT06173960 |
| atherectomy | Other | Preclinical | Peripheral Artery Disease | COMPLETED | NCT06173960 |
| Warfarin | Other | Phase PHASE3 | Valvular Heart Disease Patients | ENROLLING_BY_INVITATION | NCT07456085 |
| Rivoroxaban | Other | Phase PHASE3 | Valvular Heart Disease Patients | ENROLLING_BY_INVITATION | NCT07456085 |
| Warfarin | Other | Phase PHASE3 | Valvular Heart Disease Patients | ENROLLING_BY_INVITATION | NCT07456085 |
| Rivoroxaban | Other | Phase PHASE3 | Valvular Heart Disease Patients | ENROLLING_BY_INVITATION | NCT07456085 |
| Warfarin | Other | Phase PHASE3 | Valvular Heart Disease Patients | ENROLLING_BY_INVITATION | NCT07456085 |
| Rivoroxaban | Other | Phase PHASE3 | Valvular Heart Disease Patients | ENROLLING_BY_INVITATION | NCT07456085 |
| Ultrasound-assisted Catheter-guided Thrombolysis | Other | Approved | Pulmonary Embolism (PE) | RECRUITING | NCT07452991 |
| Ultrasound-assisted Catheter-guided Thrombolysis | Other | Approved | Pulmonary Embolism (PE) | RECRUITING | NCT07452991 |
| Saline Solution | Other | Phase PHASE4 | Coronary Artery Disease | SUSPENDED | NCT03304496 |
| Nitroglycerin 100 MCG/ML Injectable Solution | Other | Phase PHASE4 | Coronary Artery Disease | SUSPENDED | NCT03304496 |
| Saline Solution | Other | Phase PHASE4 | Coronary Artery Disease | SUSPENDED | NCT03304496 |
| Nitroglycerin 100 MCG/ML Injectable Solution | Other | Phase PHASE4 | Coronary Artery Disease | SUSPENDED | NCT03304496 |
| Oral motor intervention | Other | Approved | Deglutition Disorders in Children | COMPLETED | NCT07481565 |
| Oral motor intervention | Other | Approved | Deglutition Disorders in Children | COMPLETED | NCT07481565 |
| Invasive hemodynamic measurements | Other | Approved | Aortic Valve Stenosis | RECRUITING | NCT05459233 |
| Doppler-echocardiography | Other | Approved | Aortic Valve Stenosis | RECRUITING | NCT05459233 |
| Invasive hemodynamic measurements | Other | Approved | Aortic Valve Stenosis | RECRUITING | NCT05459233 |
| Doppler-echocardiography | Other | Approved | Aortic Valve Stenosis | RECRUITING | NCT05459233 |
| Individualized excercise | Other | Approved | Cardiomyopathy, Dilated | COMPLETED | NCT04359238 |
| Individualized excercise | Other | Approved | Cardiomyopathy, Dilated | COMPLETED | NCT04359238 |
| 18F-FDG PET/CT | Other | Preclinical | Infective Endocarditis | COMPLETED | NCT03683355 |
| 18F-FDG PET/CT | Other | Preclinical | Infective Endocarditis | COMPLETED | NCT03683355 |
| Implantable loop recorders system Reveal ICM LINQ®, | Other | Approved | Aortic Valve Disease | RECRUITING | NCT02153307 |
| Implantable loop recorders system Reveal ICM LINQ®, | Other | Approved | Aortic Valve Disease | RECRUITING | NCT02153307 |
| Observational Follow-up | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Natriuresis-Guided Down-Titration | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Standard care | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Natriuresis-Guided Up-Titration | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Observational Follow-up | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Natriuresis-Guided Down-Titration | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Standard care | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Natriuresis-Guided Up-Titration | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Observational Follow-up | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Natriuresis-Guided Down-Titration | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Standard care | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Natriuresis-Guided Up-Titration | Other | Approved | Heart Failure | RECRUITING | NCT07369856 |
| Exercise training | Other | Approved | Coronary Artery Disease | RECRUITING | NCT06579807 |
| Exercise training | Other | Approved | Coronary Artery Disease | RECRUITING | NCT06579807 |
| SAPIEN 3 Ultra RESILIA Valve | Other | Preclinical | Aortic Valve Stenosis | RECRUITING | NCT06420830 |
| SAPIEN 3 Ultra RESILIA Valve | Other | Preclinical | Aortic Valve Stenosis | RECRUITING | NCT06420830 |
| SAPIEN 3 Ultra RESILIA Valve | Other | Preclinical | Aortic Valve Stenosis | RECRUITING | NCT06420830 |
| Exercise training | Other | Approved | HIV Infections | RECRUITING | NCT04512456 |
| Exercise training | Other | Approved | HIV Infections | RECRUITING | NCT04512456 |
| Cardiostat | Other | Approved | TAVI | ACTIVE_NOT_RECRUITING | NCT04298593 |
| Cardiostat | Other | Approved | TAVI | ACTIVE_NOT_RECRUITING | NCT04298593 |
| Low dose aspirin -80 to 125 mg/day- | Other | Phase PHASE4 | Left Atrial Appendage Closure | ACTIVE_NOT_RECRUITING | NCT03568890 |
| Clopidogrel -75 mg/day | Other | Phase PHASE4 | Left Atrial Appendage Closure | ACTIVE_NOT_RECRUITING | NCT03568890 |
| Rivaroxaban, dabigatran, apixaban, or edoxaban | Other | Phase PHASE4 | Left Atrial Appendage Closure | ACTIVE_NOT_RECRUITING | NCT03568890 |
| Low dose aspirin -80 to 125 mg/day- | Other | Phase PHASE4 | Left Atrial Appendage Closure | ACTIVE_NOT_RECRUITING | NCT03568890 |
| Clopidogrel -75 mg/day | Other | Phase PHASE4 | Left Atrial Appendage Closure | ACTIVE_NOT_RECRUITING | NCT03568890 |
| Rivaroxaban, dabigatran, apixaban, or edoxaban | Other | Phase PHASE4 | Left Atrial Appendage Closure | ACTIVE_NOT_RECRUITING | NCT03568890 |
| TAVI_ViV procedure with CoreValve system | Procedure | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT03520101 |
| TAVI_ViV procedure with Edwards valve | Procedure | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT03520101 |
| TAVI_ViV procedure with CoreValve system | Procedure | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT03520101 |
| TAVI_ViV procedure with Edwards valve | Procedure | Approved | Aortic Valve Stenosis | ACTIVE_NOT_RECRUITING | NCT03520101 |
| Standard | Other | Approved | Degenerative Aortic Valve Disease | ACTIVE_NOT_RECRUITING | NCT03383445 |
| Acurate neo | Other | Approved | Degenerative Aortic Valve Disease | ACTIVE_NOT_RECRUITING | NCT03383445 |
| CoreValve | Other | Approved | Degenerative Aortic Valve Disease | ACTIVE_NOT_RECRUITING | NCT03383445 |
| Edwards | Other | Approved | Degenerative Aortic Valve Disease | ACTIVE_NOT_RECRUITING | NCT03383445 |
| Standard | Other | Approved | Degenerative Aortic Valve Disease | ACTIVE_NOT_RECRUITING | NCT03383445 |
| Acurate neo | Other | Approved | Degenerative Aortic Valve Disease | ACTIVE_NOT_RECRUITING | NCT03383445 |
| CoreValve | Other | Approved | Degenerative Aortic Valve Disease | ACTIVE_NOT_RECRUITING | NCT03383445 |
| Edwards | Other | Approved | Degenerative Aortic Valve Disease | ACTIVE_NOT_RECRUITING | NCT03383445 |
| Right Heart Catheterization | Other | Preclinical | Tricuspid Regurgitation (TR) | NOT_YET_RECRUITING | NCT07500025 |
| Right Heart Catheterization | Other | Preclinical | Tricuspid Regurgitation (TR) | NOT_YET_RECRUITING | NCT07500025 |
| Right Heart Catheterization | Other | Preclinical | Tricuspid Regurgitation (TR) | NOT_YET_RECRUITING | NCT07500025 |
| Laboratory assessments | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| [99mTc]Tc-DPD scintigraphy | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Electromyogram (EMG) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| COMPASS-31 (Composite Autonomic Symptom Score-31) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| questionnaire, the NIS-LL (Neuropathy Impairment Score in the Lower Limbs) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| The Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Color Doppler echocardiography with "two-dimensional strain" (longitudinal strain) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| 24-Hour Holter Monitoring | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Electrocardiogram (12-lead ECG) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Neurological examination includes motor strength testing; sensory testing with pinprick, light touch, temperature, and proprioception; deep tendon reflexes; and gait assessment. | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| A complete physical examination of all body systems, including height and body weight | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Laboratory assessments | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| [99mTc]Tc-DPD scintigraphy | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Electromyogram (EMG) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| COMPASS-31 (Composite Autonomic Symptom Score-31) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| questionnaire, the NIS-LL (Neuropathy Impairment Score in the Lower Limbs) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| The Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Color Doppler echocardiography with "two-dimensional strain" (longitudinal strain) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| 24-Hour Holter Monitoring | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Electrocardiogram (12-lead ECG) | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Neurological examination includes motor strength testing; sensory testing with pinprick, light touch, temperature, and proprioception; deep tendon reflexes; and gait assessment. | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| A complete physical examination of all body systems, including height and body weight | Other | Preclinical | Hereditary Amyloidosis, Transthyretin-Related | RECRUITING | NCT07124377 |
| Matching Placebo (B) | Other | Phase PHASE3 | Heart Failure | NOT_YET_RECRUITING | NCT07234422 |
| Selenium/CoQ10 | Other | Phase PHASE3 | Heart Failure | NOT_YET_RECRUITING | NCT07234422 |
| Matching Placebo (B) | Other | Phase PHASE3 | Heart Failure | NOT_YET_RECRUITING | NCT07234422 |
| Selenium/CoQ10 | Other | Phase PHASE3 | Heart Failure | NOT_YET_RECRUITING | NCT07234422 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT06683040 |
| Oxacom | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT06683040 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT06683040 |
| Oxacom | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT06683040 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT06683040 |
| Oxacom | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT06683040 |
| Mannitol | Other | Phase PHASE2 | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06540352 |
| 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride | Other | Phase PHASE2 | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06540352 |
| Mannitol | Other | Phase PHASE2 | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06540352 |
| 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride | Other | Phase PHASE2 | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06540352 |
| Rivaroxaban 15 mg | Other | Phase PHASE4 | Coronary Artery Ectasia | RECRUITING | NCT07511257 |
| Clopidogrel 75 mg | Other | Phase PHASE4 | Coronary Artery Ectasia | RECRUITING | NCT07511257 |
| Aspirin 100 mg | Other | Phase PHASE4 | Coronary Artery Ectasia | RECRUITING | NCT07511257 |
| Rivaroxaban 15 mg | Other | Phase PHASE4 | Coronary Artery Ectasia | RECRUITING | NCT07511257 |
| Clopidogrel 75 mg | Other | Phase PHASE4 | Coronary Artery Ectasia | RECRUITING | NCT07511257 |
| Aspirin 100 mg | Other | Phase PHASE4 | Coronary Artery Ectasia | RECRUITING | NCT07511257 |
| Placebo | Other | Phase EARLY_PHASE1 | Arterial Hypertension | RECRUITING | NCT06169241 |
| Beetroot extract | Other | Phase EARLY_PHASE1 | Arterial Hypertension | RECRUITING | NCT06169241 |
| Placebo | Other | Phase EARLY_PHASE1 | Arterial Hypertension | RECRUITING | NCT06169241 |
| Beetroot extract | Other | Phase EARLY_PHASE1 | Arterial Hypertension | RECRUITING | NCT06169241 |
| skin microvascular reactivity | Other | Preclinical | Heart Transplantation | RECRUITING | NCT05729009 |
| skin microvascular reactivity | Other | Preclinical | Heart Transplantation | RECRUITING | NCT05729009 |
| FIL-EAS ic care pathway | Other | Approved | Heart Failure Acute | COMPLETED | NCT04878263 |
| Conventional hospitalization | Other | Approved | Heart Failure Acute | COMPLETED | NCT04878263 |
| Clinical Follow up | Other | Approved | Mitral Valve Prolapse | ACTIVE_NOT_RECRUITING | NCT07366723 |
| mitral valve surgery | Procedure | Approved | Mitral Valve Prolapse | ACTIVE_NOT_RECRUITING | NCT07366723 |
| Clinical Follow up | Other | Approved | Mitral Valve Prolapse | ACTIVE_NOT_RECRUITING | NCT07366723 |
| mitral valve surgery | Procedure | Approved | Mitral Valve Prolapse | ACTIVE_NOT_RECRUITING | NCT07366723 |
| Clinical Follow up | Other | Approved | Mitral Valve Prolapse | ACTIVE_NOT_RECRUITING | NCT07366723 |
| mitral valve surgery | Procedure | Approved | Mitral Valve Prolapse | ACTIVE_NOT_RECRUITING | NCT07366723 |
| Disposable Flexible Cryocatheter System | Other | Approved | Lung Cancer (Diagnosis) | NOT_YET_RECRUITING | NCT07539701 |
| Disposable Flexible Cryocatheter System | Other | Approved | Lung Cancer (Diagnosis) | NOT_YET_RECRUITING | NCT07539701 |
| Disposable Flexible Cryocatheter System | Other | Approved | Lung Cancer (Diagnosis) | NOT_YET_RECRUITING | NCT07539701 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| no-touch vein graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| radial artery graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Percutaneous coronary intervention with stent implantation | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Intravascular lithotripsy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Orbital atherectomy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Exercise during hemodiafiltration session | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Not exercise | Other | Approved | Renal Dialysis | COMPLETED | NCT06584734 |
| Observational (registry) | Other | Preclinical | COVID-19 | RECRUITING | NCT05188612 |
| Anticoagulants | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Percutaneous coronary intervention with stent implantation | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Intravascular lithotripsy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Orbital atherectomy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Antiplatelet Drug | Drug | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Percutaneous coronary intervention with stent implantation | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Intravascular lithotripsy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Orbital atherectomy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Conventional physiotherapy | Drug | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| TAR Method | Other | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Percutaneous coronary intervention with stent implantation | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Intravascular lithotripsy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Orbital atherectomy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Percutaneous coronary intervention with stent implantation | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Intravascular lithotripsy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Orbital atherectomy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Percutaneous coronary intervention with stent implantation | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Intravascular lithotripsy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Orbital atherectomy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Percutaneous coronary intervention with stent implantation | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Intravascular lithotripsy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Orbital atherectomy | Other | Approved | Coronary Arterial Disease (CAD) | RECRUITING | NCT06736665 |
| Investigation of Systemic Endothelial Microvascular Function | Other | Preclinical | Angina, Microvascular | NOT_YET_RECRUITING | NCT07558018 |
| Placebos | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| Digoxin | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| no-touch vein graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| radial artery graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| Conventional physiotherapy | Drug | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| TAR Method | Other | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| Placebos | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| Digoxin | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| no-touch vein graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| radial artery graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| Conventional physiotherapy | Drug | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| TAR Method | Other | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| Placebos | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| Digoxin | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| no-touch vein graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| radial artery graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| Conventional physiotherapy | Drug | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| TAR Method | Other | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| Placebos | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| Digoxin | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| no-touch vein graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| radial artery graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| Conventional physiotherapy | Drug | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| TAR Method | Other | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| Placebos | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| Digoxin | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| no-touch vein graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| radial artery graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| Conventional physiotherapy | Drug | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| TAR Method | Other | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| Placebos | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| Digoxin | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| no-touch vein graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| radial artery graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| Conventional physiotherapy | Drug | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| TAR Method | Other | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| Placebos | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| Digoxin | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| no-touch vein graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| radial artery graft | Other | Approved | Coronary Artery Atherosclerosis | RECRUITING | NCT07552948 |
| Conventional physiotherapy | Drug | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| TAR Method | Other | Approved | Respiratory Complications | RECRUITING | NCT06814951 |
| Placebos | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| Digoxin | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT03783429 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| Placebo | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Dapagliflozin 10mg Tab | Other | Approved | Heart Failure With Reduced Ejection Fraction | COMPLETED | NCT05795400 |
| Imaging evaluation for vascular assessment | Other | Preclinical | Myocardial Infarction | ACTIVE_NOT_RECRUITING | NCT04058782 |
| short bouts of maximal exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Approved | Inflammation | RECRUITING | NCT07543666 |
| [SGLTi + previously taken RAAS blocker] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | Other | Phase PHASE2 | HFpEF | RECRUITING | NCT06655480 |
| short bouts of maximal exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| short bouts of maximal exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| short bouts of maximal exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| short bouts of maximal exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| short bouts of maximal exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| short bouts of maximal exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| short bouts of maximal exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| short bouts of maximal exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| vigorous-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| moderate-intensity exercise | Other | Phase PHASE1 | Inflammation | RECRUITING | NCT07543666 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
| Comparison of 2 cooling procedures | PROCEDURE | Phase PHASE4 | Hypothermia | COMPLETED | NCT00392639 |
| sirolimus-eluting stent | DEVICE | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT00258596 |
| TAVR Implantation with SAPIEN | DEVICE | Approved | Severe | COMPLETED | NCT02184442 |
| TAVR Implantation with SAPIEN XT | DEVICE | Approved | Severe | COMPLETED | NCT02184442 |
| Standard care | OTHER | Phase PHASE4 | Heart Failure, Diastolic | COMPLETED | NCT03753087 |
| Empagliflozin | DRUG | Phase PHASE4 | Heart Failure, Diastolic | COMPLETED | NCT03753087 |
| MitraClip | DEVICE | Preclinical | Mitral Regurgitation | RECRUITING | NCT06633159 |
| Redo Mitral valve surgery | PROCEDURE | Approved | Mitral Prosthetic Valve Stenosis and Regurgitation | COMPLETED | NCT04402931 |
| Transcatheter Valve-in-Valve Intervention | PROCEDURE | Approved | Mitral Prosthetic Valve Stenosis and Regurgitation | COMPLETED | NCT04402931 |
| Separately drugs, simvastatin, aspirin and ramipril | DRUG | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01321255 |
| FDC | DRUG | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT01321255 |
| SSI and SphygmoCor® evaluations | OTHER | Approved | Healthy Volunteers | COMPLETED | NCT01096264 |
| sirolimus-eluting stent, zotarolimus-eluting stent | DEVICE | Phase PHASE3 | Coronary Artery Disease | COMPLETED | NCT00428454 |
| Procedure: PCI | PROCEDURE | Preclinical | Percutaneous Coronary Intervention | COMPLETED | NCT01841346 |
| Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | PROCEDURE | Phase PHASE2 | Acute Myocardial Infarction | TERMINATED | NCT00350766 |
| Aspirin (80 mg/d) + clopidogrel (75 mg/d) | DRUG | Phase PHASE4 | Aortic Valve Disease | COMPLETED | NCT01559298 |
| observation | OTHER | Preclinical | Chronic Heart Failure | COMPLETED | NCT02790801 |
| home-based telerehabilitation | OTHER | Approved | Chronic Heart Failure | COMPLETED | NCT02523560 |
| Tiotropium Bromide | DRUG | Approved | Health, Subjective | UNKNOWN | NCT04137029 |
| Formoterol | DRUG | Approved | Health, Subjective | UNKNOWN | NCT04137029 |
| no intervention | OTHER | Preclinical | Acute Myocardial Infarction | UNKNOWN | NCT04241770 |
| Benznidazole | DRUG | Phase PHASE3 | Chagas Disease | COMPLETED | NCT00123916 |
| FxCordiax 120 membrane | OTHER | Approved | Hemodiafiltration | UNKNOWN | NCT03938285 |
| Theranova 400 membrane | OTHER | Approved | Hemodiafiltration | UNKNOWN | NCT03938285 |
| Human Allogeneic Umbilical Cord Blood Mononuclear Cells (hUCBMCs) systemic (i.v.) infusions | BIOLOGICAL | Phase PHASE1 | Spinal Cord Contusion | COMPLETED | NCT04331405 |
| Coronary flow reserve SE | PROCEDURE | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Pulmonary hemodynamics SE | PROCEDURE | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Mitral regurgitation SE | PROCEDURE | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Diastolic function SE | PROCEDURE | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Left ventricular outflow tract gradient SE | PROCEDURE | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| B-lines SE | PROCEDURE | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Left ventricular contractile reserve SE | PROCEDURE | Preclinical | Coronary Artery Disease | UNKNOWN | NCT03049995 |
| Clopidogrel | DRUG | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT02457130 |
| Aspirin | DRUG | Phase PHASE4 | Aortic Valve Disease | COMPLETED | NCT01559298 |
| Dabigatran Etexilate | DRUG | Phase PHASE4 | Atrial Fibrillation | RECRUITING | NCT04695106 |
| Ticagrelor | DRUG | Phase PHASE4 | Coronary Artery Disease | UNKNOWN | NCT02457130 |
| S-ICD | DEVICE | Preclinical | Sudden Cardiac Death | UNKNOWN | NCT05302115 |
| Somnocheck | DEVICE | Preclinical | Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT05436730 |
| VaSera-VS | DEVICE | Preclinical | Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT05436730 |
| Sphygmocor | DEVICE | Preclinical | Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT05436730 |
| Ambulatory blood pressure measurement device | DEVICE | Preclinical | Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT05436730 |
| Removal or leaving of LAA occluders | PROCEDURE | Preclinical | Left Atrial Appendage Occluder | UNKNOWN | NCT05014477 |
| optimizer smart | DEVICE | Approved | Heart Failure | COMPLETED | NCT05550792 |
| left atrial appendage occluder implantation | DEVICE | Preclinical | Atrial Fibrillation | COMPLETED | NCT03867227 |
| Refralon | DRUG | Preclinical | Paroxysmal Atrial Fibrillation | COMPLETED | NCT05773170 |
| Placebos | DRUG | Phase PHASE4 | Heart Failure | ACTIVE_NOT_RECRUITING | NCT03783429 |
| Digoxin | DRUG | Phase PHASE4 | Heart Failure | ACTIVE_NOT_RECRUITING | NCT03783429 |
| Ganglionated plexi ablation | PROCEDURE | Approved | Bradycardia | RECRUITING | NCT06288633 |
| Cardiovascular physical examination | OTHER | Approved | Heart Failure | RECRUITING | NCT05859048 |
| Revascularization | PROCEDURE | Approved | Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients | RECRUITING | NCT06279663 |
| a basal LV septum biopsy | OTHER | Approved | Heart Disease | ACTIVE_NOT_RECRUITING | NCT02260466 |
| Esmolol Hcl 10Mg/Ml Inj | DRUG | Approved | Myocardial Infarction | RECRUITING | NCT06376630 |
| Catheter ablation | PROCEDURE | Preclinical | Atrial Fibrillation and Flutter | RECRUITING | NCT06584266 |
| Diuretics maintenance | DRUG | Phase PHASE2 | Heart Failure | COMPLETED | NCT05964738 |
| Diuretics withdrawal | DRUG | Phase PHASE2 | Heart Failure | COMPLETED | NCT05964738 |
| late anticoagulation | OTHER | Phase PHASE4 | Mitral Regurgitation | ENROLLING_BY_INVITATION | NCT05305612 |
| early anticoagulation | OTHER | Phase PHASE4 | Mitral Regurgitation | ENROLLING_BY_INVITATION | NCT05305612 |
| Percutaneous coronary intervention with stent implantation | DEVICE | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Optical Coherence Tomography (OCT) | DEVICE | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Intravascular lithotripsy | DEVICE | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| Orbital atherectomy | DEVICE | Phase PHASE4 | Coronary Arterial Disease (CAD) | NOT_YET_RECRUITING | NCT06736665 |
| PFO closure | DEVICE | Preclinical | Patent Foramen Ovale | RECRUITING | NCT06156670 |
| [SGLTi + previously taken RAAS blocker] | DRUG | Phase PHASE2 | HFpEF | NOT_YET_RECRUITING | NCT06655480 |
| [ARNI + SGLTi + AMR] | DRUG | Phase PHASE2 | HFpEF | NOT_YET_RECRUITING | NCT06655480 |
| Dapagliflozin 10mg Tab | DRUG | Approved | Heart Failure With Reduced Ejection Fraction | ACTIVE_NOT_RECRUITING | NCT05795400 |
| Antiplatelet Drug | DRUG | Preclinical | Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) | RECRUITING | NCT04347200 |
| Anticoagulants | DRUG | Preclinical | Atrial Fibrillation | RECRUITING | NCT04347187 |
| Pharmacological cardioversion with Refralon | DRUG | Approved | Atrium; Fibrillation | COMPLETED | NCT05456204 |
| Pharmacological cardioversion with Amiodarone | DRUG | Phase PHASE4 | Atrial Fibrillation Paroxysmal | COMPLETED | NCT05445297 |
| Valsartan | DRUG | Phase PHASE2 | Heart Failure | COMPLETED | NCT03928158 |
| LCZ 696 | DRUG | Phase PHASE2 | Heart Failure | COMPLETED | NCT03928158 |
| iVAC 2L | DEVICE | Approved | Ischemic Cardiovascular Disease | RECRUITING | NCT07149714 |
| Thoracic Aortic Surgery | PROCEDURE | Approved | Ascending Aortic Aneurysm Enlargement | RECRUITING | NCT03536312 |
| Non-immunogenic staphylokinasenon-immunogenic staphylokinase 15 mg as a single intravenous bolus Other Names: Fortelyzin® | DRUG | Preclinical | Pulmonary Embolism Acute Massive | RECRUITING | NCT07245927 |
| Myval THV series | DEVICE | Preclinical | Aortic Valve Stenosis | RECRUITING | NCT06818435 |
| Ultrasound-assisted Catheter-guided Thrombolysis | DEVICE | Approved | Pulmonary Embolism (PE) | RECRUITING | NCT07452991 |
| FIL-EAS ic care pathway | OTHER | Approved | Heart Failure Acute | COMPLETED | NCT04878263 |
| Conventional hospitalization | OTHER | Approved | Heart Failure Acute | COMPLETED | NCT04878263 |
| Individualized excercise | BEHAVIORAL | Approved | Cardiomyopathy, Dilated | COMPLETED | NCT04359238 |
| Mannitol | DRUG | Phase PHASE2 | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06540352 |
| 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride | DRUG | Phase PHASE2 | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06540352 |
| Oxacom | DRUG | Phase PHASE2 | Pulmonary Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT06683040 |
| Matching Placebo (B) | DRUG | Phase PHASE3 | Heart Failure | NOT_YET_RECRUITING | NCT07234422 |
| CardiolRx | DRUG | Phase PHASE3 | Recurrent Pericarditis | RECRUITING | NCT06708299 |
| Placebo | DRUG | Phase PHASE3 | Chagas Disease | COMPLETED | NCT00123916 |
| Cannabidiol, pharmaceutically produced with < 5 ppm THC | DRUG | Phase PHASE2 | COVID-19 | TERMINATED | NCT04615949 |
Total products: 2763